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Urinary schistosomiasis, which is caused by the blood fluke Schistosoma haematobium, is a
tropical disease infecting over 100 million people in sub-Saharan Africa. Infection typically
involves repeated re-infection with long-lived parasites, and field studies have demonstrated
that protective immunity takes many years to develop in humans. In communities with endemic
schistosomiasis, distinctive patterns of infection and schistosome-specific antibody responses
are seen, including a peaked age-infection curve, a highly aggregated distribution of infection
intensities among individuals, and an age-related switch in the subclasses of antibody produced.
The antibody switch, which occurs naturally in older children, is also seen in younger children
following treatment with the antihelminthic drug praziquantel, which kills adult worms.
This study aimed to identify the important mechanisms underlying the slow development of
protective immunity, using a mathematical modelling approach. Deterministic population-level
and stochastic individual-based models were developed that describe how levels of infection
and antibody change with age for individuals living in endemic communities. These models
were used to explore different hypotheses for the slow development of protective immunity: (1)
that schistosome parasites actively suppress protective immune responses; (2) that dying worms
provide the main antigenic stimulus for protective immunity and (3) that a threshold level of
antigen must be experienced before a protective immune response is initiated. Models were
assessed for their ability to simultaneously reproduce different robust patterns of infection and
antibody responses identified in cross-sectional and post-treatment field data from Zimbabwe.
It was found that significant immunosuppression by schistosomes was not consistent with
population-level patterns of infection intensity, including the peaked age-infection curve. In
order to explain both age-related and post-treatment changes in infection intensity and antibody
responses, including the antibody switch, protective antibody responses had to be stimulated by
antigens from dying worms. Additionally, it was shown that these protective responses reduced
worm fecundity rather than reducing rates of re-infection. An antigen threshold was found to
be consistent with observed field patterns, but was not necessary to explain them.
From a large number of possible models that were considered, a single model structure and
a subset of parameter combinations were identified that were consistent with field data. This
model was used to predict the longer-term impact of mass-treatment programmes upon the
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Schistosomiasis is a tropical disease of major public health importance, with an estimated 200
million people worldwide infected with the causative trematode parasites (Gryseels et al. 2006;
Mascie-Taylor & Karim 2003). It is largely a disease of rural poverty, persisting in communities
without access to safe water supplies or proper sanitation, and is responsible for a considerable
burden of pathology. Control efforts are currently focussed upon vaccine development and mass
chemotherapy, with the principal aim of reducing pathology rather than eliminating infection
(Capron et al. 2005; Fenwick et al. 2009; WHO 2001). No vaccines have yet been licensed
for use in humans, and an increased understanding of natural immunity is highly desirable in
order to identify the relevant antigens, targets and immune pathways involved in protective
immune responses, which can be exploited by a successful vaccine. In common with other
parasitic infections, protective immunity against schistosomes takes a long time to develop
(Yazdanbakhsh & Sacks 2010), in contrast with the strong and long-lasting protective immunity
which rapidly develops following an initial encounter with many viral and bacterial pathogens.
The reasons for this slow development of protective immunity are still not fully understood.
Chemotherapy has been shown to alter the nature of the schistosome-specific immune responses,
with the data suggesting that it may have an immunizing effect (Mutapi et al. 1998), although
the long-term impact of chemotherapy upon protective immunity has not yet been assessed.
Studies of the dynamics of schistosome infection and schistosome-specific immune responses
in humans have mainly relied upon large cross-sectional and treatment-reinfection surveys in
populations with endemic infection, and mathematical models have played an important role
in interpreting these immunoepidemiological studies (Hellriegel 2001).
In this thesis, mathematical models are used to explore a number of hypotheses which
have been put forward to explain the slow development of protective immunity, and the
models are tested for their ability to reproduce a variety of robust patterns seen in both
infection and antibody data in population-based surveys. Models are also used to predict
the long-term impact of mass chemotherapy programmes upon the development of protective
immunity. This thesis focuses upon infection with Schistosoma haematobium, which causes
urinary schistosomiasis. In this introductory chapter, the basic biology and epidemiology of
S. haematobium infection is reviewed, with an overview of past and current control methods.
The current state of knowledge about protective immunity in humans is discussed, and different
hypotheses for the slow development of protective immunity are put forward. Previous
approaches to modelling schistosome transmission, immunity and control are reviewed, and
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the aims of this thesis are outlined. While the focus throughout is upon S. haematobium,
findings for other schistosome species are mentioned where relevant.
1.1 S. haematobium biology, life-cycle and disease
Humans are natural hosts for the schistosome species Schistosoma mansoni, S. haematobium,
S. japonicum, S. intercalatum and S. mekongi. The schistosome life cycle includes an
intermediate freshwater snail host, and the distribution of each schistosome species is related
to the distribution of its respective snail host species (Gryseels & Nkulikyinka 1988).
S. haematobium, which causes urinary schistosomiasis, has as its intermediate host the
Bulinus snail species, and occurs in Africa and the Arabian Peninsula (Gryseels et al. 2006).
Over 100 million people are infected in sub-Saharan Africa (van der Werf et al. 2003). Infection
occurs through contact with water containing the infective stages (figure 1.1). The life cycle for
S. haematobium is shown in figure 1.2. The water-borne infective stages (cercariae) penetrate
the human skin and transform into schistosomulae, which enter the bloodstream and are carried
via the lungs to the liver, where they mature into adult worms. Worms of opposite sexes pair up
and migrate to the vesical veins surrounding the bladder. Eggs produced by mated female worms
penetrate the blood vessel wall, and exit the body in urine. Upon contact with fresh water, eggs
hatch to release miracidia, which infect the snail host. Following asexual reproduction within
the snail, infective cercariae are released into the water (Jordan et al. 1993).
The different stages of the life cycle have different life expectancies: eggs can remain viable
for up to 7 days, miracidia for 4–16 hours, and cercariae for up to 72 hours (Anderson & May
1991a; Gryseels et al. 2006). The within-snail stages and the schistosomulae stage each last for
around 4-6 weeks (Gryseels et al. 2006). In contrast, adult worms can live for years within their
human hosts, with their mean life span estimated at 3–10 years (Fulford et al. 1995; Wilkins
et al. 1984).
More than 50% of eggs become trapped in the tissues of the bladder and surrounding
region, and pathology results from the immune reaction to these trapped eggs (King 2001b).
Morbidity ranges from anaemia and haematuria to long-term kidney and bladder damage, with
an estimated 6–13.5 million disability-adjusted life years (DALYs) lost globally to infections with
all schistosome species (Bergquist et al. 2005; King et al. 2005). S. haematobium is estimated
to cause 150 000 deaths every year due to kidney failure (WHO 2006) with an overall mortality
rate of 2 per 1000 infected persons per year (Fenwick et al. 2003). Disease severity has been
shown to be related to the duration and intensity of infection in some studies (Koukounari et al.
2007; Mahmoud 2001; Ndamba et al. 1991). However, other studies suggest that morbidity is
related to infection status rather than intensity (King 2007), with the severity of disease being
related to the location of the eggs, host and parasite genetics, and the type of immune response
that is mounted (Brouwer et al. 2003; de Vlas 1996; King 2001b; Quinnell 2003; Remoué et al.
2001). The less severe morbidities are reversible by chemotherapy (Magnussen 2003).
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(a) (b)
Figure 1.1: Water contact in rural Zimbabwe. (a) washing (b) laundry







































































   
   
   
   
   





Figure 1.3: Intensity peak and peak shift. (a) Mean intensity and prevalence of infection with
age in a population in Northern Zimbabwe (based on data from Mutapi et al. (2007)). (b)
Intensity of infection (mean number of eggs/10 ml urine) in two areas of Eastern Zimbabwe
with high and low transmission as marked (based on data from Mutapi et al. (1997)).
1.2 Epidemiology and patterns of infection
Schistosomiasis shows strong spatial clustering, related to patterns of snail distribution and
human water contact (Clennon et al. 2004; Gryseels et al. 2006; Woolhouse et al. 1998). A
characteristic age-intensity pattern is seen in endemically infected populations, with infection
intensity rising rapidly through the childhood years to peak at around 8–15 years of age, then
falling again, with a slight rise sometimes observed in much older age groups (figure 1.3a) (Fisher
1934; King 2001a). Prevalence also tends to peak in children and decline in older individuals,
but usually more gradually than infection intensity (figure 1.3a). The peak in infection intensity
is higher and occurs at a younger age in populations with higher overall infection prevalence, a
phenomenon termed the peak shift (figure 1.3b) (Woolhouse 1998).
Schistosomes, like many other helminths, are highly aggregated in human populations, with
a few individuals harbouring the majority of parasites (figure 1.4), so that the population
variance in infection intensity greatly exceeds the mean (Woolhouse et al. 1994). The extent of
aggregation has been reported to change with age, either decreasing or displaying an inverse-
convex pattern (Chan et al. 2000; Fulford et al. 1992; Woolhouse et al. 1994). This aggregated
distribution has important consequences for schistosome transmission and for intervention
programmes (Galvani 2003; Woolhouse et al. 1998).
Following chemotherapy, infection levels are greatly reduced, with mean infection intensity
being reduced by a greater proportion than prevalence (egg reduction rates are consistently
higher than cure rates, section 1.4.1). Infection levels subsequently increase again, with
substantially higher rates of re-infection being consistently observed in younger children when
compared with older children or adults, which cannot entirely be explained by differences in
exposure levels (Etard et al. 1995; Hagan et al. 1991; Kabatereine et al. 1999; Wilkins et al.
1987). Several studies have also reported pre-disposition, with post-treatment levels of re-
infection being positively correlated with pre-treatment infection intensity for both S. mansoni
and S. haematobium (Bensted-Smith et al. 1987; Etard et al. 1995; Tingley et al. 1988). This
pre-disposition is stronger in younger individuals than in older people (Bensted-Smith et al.
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Figure 1.4: Parasite aggregation. Distribution of egg counts in 10ml urine from individuals for
the two areas in Eastern Zimbabwe shown in Figure 1.3b. (Based on data from Mutapi et al.
(1997)).
1.3 Measuring infection levels
Both prevalence and infection intensity of schistosomiasis in populations are routinely measured
using parasitological methods, which are regarded as the gold-standard of detection for urinary
schistosomiasis. Two or three urine samples are collected on consecutive days from each
individual, and examined microscopically following filtration (Mott 1983). Egg counts are
recorded as the mean number of eggs in a fixed volume of urine (usually 10ml). Whilst this
method is nearly 100% specific, the sensitivity varies, depending upon observer skill, urine
sample size and infection intensity. It cannot detect single-sex infections, since eggs are only
produced by mated females. Egg counts vary throughout the day, peaking at around midday
(Doehring et al. 1983). There are also fluctuations in day-to-day urine egg counts, with zero
counts increasingly likely in lightly infected individuals (Doehring et al. 1983; Savioli et al.
1990; van Etten et al. 1997; Warren et al. 1978). False negatives may lead to significant under-
estimation of prevalence and over-estimation of reinfection rates (de Vlas 1996). Studies on
S. mansoni egg counts from stool samples also reveal considerable variation in intra-individual
egg counts, following a negative binomial distribution (de Vlas et al. 1992). For S. mansoni,
the variation in intra-individual egg counts was found to be constant for different populations
provided the sampling interval was the same, and did not change significantly with infection
intensity (de Vlas 1996). Negative and positive predictive values of tests are affected by infection
prevalence as well as by test accuracy. Population-level infection intensity may be reported as
the arithmetic or geometric mean of individual mean egg counts, or as the arithmetic mean
of ln(egg count + 1) (related to the geometric mean). Some studies report means for positive
individuals only, others for the whole population. Use of different types of mean (arithmetic or
geometric) can affect the apparent age-intensity pattern (Fulford 1994; Mutapi et al. 2003a).
A more direct measure of worm burden sometimes used in epidemiological studies is the
detection of circulating (gut-associated) anodic and cathodic antigens (CAA and CCA), which
can be detected in the blood or urine, and correlate well with worm burden (Agnew et al. 1995).
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Serum CAA levels correlate well with egg output for both S. haematobium and S. mansoni
(Ndhlovu et al. 1996a; Polman et al. 1998), and can identify low level infections in some egg-
negative individuals (Ndhlovu et al. 1996a). Serum CAA levels show lower fluctuation than egg
output (Polman et al. 1998).
The relationship between egg counts and worm burdens is difficult to quantify. Estimates
for the number of eggs produced per mated S. haematobium female vary considerably. One
study of 7 human patients undergoing bladder surgery suggested that an average 200 eggs per
mated female were passed in urine per day (range 3–560) (Cheever et al. 1975). Another study
looking at the number of adult S. haematobium worms and eggs in cadavers in Egypt found an
average of 1.28 viable eggs per 10ml urine per female worm in the genito-urinary tract (Cheever
et al. 1977). Data from this autopsy study suggests that there is lower egg production per
worm in higher density S. haematobium infections (Cheever et al. 1977; Woolhouse 1994a), and
there is evidence for reduced worm fecundity in older human hosts, from comparing levels of
CCA or CAA with egg output (Agnew et al. 1996; Ndhlovu et al. 1996a). For S. mansoni,
egg production and worm burden are linearly related regardless of host age or worm density
(Agnew et al. 1996; Wertheimer et al. 1987).
1.4 Control
Amidst increasing recognition of the severe burden of disease which schistosomiasis causes,
control efforts are being stepped up, with an emphasis upon widespread drug treatment
and vaccine development (Capron et al. 2005; Fenwick et al. 2009; WHO 2001). There has
been a switch in focus from transmission control targeted at the snail intermediate host,
which was expensive and raised environmental concerns, to morbidity control through large-
scale chemotherapy programmes, as effective drugs, particularly praziquantel, have become
affordable (Brooker et al. 2004b; Gryseels et al. 2006). Concerns have been raised about the
sustainability of this approach, which will require ongoing drug treatments to have long-term
benefits (Utzinger et al. 2003a). It is important that control programmes are well-monitored
for ongoing prevalence and intensity of infection and morbidity markers, and to detect any
development of drug resistance (King et al. 2000).
1.4.1 Chemotherapy
Currently, treatment for schistosomiasis mainly relies upon praziquantel. This has been in
use for around 30 years, and has proved to be safe and effective against all the human
schistosomes (McMahon & Kolstrup 1979; WHO 2005). The precise mechanism of action
for praziquantel is unknown, but it alters worm calcium transport, causing paralysis following
muscular contraction, and also causes severe damage to the tegument, working in synergy
with the host immune system (Harnett 1988; Nyazema et al. 1995; Utzinger et al. 2003b).
Praziquantel has little effect on eggs and immature worms, and cure rates for S. mansoni
may be improved by administering a second dose a few weeks later to kill worms which were
immature at the time of the initial treatment (Picquet et al. 1998). Oxamniquine may be used
as a second-line drug in areas where praziquantel has a low cure rate, but is effective only against
S. mansoni (Stelma et al. 1997). Metrifonate, which is effective against S. haematobium, was
used extensively until the 1990s, but has since been withdrawn from the WHO Model List of
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Essential Medicines (Danso-Appiah et al. 2008). Metrifonate treatment has to be given in three
doses over a six week period, making it less amenable for use in mass drug administration (MDA)
programmes than praziquantel, for which a single dose is effective (Danso-Appiah et al. 2008).
Another potential anti-schistosome drug is artemisinin, which acts against schistosomulae, and
works well in combination with praziquantel (Utzinger et al. 2003b); however, it cannot be
used in malarial regions, since it is also an anti-malarial and may induce resistance in malaria
parasites (WHO 2005).
As well as being made available to infected individuals through primary health care systems,
praziquantel has been increasingly used in MDA programmes (Brooker et al. 2004a; Gryseels
et al. 2006). In these preventive chemotherapy programmes, praziquantel is given at a dose of
40mg/kg bodyweight, and is currently mainly targeted at school-age children (Fenwick et al.
2009; WHO 2006). The recommended frequency of treatment depends upon the prevalence
of schistosome infection found in children in sentinel primary schools. Yearly treatment of all
school-age children is recommended for areas with high prevalence (more than 50% prevalence
in sentinel primary schools as assessed by parasitological methods). Biannual treatment of all
school-age children is recommended for areas with moderate prevalence (10–50% prevalence
in sentinel primary schools) and treatment of all school-age children twice during their time
at primary school for areas with low prevalence (<10% prevalence in sentinel primary schools)
(WHO 2006). In areas of moderate and high prevalence, adults from high-risk groups (pregnant
and lactating women, occupationally exposed groups including fishermen and farmers, or entire
communities living in endemic areas) should also be treated (WHO 2006). Strategic timing of
treatment to coincide with low or absent transmission, either following mollusciciding to remove
snails, or in seasons when snail populations are reduced or absent, can increase the impact upon
prevalence.
Cure rates for S. mansoni with a single dose of praziquantel are usually over 70%, although
rather lower rates have been reported in a recently established focus of infection in Senegal
(Picquet et al. 1998; Stelma et al. 1997; Tchuem Tchuente et al. 2001). Variable cure rates
have been reported for S. haematobium following praziquantel treatment, between 50 and
90% (De Clercq et al. 2002; Midzi et al. 2008; Saathoff et al. 2004; Sissoko et al. 2009;
Tchuem Tchuente et al. 2004), but reductions in egg output are consistently high, ranging
between 83–99.9% (Danso-Appiah et al. 2008; De Clercq et al. 2002; King et al. 2000; Midzi
et al. 2008; Saathoff et al. 2004; Sissoko et al. 2009; Tchuem Tchuente et al. 2004). There is
some evidence that eggs continue to be released from the tissues for a few weeks following the
death of adult worms, which may lead to an underestimate of the cure rate, depending upon
when post-treatment infection levels are assessed (De Clercq et al. 2002; Picquet et al. 1998;
Tchuem Tchuente et al. 2004).
Praziquantel tolerance can be selected for in animal schistosome infections (Fallon &
Doenhoff 1994), but, despite variation in cure rates in humans, there is no firm evidence to
date that resistance is developing (King et al. 2000).
1.4.2 Vaccination
Despite extensive research into vaccine candidates for schistosomiasis, none have yet been
approved for use in humans (McManus & Loukas 2008). Although irradiated cercariae can give
up to 70% protection against re-infection in murine studies (Anderson et al. 1999; Hsu et al.
14
1981), no vaccine candidate antigen has yet consistently given more than 50% protection against
infection in mice (Bergquist et al. 2005). The main aim of vaccination is shifting from reducing
infection towards reducing fecundity or pathology, as the focus of schistosomiasis control in
general is moving towards controlling morbidity. Sh28GST has entered Phase III clinical trials
as an anti-fecundity vaccine, and Sm14 has entered Phase I clinical trials (WHO 2005; Wilson &
Coulson 2006). Six other vaccine candidates have been identified in animal models (Bergquist
et al. 2005), and genome mapping and other genetic analysis has enabled new structural proteins
and antigens to be identified (Wilson et al. 2007). Mathematical modelling has suggested that
a vaccine will need to induce long-lived protection as well as a high degree of protection to have
a significant long-term impact upon infection levels (Chan et al. 1997).
1.4.3 Other control measures
In the past, snail control was a major focus of control efforts, with molluscicides widely used.
A three year mollusciciding campaign in St. Lucia gave significant reductions in prevalence and
infection intensity (Goddard & Jordan 1980). However, this is now less popular, due to the toxic
effects on fish (Gryseels et al. 2006). Biological control and habitat alteration (such as weed
removal at water contact sites) are alternative ways of controlling snail numbers. Changing
peoples’ water contact habits should enable the elimination of schistosomiasis, but in practice
this is very hard to do, particularly for children who are responsible for the bulk of transmission.
Provision of safe water supplies, latrines and good health education is essential (Gryseels et al.
2006; Utzinger et al. 2003a).
1.5 Immune responses
Immune responses to schistosomes have been extensively studied both in animal models and
in human populations. There has been considerable debate about the extent to which humans
develop protective immunity against schistosome infection (section 1.5.1), and the mechanisms
which might underlie such protection are still not fully understood. Animal models have
severe limitations in seeking to understand the role and development of protective immunity in
human schistosome infection. Mice, the most frequently used model, cannot be used to identify
relevant immune correlates of protection, owing to fundamental physiological and immunological
differences between mice and humans (Capron et al. 1999; Wilson 1990). The pathways of IgE
antibody production (known to be important in human infection) are quite different between
the two species, and IgG isotypes are not homologous between them (Mestas & Hughes 2004).
Anatomical changes in the liver following primary infection can greatly alter the course of
further infection in mice (Wilson 1990). Rats, while good models for the IgE response, are
non-permissive hosts, meaning that worms are not able to reach sexual maturity, or lay eggs,
so that the influence of these stages on host immunity cannot be assessed (Capron & Capron
1986). Infections of baboons with schistosomes appear to mirror human infection much more
closely, although S. haematobium infections differ in terms of the anatomical location of adult
worms (Nyindo & Farah 1999). Because of these limitations, the following summary focuses
upon human population studies, citing animal and in vitro studies only where the mechanisms
in question cannot be measured in humans.
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1.5.1 Evidence for development of protective immunity in humans
Reduced levels of infection in adults, and the even more striking reduced re-infection rates
in adults after treatment (compared with children) suggest that adults may develop acquired
protective immune responses against schistosomes. In endemic areas, where prevalence has been
constant over a long period of time, the effects of age and previous exposure to infection (which
will affect the development of protective immunity) are difficult to dissociate. Age-related
changes in water contact, although these do often decline in adults, are not sufficient to explain
the disparity in re-infection rates (Hagan et al. 1991; Kabatereine et al. 1999; Wilkins et al.
1987), but other age-related factors (such as hormonal changes or changes in skin composition)
could be responsible for these observations (Gryseels 1994). In areas with recently-established
foci of infection, or endemic areas with a recent immigrant population, the exposure time
is known and independent of host age, so the effects of exposure history and age can be
distinguished (Naus et al. 1999; Ouma et al. 1998; Talla et al. 1992; Webster et al. 1998).
Alternatively, the effects of age and infection history can be distinguished by comparing areas
with different levels of endemic infection (Mutapi et al. 1997).
Some studies support the idea that age itself is important: immigrants who moved into
an endemic area in Burundi showed the same peaked age-intensity profile and age-dependent
reinfection rates as long term residents within a few years of their arrival, and similar patterns
were seen in Senegal, in a recently established focus of infection (Gryseels 1994). The difference
in levels of infection seen between adults and adolescents in the epidemic focus in Senegal,
who had all been exposed to infection for the same length of time, could not be explained by
differences in water contact (Scott et al. 2003). On the other hand, peak shifts between endemic
areas with different levels of infection strongly suggest that acquired immunity is acting as a
function of cumulative exposure rather than of age (Mutapi et al. 1997; Woolhouse 1992b,
1998). Several immune correlates of protection have been identified from re-infection studies
(see section 1.5.4), and there is evidence of earlier changes in the balance of antibodies in more
intensely infected populations (Mutapi et al. 1997), supporting the idea of immune involvement.
This protective immunity appears to develop slowly, as in communities with endemic infection
susceptibility only decreases in older children or adults, despite evidence that individuals are
repeatedly exposed and infected from a young age (Woolhouse et al. 2000).
1.5.2 The immune interaction with different life cycle stages
The human host encounters four distinct stages of the schistosome life cycle: cercaria,
schistosomulum, adult worm and egg, and each stage interacts differently with the immune
system (Dunne & Cooke 2005; Jenkins et al. 2005). These stages differ in their life span
(section 1.1) and gene expression (Jolly et al. 2007). Detecting these distinct interactions is
complicated by the frequent presence within the host of more than one parasite life stage, and
by antigens shared between different schistosome stages (Curwen et al. 2004). These antigens
may be somatic, surface or excretory.
In common with other helminth infections, immune responses to schistosomes are dominated
by Th2 responses (Maizels et al. 1993). These are associated with the Th2 subset of
differentiated T helper cells, which tend to be stimulated by extracellular antigens, and are
characterised by the cytokines they secrete (cytokines are proteins secreted by immune cells
which affect the behaviour of other cells). Th2 cells secrete the cytokines interleukin (IL)-4,
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IL-5, IL-10 and IL-13, and stimulate B cells to produce antibody (Janeway et al. 2001; Maizels
et al. 1993). Eggs are potent inducers of Th2 responses (Pearce 2005), while adult worms are
thought to reduce their stimulation of the immune response through reduced surface antigen
expression and adsorption of host molecules (Skelly & Wilson 2006; Smithers et al. 1969).
Cercariae can stimulate local inflammatory responses in the skin (Jenkins et al. 2005).
1.5.3 What is the target of protective immunity against schistosomes?
Possible outcomes of protective immune responses are killing of cercariae or immature
schistosomulae, killing of mature adult worms, or reduced adult worm fecundity. Human re-
infection studies cannot distinguish which stage of the schistosome life cycle is being targeted
by protective immune responses, since they only look at egg output, which would be reduced
by all three outcomes. There is evidence of all of these being targets of the protective immune
response, from animal, human or in vitro studies, although this varies by schistosome species.
Results for S. mansoni and S. haematobium are discussed below.
Killing of cercariae or schistosomulae
Antibody-dependent cell-mediated cytotoxicity (ADCC) has been identified as a major human
immune effector mechanism against both S. mansoni and S. haematobium schistosomulae in
vitro, with eosinophils the main cell type involved (Butterworth et al. 1975, 1974; Hagan et al.
1985). Several in vitro and murine studies have shown that S. mansoni schistosomulae become
less susceptible to immune-mediated killing (including oxidative killing and ADCC) as they
mature (Ahmed et al. 1997; Mkoji et al. 1988; Moser et al. 1980).
Killing of adult worms
Studies of S. mansoni have demonstrated that adult schistosomes develop a tough outer
membrane which can be rapidly repaired, reduce their surface expression of antigens and adsorb
host molecules onto their surface, as well as producing immune evasion molecules which protect
against oxidative killing by phagocytes (Carvalho-Queiroz et al. 2004; Dunne & Cooke 2005;
Sher & Moser 1981; Skelly & Wilson 2006; Smithers et al. 1969). Significant killing of adult
worms has been shown in infections of cattle with their natural pathogens S. bovis and S. matthei
(both closely related to S. haematobium), and in S. bovis infection in mice (Agnew et al. 1993;
Bushara et al. 1983, 1980; Saad et al. 1980). However, no immune-mediated killing of S. mansoni
or S. haematobium was seen in murine infections (Agnew et al. 1993).
Reduced worm fecundity
Suppression of egg production has been shown in cattle infections with S. bovis and S. matthei,
and in S. haematobium infections in mice (Agnew et al. 1993; Bushara et al. 1983, 1980; Saad
et al. 1980). Transfer of S. haematobium worms from infected to näıve baboons gave rise to an
increase in worm fecundity, which suggested that anti-fecundity immune responses were acting
(Webbe et al. 1976). In contrast, murine infections with S. mansoni showed no evidence of
immune-mediated reduction in fecundity, and transfer of S. mansoni worms from infected to
näıve baboons did not affect their egg output (Damian et al. 1986).
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In vitro studies have demonstrated that IgA antibodies against the S. mansoni antigen
Sm28GST from infected human subjects reduce both worm fecundity and egg hatching
capability (Grzych et al. 1993). In human population studies, some evidence has been found for
reduced worm fecundity in infections with S. haematobium but not S. mansoni. Comparisons
of egg output with levels of circulating cathodic antigen (CAA) (a more direct measure of
worm burden) show that worm fecundity is reduced in older hosts for S. haematobium but
not S. mansoni infections (Agnew et al. 1996). Additionally, autopsy studies looking at
S. haematobium indicated reduced fecundity in more heavily infected patients, although this
could be due to other (non-immune) density dependent mechanisms (Cheever et al. 1977;
Woolhouse 1994a).
1.5.4 Immune responses associated with protection or susceptibility
IgG1, IgG3 and IgE antibodies are able to mediate a killing effect of S. mansoni schistosomulae
by eosinophils in vitro (Gounni et al. 1994; Khalife et al. 1989). Blocking of the IgG1 and
IgG3-mediated ADCC responses by IgG4, IgG2 and IgM has been reported (Khalife et al.
1986, 1989).
High pre-treatment eosinophilia is associated with protection against reinfection with
S. mansoni (Ganley-Leal et al. 2006; Sturrock et al. 1983) and S. haematobium (Hagan et al.
1985). High post-treatment IgE (specific for larval or adult worm antigens) has been associated
with protection against reinfection in a number of human studies for both S. mansoni and
S. haematobium, independently of host age (Butterworth et al. 1996; Demeure et al. 1993;
Dunne et al. 1992a; Hagan et al. 1991; Rihet et al. 1991). Dunne et al. (1992b) found that
individuals with higher levels of post-treatment IgE against a 22kDa antigen in the worm
tegument were highly protected against reinfection. IgE responses to egg antigens give a more
mixed picture, being apparently protective for S. haematobium (Hagan 1992) but associated
with reinfection for S. mansoni (Dunne et al. 1992b). B cells bearing the low-affinity IgE
receptor (CD23) have been associated with protection against re-infection with S. mansoni
(Mwinzi et al. 2009). Worm-specific IgG1 has also been associated with protection against
S. mansoni re-infection (Satti et al. 1996). IgA against the Sm28GST molecule was found to
be protective against reinfection with S. mansoni in a Kenyan population (Grzych et al. 1993).
Several antibody isotypes have been found to be positively associated with reinfection levels
following chemotherapy, including IgM and IgG2 directed against S. mansoni egg antigens
(Butterworth et al. 1988), IgG2 and IgG4 directed against larval S. mansoni antigens (Demeure
et al. 1993) and IgG4 directed against S. mansoni and S. haematobium worm and egg antigens
(Hagan et al. 1991; Rihet et al. 1992). While these isotypes demonstrate blocking activity
in vitro, competing for the same binding sites on eosinophils as the protective isotypes, the
immunoepidemiological evidence for blocking activity in vivo is less convincing (Woolhouse
1994b). The observed patterns of correlation of blocking isotypes with reinfection, blocking
responses peaking earlier than protective responses, and increasing ratios of protective:blocking
antibodies with host age can all be explained if these ‘blocking’ isotypes are in fact neutral but
have a shorter immunological memory than protective antibody responses (Woolhouse 1994b).
Th2 cytokines have also been associated with protection. Pre-treatment IL-5 was inversely
correlated with subsequent reinfection level in one reinfection study with S. mansoni (Roberts
et al. 1993). In another study, levels of IL-4 and IL-5 were both negatively correlated with
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reinfection following treatment for S. haematobium (Medhat et al. 1998), and pre-treatment
S. mansoni -specific IL-5 has been shown to be strongly related to post-treatment IgE levels
(Walter et al. 2006). Low IL-10 and high IFN-γ (associated with Th1 responses, which are
antagonistic to Th2) have also been associated with becoming reinfected (Mduluza et al. 2003;
Medhat et al. 1998).
1.5.5 Population-level patterns of schistosome-specific antibody and
cytokine responses
Studies in human populations have demonstrated that schistosomes induce a wide range of
antibody and cellular responses, with considerable heterogeneity seen between individuals
in terms of the magnitude of particular responses (Mutapi & Roddam 2002), although the
extent of this heterogeneity has not been previously quantified. It should be remembered
that specific humoral or cellular responses to schistosome antigens may represent protective
responses (reducing reinfection, reducing worm fecundity or killing adult worms directly); they
may simply be markers of infection (having no impact upon the pathogen) or they may control or
reduce the impact of other protective responses (for example, suppressive cytokines or blocking
antibodies). Depending upon the longevity of the immune memory of individual responses,
they may correlate with current infection levels or with cumulative exposure to infection. Long-
lasting responses will also tend to increase with host age.
As well as variation in individual responses, variability is seen in the types of schistosome-
specific responses made at a population level. One cross-sectional population study of
S. haematobium adult worm-specific cytokine responses suggested that suppressive immune
responses (with high IL-10) were gradually surpassed by Th2 responses (with increased IL-4
and IL-5) with increasing age, as shown in figure 1.5a (Mutapi et al. 2007). Another study
reported no age-related changes in levels of S. haematobium egg antigen specific IL-4, IL-5, IL-
10 or IFN-γ (Scott et al. 2001). Several studies have shown levels of worm or egg-specific IgE
increasing with age in endemic communities (Butterworth et al. 1996; Dunne et al. 1992a; Hagan
et al. 1991; Mutapi et al. 1997; Ndhlovu et al. 1996b). Different studies have shown schistosome-
specific IgG1 and IgG4 responses either increasing or decreasing with age (Butterworth et al.
1996; Mutapi et al. 1997; Ndhlovu et al. 1996b). Worm-specific IgM has often been reported
to decline with age (Mutapi et al. 1997; Ndhlovu et al. 1996b), but egg-specific IgM has been
reported to increase or decrease with age in different studies (Mutapi et al. 1997; Ndhlovu et al.
1996b). One striking pattern reported for S. haematobium was a very rapid switch with age
from an IgA to an IgG1 response (figure 1.5b), which was characterised by a strong negative
correlation between the two responses at the population level (Mutapi 1997; Mutapi et al.
1998). This antibody ‘switch’ occurred earlier in a more heavily infected population (Mutapi
et al. 1997). Negative correlations between different isotypes in a separate study suggest that
a similar switch occurs (Ndhlovu et al. 1996b), but this type of pattern has rarely been looked
for or reported in other studies of schistosome-specific antibodies.
1.5.6 Effects of treatment on immunity
In vitro and murine studies have demonstrated that praziquantel treatment exposes previously
hidden antigens following drug-induced worm death (Harnett & Kusel 1986; Redman et al.
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Figure 1.5: Age-profiles of S. haematobium-specific immune responses. (a) IL-10 and IL-5
cytokines against whole worm antigen (b) IgA and IgG1 antibodies against egg antigen. Note
that these data come from 2 different studies in Zimbabwe, (a) from Mutoko-Rusike, adapted
from Mutapi et al. (2007), (b) from the Burma Valley, taken from Mutapi et al. (1998).
alter host immune responses (Bergquist et al. 2004; Mutapi et al. 2005, 1998). An array
of changes in antibody responses to adult and/or egg antigens have been reported following
chemotherapy, varying with time after treatment, age, and study location (Corrêa-Oliveira
et al. 2000; Fitzsimmons et al. 2004; Mutapi 2001). While studies often show marked alteration
in antibody isotypes following treatment, the actual isotypes involved vary widely between
studies. Several studies, though not all, report increased levels of anti-egg and/or anti-worm IgE
following treatment, for S. haematobium and S. mansoni (Butterworth et al. 1996; Fitzsimmons
et al. 2004; Gomes et al. 2002; Grogan et al. 1996; Mutapi et al. 1998). Levels of IgG subtypes
and IgA may increase or decrease following treatment (Mutapi 2001; Mutapi et al. 2003b).
Responses to egg and adult antigens do not always correlate with each other, and antibody
levels change with time after treatment (Mutapi et al. 2003b). One study showed a sustained
switch following chemotherapy in children from a predominant IgA-response to S. haematobium
eggs and adult worms to a predominant IgG1 response, which also occurred more slowly with
age in the same population (figures 1.5b and 1.6) (Mutapi 2001; Mutapi et al. 1998). A separate
study showed that the increase in IgE and IgG3 levels seen at 18 weeks post-treatment was
proportional to pre-treatment egg counts (Mutapi et al. 2003b). The magnitude of the increase
in antibody level may reflect previous immunity as well as pre-treatment worm burden, as
significantly increased responses to the Sm22.6 antigen are seen in adults with low S. mansoni
egg counts as well as in heavily infected adolescents, suggesting that in adults a memory response
to previous infection is boosted by treatment (Fitzsimmons et al. 2007). Another study found
that protective IgE responses against S. mansoni post-treatment were associated with high IL-5
levels pre-treatment, suggesting that a pre-existing Th2 environment was required for protective
antibody responses to be developed (Walter et al. 2006).
Treatment has also been reported to boost levels of schistosome-specific Th2 cytokine
responses. Levels of S. haematobium egg and worm-specific IL-4 were increased 5 weeks after
praziquantel treatment (Grogan et al. 1996). Levels of S. mansoni adult worm-specific Th2
cytokines IL-4, IL-5, IL-13 and IL-10 were significantly raised seven weeks after treatment in
one study (Joseph et al. 2004b). In another study, S. mansoni increases in adult worm-specific
IL-5, IL-4, IL-13 and IL-10 and TGF-β were seen 21 days after treatment (Fitzsimmons et al.









































Figure 1.6: Levels of S. haematobium egg antigen-specific IgA and IgG1 in a cohort of 6–15
year olds before treatment, and 18, 24, 30 and 36 weeks post treatment with praziquantel. Data
taken from Mutapi et al. (1998).
transiently decreased one day after treatment, associated with a rapid rise in plasma IL-5 a day
after treatment. As well as striking changes in the antibody isotypes produced after treatment,
changes are seen in the antigens recognised by sera from infected individuals following treatment
(Mutapi et al. 2005). Drug-induced anti-schistosome responses do differ from naturally-acquired
responses, due to the different patterns of antigen exposure involved (Corrêa-Oliveira et al.
2000; Mutapi et al. 2005). Cluster analysis of population antibody responses suggests that in
natural infection, a modified Th2 response (dominated by IgG1, IgM and IgG4) is developed,
while following treatment, individuals gain a balanced Th1/Th2/Treg profile, with high levels
of IgG1, IgM and IgE (Maizels & Yazdanbakhsh 2003; Mutapi et al. 2005).
1.6 Measuring immune markers
Antibody and cytokine levels are both measured by enzyme linked immuno-sorbent assay
(ELISA). Levels of non-specific cytokines are measured directly in blood samples (Milner et al.
2010), and antigen-specific cytokine responses are assessed by measuring cytokine levels in the
supernatants from whole blood re-stimulations with schistosome antigens (Joseph et al. 2004a;
Mutapi et al. 2007). Cytokine concentrations in the blood or supernatant are calculated by
interpolation from a standard curve which is constructed using cytokine samples of known
concentration. Concentrations of total antibody isotypes can be calculated in a similar way.
Levels of specific antibody may be measured directly in the blood using an ELISA with the
antigen of interest, but these are reported as optical densities (relative measures of intensity
from the ELISA) rather than absolute concentrations, since there is no straightforward way to
calculate concentrations of antigen-specific antibodies. These optical densities are not directly
comparable between different studies, due to a lack of standardisation of laboratory protocols
(Mutapi 1997).
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1.7 Hypotheses for the slow development of protective
immunity in human schistosomiasis
Several different hypotheses have been put forward to explain why protective immunity develops
slowly in human schistosome infection. These are outlined below. The first three are explored
further in this thesis.
1.7.1 Parasite-induced immunosuppression
There is growing evidence that schistosomes are able to modulate the host immune response,
suppressing non-specific responses to bystander antigens and other pathogens as well as specific
responses to schistosomes (reviewed by Maizels & Yazdanbakhsh (2003)). In the mouse model of
S. mansoni infection, suppression of immunopathological responses to trapped eggs in chronic
infection has been clearly shown (King 2001c), and suppressor activity has been transferred
from chronically to acutely infected mice by adoptive transfer of spleen cells (Weinstock &
Boros 1981). In humans, experiments using peripheral blood mononuclear cells from chronically
infected individuals have shown that schistosome antigen-specific proliferation and cytokine
production are reduced in chronic infection (Araújo et al. 1996; Colley et al. 1986; de Jesus
et al. 1993; Grogan et al. 1998a; King et al. 1996; Viana et al. 1994). This does not appear to
be due to tolerance (deletion of antigen-reactive T cells), since antigen-specific responses can be
restored in vitro, either by neutralization of interleukin (IL)-10 or by culture with dendritic-like
cells (which improve antigen presentation by unelucidated contact-dependent and -independent
mechanisms) (Araújo et al. 1996; Corrêa-Oliveira et al. 1998; Grogan et al. 1998b; King et al.
1996; van den Biggelaar et al. 2000). Antigen-specific proliferation and interferon-γ production
in chronically infected individuals are inversely correlated with infection intensity (de Jesus
et al. 1993; Grogan et al. 1998a), and schistosome antigen-specific IL-10 – a possible marker
for suppression – has been found in some studies to be positively correlated with infection
intensity (Mutapi et al. 2007; Reimert et al. 2006). This suggests that the degree of suppression
is related to infection intensity (as estimated from egg counts in urine or faeces). Schistosome-
specific IL-10 has also been associated with the suppression of non-specific cell proliferation and
responses to bystander allergen antigens in humans (Grogan et al. 1998a; van den Biggelaar et al.
2000). Proliferative and cytokine responses to schistosome antigens are restored by praziquantel
treatment, which kills adult worms (Grogan et al. 1996; van den Biggelaar et al. 2004), implying
that suppression is induced by worms.
There is also evidence that cercariae can downregulate host immune responses (Jenkins et al.
2005). Murine studies have shown that IL-10 is induced soon after exposure to schistosome
cercariae (He et al. 2002; Kumar & Ramaswamy 1999; Ramaswamy et al. 2000). The presence
of IL-10 enhances cercarial migration through the skin (Ramaswamy et al. 2000). Cercarial
excretory/secretory products and molecules in the cercarial glycocalyx have both been shown to
enhance cercarial survival at local skin sites (Fallon et al. 1996; Harn et al. 1989). Recent studies
have suggested that cercariae can also have systemic immunomodulatory effects, affecting




Praziquantel kills adult worms, exposing the immune system to previously hidden antigens
(Harnett & Kusel 1986; Redman et al. 1996), and enhancing immune recognition of specific
antigens (Mutapi et al. 2005). The antibody ‘switch’ observed in children following treatment
mimics changes which occur naturally with age in endemic populations (Grogan et al. 1996;
Mutapi et al. 1998), suggesting that in the absence of chemotherapy, these changes are triggered
by natural worm death (Mutapi et al. 1998; Woolhouse & Hagan 1999). If dying worms are
the main trigger for protective responses, then in natural infections the necessary exposure to
dying worms might be expected to be delayed for several years after initial infection, due to the
long schistosome adult worm life span (Woolhouse & Hagan 1999). If the protective response
stimulated by this release of antigens from dying worms reduces subsequent re-infection, it is
proposed that the protective response targets shared epitopes on invading cercariae. In this
scenario, it is suggested that the immune system has insufficient exposure to these antigens
to stimulate a protective response following cercarial exposure alone, either due to reduced
expression levels on cercariae or short exposure time (Fitzsimmons et al. 2007; Woolhouse &
Hagan 1999). In S. mansoni, one candidate antigen for this type of immune mechanism is
Sm22.6, which is expressed at high levels by adult S. mansoni worms, at much lower levels on
cercariae and not at all by the egg stage. The IgE response to Sm22.6 is strongly boosted by
treatment of infection, and has been shown to be associated with protection against re-infection
(Fitzsimmons et al. 2007; Webster et al. 1996). If, on the other hand, responses generated by
these previously hidden adult antigens are assumed to affect the adult stage, either leading to
the killing of adult worms or reduced fecundity, then it might again be assumed that surface
expression of these antigens is too low to trigger a protective response.
Both the mean worm life span and the distribution of worm survival times are expected
to affect the timing of exposure to antigen from dying worms. Maximum life spans of up
to 30 years have been reported for S. mansoni and S. haematobium (Berberian et al. 1953;
Christopherson 1924; Fairley 1931; Harris et al. 1984), but this should not be confused with the
average worm life span, which is considerably shorter. The mean life span of adult schistosomes
in their human hosts has been estimated at between 3 and 10 years from studies with interrupted
transmission (Goddard & Jordan 1980; Vermund et al. 1983; Warren et al. 1974; Wilkins et al.
1984). There is little data available to determine the distribution of worm survival times. In
studies with interrupted transmission, it has not been possible to estimate the shape of the
worm survival curve due to egg output variability and insufficient follow-up times, and survival
has been assumed to be exponentially distributed. However, one study did report S. mansoni
egg output declining more rapidly with time after the cessation of transmission, suggesting
non-exponential worm survival (Goddard & Jordan 1980). Data on S. haematobium survival
in experimental animal hosts is limited; data from some studies appears to be consistent with
exponential worm decay (Cheever et al. 1988, 1974), whilst other studies suggest that worm
burdens decline more slowly initially (Webbe et al. 1974).
1.7.3 Antigen threshold
It has been proposed that individuals must be exposed to a certain threshold level of schistosome
antigens before they begin to mount a protective immune response (Mutapi et al. 2008;
Woolhouse & Hagan 1999). This is implicit in the dying worms hypothesis (with the assumption
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that low levels on cercariae or on the surface of living worms are insufficient to trigger a
protective response), but is explored explicitly in this hypothesis. This antigen threshold might
be supposed to rely upon current levels of antigen or cumulative exposure to antigen. Mutapi
et al. (2008) showed that groups of people from areas with endemic S. haematobium infection
recognise more schistosome antigens, and produce higher levels of IgG directed against them,
with increasing age or infection level. This is consistent with the hypothesis that these different
antigens need to be experienced at certain threshold levels before they trigger an antibody
response, since these people are all likely to have been regularly exposed to infection from a
very early age. In malaria, class switching in antibody responses against malarial merozoite-
associated antigens has been shown to be associated with cumulative exposure to infection
(Tongren et al. 2006), hinting at a similar mechanism.
At a cellular level both B and T cells require minimum threshold levels of receptor binding in
order to be activated (Carter & Fearon 1992; Viola & Lanzavecchia 1996), which could explain
how a threshold based upon current levels of antigen might work. A requirement for a threshold
level of cumulative antigen exposure could represent a succession of cellular activation and
expansion events that are required upstream of antibody production, particularly for antibody
class switching. This could include repeated T cell activation and accumulation of a polarised T
cell response leading to a change in the cytokine environment, which is a strong determinant of
antibody class switching. The Th2 cytokines IL-4 and IL-13 induce IgG4 or IgE class switching
by B cells (Capron et al. 1992; Jeannin et al. 1998), and the Th1 cytokine interferon-γ inhibits
IgE production (Capron et al. 1992). The regulatory cytokine IL-10 inhibits class switching
to IgE, and can induce IgA, IgG4 or IgG1 production, depending upon which other cytokines
are present (Beniguel et al. 2003; Jeannin et al. 1998). There is antagonism between different
cytokine responses, and the interactions between cytokines have highly nonlinear dynamics
(Abbas et al. 1996; Callard et al. 1999). Due to these non-linear interactions, mathematical
models have predicted that with repeated antigen exposure, it is possible to see a delayed but
rapid change in the cytokine balance over time (Schweitzer & Anderson 1992a).
1.7.4 Multiple strains
Theoretical work has suggested that responses must be generated against several different
schistosome strains to gain full protection, taking time to develop as individuals are exposed to
successive strains (Galvani 2005). A high degree of genetic variability has been demonstrated
within S. haematobium populations, from both snail and human hosts (Brouwer et al. 2001;
Davies et al. 1999), but antigenic differences have not yet been studied. Since this hypothesis
already has a good theoretical basis, and there is no available data on antigenically-distinct
strains with which to test it, it is not further considered in this thesis.
1.8 Mathematical modelling of helminth infections
Mathematical modelling is a valuable tool in studying complex host-pathogen interactions such
as human schistosomiasis. To be useful and relevant, models should make use of as much field
and laboratory data as possible “otherwise, theory soars free of the constraints of data and
experiment and field measurement simply contribute to an ever expanding sea of descriptive
detail” (Anderson 1998). Many different types of mathematical models have been used to
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aid understanding of schistosome infection and other helminths. The structure and type of
model used depends upon the type of questions that are being asked, and the data available to
parameterise or validate them.
In deterministic models, there is no allowance for chance events, so that there is only
one possible outcome for a particular set of parameters and starting conditions (Garnett
2002). Deterministic models composed of coupled differential equations can provide good
approximations to disease dynamics in large populations (Anderson & May 1991a; Chan et al.
1999). Chance is taken into account in stochastic models, so that a range of different possible
outcomes can occur for a single set of parameters (Garnett 2002). Individual based models
(IBMs) are fully stochastic models which simulate the behaviour of individuals. In infectious
disease modelling, they can track individual births and deaths and infection events for hosts, and
even for individual parasites (Habbema et al. 1996). IBMs allow large amounts of variability
to be taken into account, but are much more computationally intensive than deterministic
models (requiring multiple repeated simulations for each parameter set), and are harder to
analyse mathematically (Chan et al. 2000). However, increasing computing speed and power
has allowed much more widespread use of stochastic models (Garnett 2002), and they have a
valuable role to play in the modelling of helminth infections, where the distribution of infection
(and antibody) between individuals is of interest.
1.8.1 Modelling of transmission
A number of models of schistosome transmission have been developed which track the
mean number of schistosomes worms per person and the prevalence of patent snail infection
(Barbour 1996; MacDonald 1965; Woolhouse 1991). Further additions to these transmission
models have included that of a pre-patent period for snails, density dependence within the
human host, explicit modelling of snail and larval population dynamics, and worm mating
probabilities (Barbour 1996; Woolhouse 1991). The basic reproductive rate, R0, is defined for
macroparasites (pathogens which do not undergo direct replication within their primary host)
as the average number of mature female offspring produced by a single mated female worm over
her reproductive life span, in the absence of any density dependent constraints (Halloran 2001).
R0 determines whether or not a pathogen can become endemic in a particular setting (it must
exceed 1 for this to occur), and also determines the magnitude of the control effort which is
required to eradicate it (Halloran 2001). Transmission models have been used to give an estimate
of 4–5 for R0 for S. haematobium (Woolhouse et al. 1996). Models including heterogeneities in
water contacts both between individuals and between sites have shown that R0 may be even
larger than these earlier estimates (Woolhouse et al. 1998). It has generally been assumed in
previous models that individuals retain a set level of exposure for life relative to others (Chan
& Isham 1998; Woolhouse et al. 1998). However, other models have demonstrated that the
extent of prediposition can have a substantial impact upon the population-level distribution
of infection, (Quinnell et al. 1995), and in seeking to account for observed levels of infection
aggregation, it will be important to take this into account.
Other models focussing upon explaining patterns of infection in human populations with
endemic infection have assumed that infection rates remain constant over time, rather than
model transmission explicitly (Duerr et al. 2003a; Woolhouse 1992b). Similar models have been
developed which describe prevalence rather than mean infection intensity (Woolhouse 1998).
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1.8.2 Models including acquired immunity
In models of schistosomiasis and helminth infections
Immunity has frequently been modelled as a single parameter, related to cumulative worm
burden, with protection being either life-long or decaying over time. A successful approach
has been to adapt the basic immigration death model to include acquired immunity as a
density dependent process with memory (Anderson & May 1985; Roberts & Grenfell 1991;
Woolhouse 1994a). As well as tracking worm burden with age, ‘experience of infection’
(related to cumulative exposure with some immune attrition over time) is modelled, and
resistance is related to this experience level (Woolhouse 1992b). A limitation of this approach
is relating these mathematical variables to real immunological responses. It is suggested that
‘experience of infection’ may be correlated with the number of specific memory cells, while
‘resistance’ is correlated with levels of protective antibodies or eosinophilia (Woolhouse 1994a).
Different schistosome stages can trigger the immune response in these models, by relating
infection experience to cumulative exposure to larvae, adult worms or eggs (Woolhouse 1994a).
Resistance may be modelled as reducing susceptibility, increasing worm death rates or reducing
worm fecundity. When eggs are included in the model, egg output has been assumed to be
proportional to worm burden (Chan et al. 2000; Woolhouse 1994a). This approach has been
adapted for stochastic models, with immunity modelled as a discrete variable (Chan et al. 2000).
Galvani (2005) modelled strong immunity developing against numerous individual strains to
generate a similar overall age-related pattern of infection burden.
Despite the simplicity with which the immune responses are represented in these models,
they have been able to elegantly demonstrate several phenomena, including peak shifts, the
expected changes with age in the correlation of a protective response with egg counts, and
the inconsistency of population-level data with the blocking antibody hypothesis (Woolhouse
1992b, 1994b).
A different approach has been modelling specific within-host immune mechanisms. A sub-
section of the immune responses, including T cell and cytokine dynamics, have been explicitly
modelled along with host parasite burden (Austin & Anderson 1996). This approach has
been used to look at the effects of epitope variation on immunodominance (Austin & Anderson
1996), and at the complex relationships between parasite level, T cell proliferation and cytokine
production (Schweitzer & Anderson 1992b). However, these models have become outdated as
understanding of the immune responses involved has changed over recent years, and currently
there is a lack of within-host data from humans with which to test this type of model.
In models of other infectious diseases
Immune responses have been included in a large number of different models of both within-host
and population-level dynamics of other infectious diseases. The level of immune detail included
in these models has been partly driven by the data available, the research question being asked,
and how well the immune response to a given infection has been characterised. In population-
level models of viral or bacterial epidemics, immunity is often included as a compartment of
‘recovered’ or immune individuals, whose immunity is either lifelong or wanes over time (Earn
et al. 2000; Grassly et al. 2005). In macroparasite models of infection intensity, immunity is
more usually included as an additional compartment describing a level of partial immunity
(Anderson & May 1985), as described in the previous section on helminth models.
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Within-host models including CD4+ and CD8+ T cells have been used to further the
understanding of the dynamics of a range of viruses, including hepatitis B and C, CMV, HTLV,
SIV, and particularly HIV (Asquith et al. 2009; Perelson 2002; Ribeiro 2007). These models
rely upon detailed data on infection and T cells over time within the same individuals or
use data from in vivo T cell labelling. Some models have also included B cell kinetics and
isotype class-switching in response to viral infections (Funk et al. 1998). For malaria, where
the immune markers of protection are less well characterised (similar to the current situation
for schistosomiasis), within-host models have tended to include more general representations
of immune responses. Multi-strain models fit to time-series parasitaemia data have included
variant-specific and variant-transcending responses (Molineaux et al. 2001; Paget-McNicol
et al. 2002), or specific antibody responses (with a threshold parasite load required to trigger
them)(Paget-McNicol et al. 2002). Recent models incorporating immunity to malaria into
population-level transmission models have included immune responses in a phenomenological
way, related to cumulative exposure or age (Filipe et al. 2007; Maire et al. 2006). These models
were fit to infection prevalence data, not to data on immune markers.
Data on within-host T or B cell dynamics are not available for schistosome infection, so
detailed within-host models cannot currently be fitted to data; however, cross-sectional data on
antibody responses are available. In this thesis, B cells rather than generic immune responses are
modelled, and models are tested for their ability to reproduce qualitative patterns seen across
different specific antibody responses (which could not be done in models with only generic
representations of immune responses).
1.8.3 Models incorporating control measures
A number of models have been used to assess the effects of control measures (Woolhouse 1992a).
Models can assess how hard eradication would be to achieve, by looking at the effect on R0.
Alternatively, models may assess the rate of return to endemic levels following the intervention.
Such models can be used for cost-benefit analysis, to advise local policy makers (Woolhouse
1992a).
A number of models have looked at the effects of chemotherapy, either modelling it as an
increased worm death rate (assuming frequent treatment) or as discrete reductions in worm
burden (Anderson & May 1985; Chan et al. 1996, 1999; de Vlas et al. 1996). Two very
different simulation approaches which have been used to predict the effects of chemotherapy in
specific populations are the EpiSchisto and Schistosim programmes (Chan et al. 1999; de Vlas
et al. 1996). The EpiSchisto model used a deterministic framework to predict the prevalence
of infection following treatment, and was validated using data from Zanzibar. The model
only required data on initial conditions, and was able to predict post-treatment prevalence
well, especially on larger population scales, although it performed less well at higher infection
prevalence (Chan et al. 1999). Schistosim is a fully stochastic microsimulation model, requiring
a large number of parameters to be estimated. It was used to make predictions about the effects
of chemotherapy in Burundi, and was able to predict short term effects very well, but not long
term effects (de Vlas et al. 1996). This lack of ability to predict long-term effects may have arisen
from changes in transmission following treatment or ageing of the sampled population (neither
of which which were taken into account by the model), or because the effects of treatment on





































































Figure 1.7: Output from an immigration-death model, showing changing parasite burden with
age: (a) with infection rate declining exponentially with age starting at level indicated, no
immunity (after Woolhouse (1992b) (b) as (a), with age at first exposure inversely related to
infection rate (as in Fulford et al. (1992)) (c) with constant infection rates as indicated, with
immunity included (after Woolhouse (1992b)
should be considered in future modelling of treatment of schistosomiasis.
Assumptions about immunity can make a big difference to such models. One model showed a
progressively shorter and slighter impact of treatment with stronger and longer-lived immunity
(Chan et al. 1996). This was because, to keep prevalence constant in the model, increased
immunity had to be balanced by a higher value for R0. If chemotherapy is assumed to be
removing the stimulus for protective immunity, then it can lead to transient increases (or
‘overshoots’) in infection above pre-treatment levels after treatment ceases (Chan et al. 1996).
This model assumed that the antigens stimulating protective immunity came from live adult
worms, which are removed by treatment. However, if this antigen is assumed to come from
dying worms (section 1.7.2), then treatment is expected to boost protective immunity, and
different long-term effects on infection may be seen. This has not been modelled previously.
Several models have assessed the hypothetical effects of schistosome vaccination (Chan et al.
1997; Woolhouse 1995). Assumptions about both natural and vaccine-induced immunity are
crucial for these models, and will need to be reassessed as the biological understanding of
immunity develops. However, these models are able to make several solid predictions. They
show that the type of vaccine-induced protection (reducing susceptibility or egg output) may
not make much difference to population level effects, in terms of subsequent infection intensity,
and age of peak intensity (Chan et al. 1997). The models also demonstrate that increasing the
duration of protection will have a greater impact than increasing the degree of protection, and
that using vaccination in combination with chemotherapy will have the greatest impact upon
worm burdens both short-term and long-term (Chan et al. 1997).
1.8.4 Taking helminth models to data
Different approaches have been taken to challenging these models with data. A number of
studies have attempted to reproduce qualitative patterns seen in field data (Chan et al. 2000;
Duerr et al. 2003a; Fulford et al. 1992; Galvani 2003; Woolhouse 1992b). These studies have
usually only attempted to reproduce one or two patterns at a time. Such patterns can often
be reproduced by several different models which imply different underlying mechanisms (Duerr
et al. 2003a). A case in point is the peaked age-intensity curve seen in populations with endemic
schistosome infection. This can be reproduced by permitting the rate of infection to decline
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exponentially with age, or to vary with age as a convex pattern (based on observed water contact
rates), by including host heterogeneity coupled with parasite-induced host mortality, or with
the inclusion of an acquired immunity process related to cumulative worm burden (even with
age-constant exposure) (Duerr et al. 2003a; Fulford et al. 1992; Woolhouse 1992b; Woolhouse
et al. 1994). Requiring models to also reproduce additional patterns can distinguish between
some of these possibilities. Models with declining rates of infection with age cannot reproduce
the peak shift unless the age at first exposure also varies with the infection prevalence (figure
1.7 (a) and (b)); (Fulford et al. 1992; Woolhouse 1992b). Models with acquired immunity can
also reproduce the peak shift (Woolhouse 1992b) (figure 1.7c).
Aggregated infection can be generated by including variability in host susceptibility or
exposure, or if infection is modelled as a ‘clumped’ process, where there is aggregation in
the number of worms acquired per contact (Duerr et al. 2003a). Density-dependent processes,
including acquired immunity related to previous exposure, reduce infection aggregation (Duerr
et al. 2003a; Galvani 2003). Immune responses targeting re-infection have been shown to reduce
aggregation to a greater extent than anti-fecundity responses (Galvani 2003), and models have
been used to show that aggregated host exposure is much more able to explain observed levels
of infection aggregation than heterogeneity in individual immune responses (Chan & Isham
1998).
Other studies have assessed the ability of models to reproduce more quantitative patterns,
based on large data sets for particular populations. De Vlas et al. (1996) assessed the ability of
their model to reproduce population prevalence of infection, and of different levels of infection
at multiple time points after treatment. Chan et al. (1999) assessed the ability of their model
to reproduce school- and district-level prevalence measured at five different time points after
treatment using likelihood methods. Another approach that has been taken is formal fitting of
a model to population data (Woolhouse et al. 1996).
A different approach which has not yet been used for helminth modelling but which could be
a useful tool for distinguishing between different mechanisms giving rise to observed patterns is
pattern-oriented modelling (POM). This has been developed in ecology for agent (or individual)-
based simulation models (Grimm et al. 2005). In this approach, models are identified which
can reproduce multiple patterns observed in real systems at different levels or scales. This can
guide the design of model structure and aid parameter estimation. In very different settings,
POM has been used to discriminate between different possible model structures and to vastly
narrow down potential parameter ranges and combinations (Janssen et al. 2009; Rossmanith
et al. 2007; Swanack et al. 2009; Wiegand et al. 2008). This approach allows both quantitative
and qualitative patterns to be considered, and the use of multiple different patterns makes it
less likely that models including different biological processes will be able to reproduce all of
these patterns. The pattern-oriented approach used in this thesis is outlined in appendix A.
Previous modelling work has generally focussed upon reproducing patterns of infection
intensity rather than markers of the immune response (an exception being Woolhouse (1992b),
who looked at correlations between infection and antibody). With increasing amounts of data
available on patterns of schistosome-specific immune markers (section 1.5.5), it is of interest to
investigate whether models can also reproduce these patterns.
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1.9 Aims
The aims of this study were:
1. To characterise and quantify robust patterns of infection and specific antibody responses
in populations with endemic S. haematobium infection which could be used to test
mathematical models. In particular, to identify quantitative limits for infection patterns
which have previously been used for qualitative modelling, and to characterise antibody
patterns which have not been used in modelling studies before, including the antibody
switch.
2. To develop mathematical models of specific immune responses to schistosomes which
could be used to predict population-level patterns of infection and antibody, building
upon earlier model frameworks for helminth immunoepidemiological models to incorporate
explicit immune pathways and allow different distributions of worm survival.
3. To use these models in a pattern-oriented modelling approach (outlined in appendix
A) to formally test for the first time whether the following hypotheses for the slow
development of protective immunity against schistosomes were consistent with population-
level patterns of infection and antibody:
• Worm-induced immunosuppression/immunomodulation of protective host responses
will delay the development of protective responses
• Exposure to dying worms is necessary for the development of protective immunity
• A threshold level of antigen exposure must be exceeded before a protective immune
response can be mounted
4. To use models in which dying worms stimulate protective immune responses to predict
the impact of mass treatment programmes upon the development of natural protective




In chapter 2, patterns in field data for both infection intensity and schistosome-specific antibody
responses are analysed in more detail to draw up a set of robust criteria against which models
can be tested.
In chapter 3, deterministic models including a single protective antibody response are used
to explore the ability of models including suppression, dying worms or an antigen threshold
to delay the development of protective immunity and reproduce peaked infection curves and a
peak shift.
In chapter 4, deterministic models are used to identify the mechanisms capable of explaining
the antibody switch as well as the peaked age-intensity curve and the peak shift. Models with
two antibody responses are used to systematically explore the potential role of different life
cycle stages providing antigen for the two responses, cross-regulation between the two antibody
responses and an antigen threshold.
In chapter 5, stochastic individual based models with cross-regulation or an antigen threshold
are used to further discriminate the ability of selected models which were successful in the
deterministic model analysis to reproduce observed aggregation of infection and antibody co-
distributions, and observed patterns of antibody after treatment.
In chapter 6, model structures and parameter combinations for which all of the patterns of
infection and antibody were reproduced are used to make predictions about the impact of
large-scale treatment programmes upon the development of protective immunity and subsequent
impact upon infection levels, both during these treatment programmes and after their cessation.
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Chapter 2
Patterns in field data
2.1 Introduction
In using mathematical models to understand the development of protective immunity in human
schistosomiasis, it is important to first characterize the key patterns of infection and immune
markers seen in field data, which must be replicated by a successful model. Previous helminth
modelling work has mainly focussed on reproducing patterns of infection intensity, including
age-related changes in both mean levels of infection and the distribution of infection (Anderson
& May 1985; Chan & Isham 1998; Fulford et al. 1992; Woolhouse et al. 1994). Correlations
between infection intensity and antibody have also been studied (Woolhouse 1992b). In addition
to looking at distributions of infection, my analysis will also attempt to reproduce patterns of
antibody distribution and correlations between different antibody responses.
A wide range of immune cells and molecules have been measured with the aim of identifying
immune correlates for protection in schistosomiasis, including antibody isotypes (both antigen-
specific and total levels), cytokines (background levels in sera, or levels produced after re-
stimulation of whole blood or peripheral blood mononuclear cells with specific antigens), as
well as numbers of different cell types (such as eosinophils and T cell subtypes) (Butterworth
et al. 1996; Demeure et al. 1993; Hagan et al. 1985; Medhat et al. 1998; Mutapi et al. 2007). As
several different responses have been associated with reduced re-infection rates after treatment,
it seems unwise to attempt to fit models to a single immune variable. I have chosen instead
to develop models which replicate qualitative and semi-quantitative patterns seen in the field
data.
Of the data available to me (on antibody responses, cytokines and some eosinophil data),
I have decided to focus upon antibody responses. These have been well characterised in the
literature and have a clearly defined cellular source. From a modelling perspective, the B cell
maturation pathways and production of antibody are much more clearly defined than those
leading to production of cytokine (which can come from a variety of cellular sources) and so
can be more confidently represented in some detail. Additionally, antigen-specific antibody
can be directly detected in sera. Measures of antigen-specific cytokine levels use an indirect
assay where cells are re-stimulated ex vivo, meaning that these represent a potential cellular
response to a particular antigen preparation rather than directly corresponding to an actual
cytokine response made in vivo. Background cytokine levels in sera are generally very low
and are not specific for schistosomes but could be stimulated by any other pathogens present
32
in the host. The main drawbacks of using antigen-specific antibody data are that, firstly, it
is not possible to measure actual concentrations, and the optical densities which are reported
are not directly comparable between different studies in which different protocols are used,
and secondly, there is some uncertainty surrounding where negative cutoff values lie (i.e. at
what level of measurement there is actually no antibody being made – this is also an issue for
cytokine data (Uh et al. 2008)). There are seven main secreted human antibody isotypes (IgA,
IgE, IgM, IgG1, IgG2, IgG3 and IgG4), which have been measured for a number of different
schistosome antigens and antigen mixtures. None of these isotypes have as yet been exclusively
associated with protection against schistosomiasis and there is not an easy way to amalgamate
the different isotype data into a single variable. Therefore, rather than characterise specific
isotype responses, my aim here is to identify broad patterns in the antibody data which can be
replicated by a model.
In this chapter, I have reviewed the established patterns for infection and antibody
which have been published by other authors (section 2.1.1), and then carried out additional
analysis of infection and antibody data for endemic Schistosoma haematobium, with the aim
of quantitatively characterizing features of the age-intensity profile (section 2.3.1), age-related
distributions of both infection and antibody (sections 2.3.2 and 2.3.3), and the post-treatment
antibody switch (section 2.3.4).
2.1.1 Previously identified patterns for infection and antibody
Cross-sectional studies in populations with endemic infection of all of the major human
schistosome species consistently show that mean levels of infection (estimated from egg output
in stool or urine) follow a convex or ‘peaked’ curve with host age, with peak levels of infection
intensity occurring in childhood and lower levels of infection found in adults (Clarke 1966;
Fisher 1934; Fulford et al. 1992). Prevalence of infection also tends to follow a peaked curve
with host age but does not decline as rapidly as infection intensity in older individuals (Mutapi
et al. 2007).
Mathematical models predict that if acquired immunity with memory of previous pathogen
exposure is acting to reduce levels of schistosome infection, then in areas with higher rates of
infection, the peak level of infection will occur at a higher level and at a younger age than in
areas with lower infection rates, a phenomenon termed the ‘peak shift’ (Woolhouse 1998). This
has been demonstrated for infection curves for S. mansoni in Kenya (Fulford et al. 1992) and
for prevalence curves for S. haematobium in Zimbabwe (Woolhouse et al. 1991).
Schistosomes are not equally distributed between their hosts: within an endemic population,
a few individuals will carry the majority of parasites, with most people having very light or
no infection at a given moment in time (Chandiwana et al. 1991; Guyatt et al. 1994; Mutapi
et al. 1997). This is called an aggregated or overdispersed distribution, and has also been
reported for a range of other parasitic species (Basáñez & Boussinesq 1999; Bundy et al. 1988).
Chan & Isham (1998) concluded from their modelling work that this aggregation can mostly
be explained by differences in infection rates, and other modelling exercises have also tended
to assume this as the main source of aggregation in infection levels (Galvani 2003; Woolhouse
et al. 1994).
Age profiles of schistosome-specific antibodies vary somewhat between different studies.
Antibody levels also tend to be aggregated between individuals (Mutapi & Roddam (2002),
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section 2.3.3) and different isotypes are often highly correlated. One pattern to emerge in two
separate studies of S. haematobium in Zimbabwe is the clustering of different isotypic responses
into two different age-related patterns – one group increasing with age (including IgE against
adult worm antigen) and another group declining with age (Mutapi et al. 1997; Ndhlovu et al.
1996b).
Another pattern previously reported for schistosome-specific antibody is a ‘switch’ from an
IgA to an IgG1 response directed against schistosome egg and adult worm antigen preparations
at both a population and an individual level, occurring around age 14-16 (Mutapi et al. 1998).
This switch (from egg-specific IgA to IgG1) was also reported to occur in younger individuals
following praziquantel treatment (Mutapi et al. 1998).
2.1.2 Additional patterns and parameters to be identified
The convex age-intensity curve is always seen for S. haematobium in endemic populations, and
can be qualitatively reproduced in models through a variety of mechanisms (Fulford et al. 1992;
Woolhouse 1992b). For more quantitative analysis, I wanted to determine the age-range over
which the peak in infection intensity occurs, and to what extent infection is reduced in adults
relative to the peak level seen.
I also wanted to get an estimate of typical levels of aggregation in both infection and
antibody, and see how this varied with host age. I looked at patterns of co-distribution
for different antibody isotypes, to determine how widespread the antibody switch pattern is
(referred to in section 2.1.1), using correlation and percentile cutoffs as alternative ways of
characterizing these patterns. Finally, I quantified the extent and longevity of the reported
antibody switch following praziquantel treatment.
Analysis framework for chapter 2
• The aim of the analysis in this chapter is to
– Identify robust patterns in field data on infection intensity and antibody
– Determine upper and lower bounds on quantitative patterns
– Use these patterns to draw up criteria
• In subsequent chapters, models will be tested against these criteria, using the pattern-
oriented modelling approach (see appendix A)
• Data used is for S. haematobium from studies in Zimbabwe and other published studies
from Africa
• Patterns analysed:
– shape of age intensity curve (age and relative height of peak)
– aggregation in infection
– aggregation in antibody responses
– dichotomous relationship between antibody responses
– changes in antibody levels after treatment
• Even qualitative criteria, or criteria with large uncertainty, can be powerful in
discriminating between different models, particularly when a number of different
criteria are used together.
34
2.2 Data sources and methods
2.2.1 Field data
Data on S. haematobium infection intensity was taken from (pre-treatment) baseline studies of
six Zimbabwean populations from three different field studies: Valhalla and Kaswa were both
part of the Burma Valley study conducted in 1994 (Mutapi et al. 1997); the Mutoko-Rusike
study was conducted in 2003 (Mutapi et al. 2007), and Magaya, Chipinda and Chitate were
all part of the Murehwa study conducted in 2008/2009 (unpublished data). These were all
school-based studies, with additional participation of adults from the local community. There
was additional recruitment of pre-school children with their parents in the Chitate population.
Infection intensities were calculated using the arithmetic mean egg count from two or three 10ml
urine samples collected on consecutive days, processed using the urine filtration method (Mott
1983). Antibody data for the main analysis came from the Burma Valley study (Valhalla and
Kaswa), with some additionally coming from the Mutoko-Rusike study. Antibody data for the
post-treatment switch came from the Burma Valley study. Antibodies specific for different crude
homogenates (whole worm homogenate (WWH), schistosome egg antigen (SEA) or cercarial
antigen preparation (CAP)) were measured by ELISA, quantified as optical densities (OD)
read at 492nm (Mutapi et al. 1997).
2.2.2 Data from the literature
A survey of the wider literature was undertaken to pinpoint the age of the peak level of
infection and any trends in the relationship between infection levels in adults and the peak
level of infection. To be included, studies had to measure infection intensities of endemic
S. haematobium, had to include both children and adult subjects (over the age of 20), and had
to give infection levels for at least four different age groups. Adult age groups were chosen to
be as close to that used in the data analysis as possible (24-34 years old). Data was taken from
results tables where given, otherwise it was extracted from graphs using the software application
Datathief III version 1.5.
Data on water contact for the Burma Valley area, which had been collected by direct
observation of water contact sites, was taken from figure 1 in Chan et al. (2000) using Datathief.
2.2.3 Statistical analysis
Infection and antibody data were grouped by age to plot age profiles, with five age groups chosen
to give roughly equal numbers of individuals in each group for the Burma Valley populations
(age groups: ≤8, 9-10, 11-12, 13-23, 24-34 years old). Standardized variances were calculated
for both infection and antibody, for the whole population and in two age groups (0-14, 15-
34 years old), in order to have sufficiently large group sizes to give stable variance estimates.
The two age groups were chosen to coincide with the sudden change (or ‘switch’) in antibody
isotypes seen in the Burma Valley populations.




Correlations between infection and antibody levels were calculated using a two-tailed
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Spearman’s rank correlation coefficient (this was preferred to parametric methods since the
data are highly skewed). All tests used a significance cut-off level of 1%. The age-contact curve
was fitted to the data points by least squares, using the solver function in Microsoft Excel 2003.




Age infection profiles for six Zimbabwean communities with endemic S. haematobium infection
are shown in figure 2.1. The key parameters of interest (age and level of peak infection, and
ratio between adult and peak infection levels) for these populations are given in table 2.1. Note
that data was only included for individuals up to the age of 34, because data on water contacts
for the Burma Valley populations showed that this remained fairly stable for adults up to
this age, although they declined at older ages (figure 2.2). Table 2.1 also includes information
on the infection peak and its relationship to infection in adults for a number of studies of
endemic schistosomiasis taken from the literature, which give mean infection intensities by age
group, and cover a sufficiently wide age range to capture both the peak and adult levels. For
S. haematobium, the peak infection intensity in these studies was recorded between the ages of 6
and 18 years old (cf. 12–25 years old for S. mansoni, Fulford et al. (1992)). Adult age groups for
comparison were chosen to be as close to the range used in the analysis in figure 2.1 as possible.
Results from studies giving means of log-transformed egg counts were back-transformed to give
geometric means. It is difficult to compare these studies or use all of the estimates for the
ratio between adult and peak levels of infection since the different studies use a range of types
of means (arithmetic or geometric mean, including the whole population or only those with
infection), which give very different answers. From the studies which use arithmetic means for
S. haematobium infections, the ratio of final:peak infection level is 0.5–26%. It should be noted
that most of the additional populations in this analysis come from Clarke (1966), who did not
use fixed volumes of urine for egg counts. No clear relationship could be seen between the
age of the peak and the level of reduction. Using different age groupings for the populations
shown in figure 2.1 changed the ratio of final:peak infection level substantially for some of the
populations (Valhalla - ratio up to 34%, Chipinda - ratio up to 30%), indicating that this metric
is not stable for these populations.
2.3.2 Infection distributions
Figure 2.3 shows the distributions of infection for the Burma Valley populations (Kaswa and
Valhalla), by two age groups. The age groups were chosen to coincide with the sudden change
in antibody isotypes seen in the Burma Valley populations. Standardized variances (σ2/x2)
are given in the figure. Mean infection intensity and standardized variance for infection were
calculated for all of the populations in figure 2.1, for the whole population (up to age 34) and
subdivided into two age groups. Figure 2.4 shows the infection intensity and standardized
variance for each of the villages by age group. Both infection intensity and the standardized
variance varied considerably across the different villages, and while infection intensity decreased
in the older group for all of the villages apart from Chitate, the standardized variance varied
substantially with age, increasing or decreasing with age for different populations. Overall
prevalence of infection in these populations (up to age 34) varied from 9.8% in Chitate up to
67.6% in Valhalla (data not shown).
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Figure 2.1: Age-intensity graphs for six Zimbabwean populations with endemic S. haematobium.
Grey bars represent arithmetic mean egg counts per 10ml urine for the five age-groups shown,
error bars represent standard error of the mean. The numbers at the top of each graph show























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.2: Age-related water contact frequency. Data is for the Burma Valley region in
Zimbabwe, with data points extracted from figure 1 in Chan et al. (2000). The two-part
















































































































































































































SV = 16.9 
Kaswa 0-14 year olds
Valhalla 0-14 year olds
Kaswa 15-34 year olds




Figure 2.3: Infection intensity distributions for the Burma Valley populations divided into two
age groups. (a) Kaswa, age 0–14, (b) Kaswa, aged 15–34 (c) Valhalla, aged 0–14 and (d)
Valhalla, aged 15–34 years old. SV = standardized variance (σ2/x2). Note that the intervals














































































































Figure 2.4: (a) Mean intensity and (b) standardized variance for infection levels for each of the
six populations by two age groups and all together.
2.3.3 Antibody distributions
Mutapi et al. (1998), using the same dataset from the Burma Valley populations, showed
that there is a switch from IgA production in children to IgG1 production in adults against
SEA antigen. They used partial correlation analysis to demonstrate a consistent significant
negative correlation between IgA and IgG1 directed against SEA for both populations and
across two age groups, and also between IgA and IgG1 directed against WWH antigen for adults
in Valhalla (Mutapi 1997). I wanted to see whether this striking change (or ‘switch’) in the
antibody response was limited to the IgA and IgG1 responses in these particular populations,
or whether it was a more widespread phenomenon across different isotypes and in different
population settings. I first of all looked for significant negative correlations between different
antibody isotypes across the full population age range (using an age range of 0-34 as with my
previous analyses), and found that this was able to discriminate well the dichotomous antibody
relationship that I was trying to detect. In the Burma Valley populations, these negative
correlations all occurred between isotypes which change significantly with age in opposite
directions – i.e. one of the pair increased with age and the other decreased (as assessed by one-
way ANOVA or the equivalent non-parametric Kruskal Wallis test, using age as a categorical
variable in the five age groups used for the infection profiles). In Kaswa, significant negative
correlations were found between the IgG4 and IgA anti-SEA responses, IgG1 and IgA anti-
WWH responses and the IgM and IgG1 anti-WWH responses as well as the SEA IgA and IgG1
antibodies (figure 2.5). In Valhalla, all of these correlations were also seen, and additionally
a negative correlation between IgA and IgM SEA antibodies (figure 2.6). For the negative
correlations which were significant at the 1% level, the correlation coefficient varied between
-0.662 and -0.247.
Since this antibody dichotomy (or ‘L-shaped’ relationship) is not technically a negative
correlation, I also tried to characterize the relationship by looking at each pair of antibody
isotypes in turn to identify combinations for which no individuals ever make high levels of
both isotypes, using different percentile cutoff levels (calculated separately for each isotype
across the whole population), using a range of percentiles from 50%-85%. For the Burma
Valley populations, I found that the SEA IgA-IgG1 dichotomy could be detected at the 70th
percentile for both populations (i.e. both antibodies being produced above the 70th percentile
by any one individual is never observed). The 85th percentile was not sufficiently discriminatory
in Valhalla, but the 80th percentile was able to pick out responses which looked dichotomous
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(these were all also identified by correlation analysis apart from the SEA IgA-IgE switch
suggested for Valhalla) (figures 2.5 and 2.6). It should be noted that with the population
sizes used for this analysis (around 100 individuals each for Kaswa and Valhalla), you would
expect by chance to only see four individuals simultaneously exceed the 80th percentile for two
independent antibody responses – only 2.25 people for the 85th percentile and 9 people for
the 70th percentile. When the dichotomous relationships identified by correlation analysis were
plotted by age group, a clear change was seen ocurring with age in both the individual antibody
distributions (distributions plotted in appendix B, standardized variances plotted in figure 2.7),
and in their co-distributions (figure 2.8). For these responses in the Burma Valley populations,
antibodies which increased with host age all demonstrated a decrease in their standardized
variance in the older age group, with the reverse being observed for antibodies which decrease
with host age (figure 2.7). The marked change in the co-distribution showed that the switch
not only happened very rapidly on an individual scale (as nobody was found producing high
levels of both isotypes), but also over a relatively short period at a population level, with only
a few individuals falling outside the majority response for their age group (figure 2.8).
In Mutoko-Rusike, there were no significant negative correlations between different isotypes
directed at the same antigen preparation (for cercarial, egg or adult worm antigen preparations).
Most antibodies were significantly positively correlated with each other (data not shown), and
no responses showed a dichotomy for the percentile levels tested, up to and including the 85th
percentile.
Correlations between antibody responses and infection levels were also looked at (figures 2.5
and 2.6). Negative correlations were seen between SEA IgG1 and infection level for Valhalla. No
antibody-infection relationships were identified using percentile cutoffs. Positive correlations
between infection intensity and antibody levels were seen for a range of isotypes in all four
populations, including SEA IgA (for Valhalla) and SEA IgG4 (Valhalla and Mutoko-Rusike).
2.3.4 The post-treatment antibody switch
I wanted to quantify both the extent of the switch and the length of time over which the
antibody responses remained switched. Data was available from a subset of the Burma Valley
population aged 6–15 years old for whom SEA IgA and IgG1 were measured pre-treatment
and at 18, 24, 30 and 36 weeks after praziquantel treatment. Data on other isotype responses
(measured at 18 and 36 weeks) were not used for quantifying the post-treatment antibody
switch due to small sample sizes at 36 weeks (Mutapi et al. 1998). The data used is shown
in figure 2.9. IgG1 showed a substantial increase after treatment, and IgA a very rapid drop.
A conservative limit for identifying such a switch in model outputs (substantially exceeded in
this data set) was set as a doubling in the response which increases naturally with age, and
a halving of the response which decreases naturally with age. This was exceeded at all time






















Figure 2.5: Co-distributions between different antibody isotypes directed against (a) SEA
antigen (b) WWH antigen for Kaswa. Co-distribution of each antibody response with mean
S. haematobium egg output is also shown. Upper-right half of graph: significant correlations
marked. * p < 0.05, ** p < 0.01; red = negative correlation, blue = positive correlation.
Lower-left half of graph: percentile cutoffs marked. Percentile: $$$$$ = 65th, $$$$ = 70th, $$$































Figure 2.6: Co-distributions between different antibody isotypes directed against (a) SEA
antigen (b) WWH antigen for Valhalla. Co-distribution of each antibody response with mean
S. haematobium egg output is also shown. Upper-right half of graph: significant correlations
marked. * p < 0.05, ** p < 0.01; red = negative correlation, blue = positive correlation.
Lower-left half of graph: percentile cutoffs marked. Percentile: $$$$$ = 65th, $$$$ = 70th, $$$
























































































































































Figure 2.7: Changes in mean levels and standardized variances for antibodies which are
negatively correlated with other isotypes, by two age groups in (a,c) Kaswa and (b,d) Valhalla.
The left hand group of antibodies in each graph are those that decline with host age; the right





































































































































































































































































































































Figure 2.8: Changes in co-distributions between antibodies for which a switch is seen by two
age groups and altogether for (a) Kaswa and (b) Valhalla. Grey circles: 0–14 year olds, black









































Figure 2.9: Changes in antibody levels after treatment. Levels of SEA IgA and IgG1 in a cohort
of 6–15 year olds from Valhalla and Kaswa before treatment, and 18, 24, 30 and 36 weeks post
treatment with praziquantel. Sample sizes were 73, 66, 61, 52 and 48 at 0, 18, 24, 30 and 36
weeks respectively. Data previously published in Mutapi et al. (1998).
2.4 Discussion
The analysis of infection curves for S. haematobium from original data sets and extracted from
the literature gave a good estimate for the age range over which the infection peak is likely
to occur. Although the use of different types of mean (arithmetic, geometric, including all
individuals or only those positive for infection) can affect the apparent timing of the peak
(Mutapi et al. 2003a), this was not expected to have a very dramatic effect, and estimates from
studies using geometric means fell within the range of peak ages from studies using arithmetic
means. Estimates for the ratio between adult and peak levels of infection were affected by the
different means used, and these could not be combined across different types of mean as they
gave substantially different answers. No clear pattern could be determined between this ratio
and the age or height of the peak infection level, perhaps partly because of the noted instability
of this ratio or because of the small number of datasets available for comparison. Earlier
models of schistosome infection suggest that comparisons of adult infection levels between
populations with different infection rates could give insight into the type of immunity that
is acting (Woolhouse 1994a), and the ratios of infection level were expected to give similar
information, but it was not possible to draw such conclusions from this limited dataset.
The different populations in this analysis showed different directions of change for
standardized variance with age – previous studies of other parasite species have suggested that
aggregation tends to decrease in older people (Quinnell et al. 1995), although earlier analyses
of the Burma Valley data set and other data suggest a more complex pattern of aggregation
with age for the schistosomes (Chan et al. 2000; Quinnell et al. 1995; Woolhouse et al. 1994).
The small number of populations analysed here, and the limited sample sizes (meaning that
more age groups could not be used), prevented a definitive conclusion from being drawn as to
how infection aggregation varies with host age.
The antibody ‘switch’, previously reported from some of this data for IgA:IgG1 responses,
was found between several other isotypes in the same dataset. A separate study from Zimbabwe
(Ndhlovu et al. 1996b) reports correlations between isotypes which increase or decrease with
age which closely match the patterns seen here (although different isotypes are involved).
Unfortunately, we do not have access to the raw data for this study, but the patterns reported
back up the idea that age-related antibody switches occur in different populations. Little
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Table 2.2: Summary of quantitative model criteria drawn up on the basis of the data analysis
described in this chapter
Criteria minimum level maximum level
Age of infection peak (years) 6 20
Level of infection in adults relative to
the peak level (%)
0 40




Antibody standardized variance 0.1 14
Spearman’s correlation coefficient for
antibody switch
-1.0 -0.2
Fold change in antibody responses at
18 and 36 weeks post-treatment
compared with pre-treatment
2 ∞
analysis of the distribution of schistosome-specific antibody responses has been previously
published, beyond correlation analyses, and the observation that they are frequently aggregated
(Mutapi & Roddam 2002; Ndhlovu et al. 1996b). The analyses here have confirmed that most
antibody responses against schistosome antigen preparations are aggregated. A clear directional
pattern in age-related changes in standardized variance was seen for antibodies involved in
switching in the Burma Valley datasets (SV moving in the opposite direction to mean levels
with age). No evidence of an antibody switch was seen in the data from Mutoko-Rusike; this
may be because relatively few adults were included in this dataset, although it may point to
limited robustness of this pattern in different infection settings.
Our attempt to find an alternative metric to characterize the antibody ‘switch’ met with
limited success. While correlation analysis was not ideally suited to picking out what is really
a dichotomous relationship, it performed better than the percentile cutoffs which had to be
raised to very high levels (70-85%) to detect antibody switches. The drawback of using high
percentile levels was that, for some of the populations, the probability of observing no exceptions
by chance became unacceptably high. While it did give an alternative method of picking out
strong dichotomies in the antibody data, correlation levels were used in subsequent analysis to
choose model outputs which reproduced the antibody switch.
The analysis described in this chapter enabled me to draw up a list of quantitative criteria
against which to test model outputs, with ranges or limits identified for the age of the
infection peak, the ratio between adult and peak levels of infection, infection prevalence and
standardized variance, standardized variance for antibody distributions and the correlation




Explaining the slow development
of protective antibody responses
and observed infection profiles
Part of this work has been published (Mitchell et al. 2008), and a copy of the publication is
included in appendix F.
3.1 Introduction
In human populations with endemic schistosomiasis, a characteristic age-intensity pattern is
seen, with infection intensity (measured by egg output in faeces or urine) rising rapidly through
the childhood years to peak in older children or teenagers (peaks have been recorded between
6–20 years of age for S. haematobium and between 12–25 years of age for S. mansoni), then
falling again in adulthood (Clarke 1966; Fisher 1934; Fulford et al. 1992). The peak level of
intensity is higher and occurs at a younger age in populations with a higher overall infection
intensity when compared with areas of lower infection intensity, a phenomenon termed the ‘peak
shift’ (Woolhouse 1998). It has also been observed that these peaks tend to be more convex
(more sharply peaked) at higher levels of overall population infection intensity (Anderson &
May 1991a; Fisher 1934). The peak shift is reproduced by simple mathematical models of
acquired immunity, which assume that partial protective immunity develops as a function of
infection level (Woolhouse 1992b). Protective immunity seems to develop slowly, as individuals
endure chronic infection by long-lived adult worms, with frequent superinfection (Woolhouse &
Hagan 1999).
I explored three hypotheses for the slow development of protective immunity: (1)
immunosuppression by parasites (adult worms or cercariae); (2) that dying worms are the main
source of protective antigen; and (3) an antigen threshold requirement for antibody production.
The rationale and supporting evidence for these hypotheses is set out in more detail below. The
aim of this study was to determine the effects of each of these mechanisms upon population-
level patterns of infection and immunity, in particular whether they could significantly delay
the development of protective immunity and delay the age at which infection intensity peaks.
More quantitatively, I determined whether these models could reproduce age-intensity curves
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falling within the limits set out in chapter 2, with a peak between the ages of 6 and 20 and
levels of infection in adults being less than 40% of peak intensity levels. Additionally, I verified
that the models were still able to reproduce the peak shift when infection rates were varied.
Simple mathematical models of immunity were used building upon previous work by Woolhouse
(1992b, 1993). I focussed upon representing antibody responses in the models, since these have
frequently been associated with protection in schistosomiasis (Butterworth et al. 1996; Dunne
et al. 1992a; Grzych et al. 1993; Hagan et al. 1991; Rihet et al. 1991) and have clearly defined
cellular pathways leading to their production (Gray 2002). As in earlier models, a variety of
potential antigen sources were considered: cercariae, live worms, and eggs, with dying worms
also being considered as a distinct source of antigen. Protective antibody was assumed to
mediate protection through either reducing reinfection, killing adult worms or reducing worm
fecundity (Agnew et al. 1993; Smithers & Terry 1967). The proposed mechanisms were then
introduced as detailed below.
3.1.1 Immunosuppression
As detailed in chapter 1 (section 1.7.1), there is substantial evidence that schistosomes are
able to modulate the host immune response, suppressing specific immune responses (Maizels
& Yazdanbakhsh 2003). Antigen-specific proliferation and cytokine production are reduced
in chronic human infection (Grogan et al. 1998a; King et al. 1996), and the extent of this
suppression is related to infection intensity (de Jesus et al. 1993; Grogan et al. 1998a). These
responses are restored by praziquantel treatment (Grogan et al. 1996; van den Biggelaar et al.
2004), suggesting that suppression may be related to worm burden. Murine studies have also
demonstrated that cercariae can downregulate local host immune responses (Jenkins et al.
2005), and recently it has been suggested that cercariae can also modulate systemic responses
to schistosomes (A.M. Mountford pers. comm.)
Suppression was included in the model alongside protective antibody responses, acting to
reduce these responses, so having the effect of increasing the rate of superinfection, increasing
worm survival or increasing worm fecundity, up to the levels seen in the absence of protective
immunity. Suppression was incorporated as a function of cercarial exposure or alternatively as
a function of current worm burden, which reflects the correlation seen between suppression and
infection intensity. In contrast to protective responses, suppression was assumed to have no
immune memory, as it is lifted by chemotherapy (Colley et al. 1986; Grogan et al. 1996).
3.1.2 Dying worms
As discussed more fully in section 1.7.2, this hypothesis arises from the observation that
antibody changes that occur naturally in older children can be speeded up by praziquantel
treatment (Mutapi et al. 1998, 1997). Praziquantel kills adult worms, exposing the immune
system to previously hidden antigens. It is hypothesised that in natural infection, this exposure
is delayed for a number of years by the long worm life span (Woolhouse & Hagan 1999).
Responses generated by these adult antigens are expected to act against shared epitopes on
invading cercariae, or expressed at low levels on the worm surface. It is proposed that the
immune system has insufficient exposure to these antigens, either due to reduced expression
level (on cercariae or adult worms) or short exposure time (to cercariae), to form a protective
response prior to worm death (Fitzsimmons et al. 2007; Woolhouse & Hagan 1999).
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The life span of adult schistosomes in their human hosts has been estimated at between 3
and 10 years from studies with interrupted transmission (Goddard & Jordan 1980; Vermund
et al. 1983; Warren et al. 1974; Wilkins et al. 1984). The distribution of worm survival times,
as well as the mean survival time, is expected to affect the timing of exposure to antigen from
dying worms, but the distribution of schistosome survival times has not yet been characterised.
Dying worms were incorporated into the model as an additional source of antigen, assumed
to be proportional to the instantaneous number of worms killed, since the released antigens are
not expected to stay in the body for a long period of time after worm death. Different worm
survival curves were used to test their impact upon the timing of the peak and the peak shift.
3.1.3 Antigen threshold
It has been proposed that individuals must be exposed to a certain threshold level of schistosome
antigen before they begin to mount a protective immune response (Mutapi et al. 2008;
Woolhouse & Hagan 1999). This is supported by evidence from a cross-sectional survey in
a population with endemic S. haematobium infection that increased numbers of worm antigens
are recognised by sera from groups with greater experience of infection (Mutapi et al. 2008). The
basis for this hypothesis is discussed in section 1.7.3. This antigen threshold might be supposed
to rely upon current levels of antigen or cumulative exposure to antigen. B and T cells both
need minimum threshold levels of receptor binding in order to be activated (Carter & Fearon
1992; Viola & Lanzavecchia 1996), which could be a mechanism for how a threshold based upon
current levels of antigen might work. A requirement for a threshold level of cumulative antigen
exposure could represent a succession of repeated T cell activation and expansion events, with
T cell polarisation leading to an eventual change in the cytokine environment, which can alter
the antibody isotypes which are made.
Antigen thresholds were included in the model as levels of either current or cumulative
antigen exposure which needed to be exceeded in order for an antibody response to be initiated.
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Analysis framework for chapter 3
• The aim of the analysis in this chapter is to explore different hypotheses to explain the




• Models are tested for their ability to pass the infection intensity criteria:
– Peaked age infection curve (peaking in the right age range) with sufficient
reduction of infection in adults relative to the peak
– Peak shift between areas with different rates of infection
• Deterministic models are used which describe mean population infection intensity and
a single protective antibody response, enabling the model to be tested against all of
the above criteria, and to look at the timing of the antibody response.
• The level of suppression is assumed to be proportional to either the current number of
live worms, or current exposure to cercariae. This may represent either parasite-derived
homologues of immune mediators or host-derived mediators produced in response to the
parasite. (Suppression at a constant level irrespective of infection level is considered
but is indistinguishable from a weaker antibody response in this framework). An
alternative approach which was not taken here would be to explicitly model the cells
and cytokines involved in suppression.
• As part of the dying worms hypothesis
– Different stages of the lifecycle are compared as the source of protective antigen
(cercariae, live worms, dying worms, eggs) - the timing of exposure to each stage is
expected to differ, with possible effects upon the timing of the immune response.
– Different worm survival distributions are explored (as these will affect the timing
of exposure to dying worms): for fixed worm survival, a delay differential
equation is used; for non-exponential worm survival, multiple identical adult worm
compartments are used
• Additionally, different structures for the immune mechanisms are included, to check
whether they affect the results:
– Plasma cell populations only, without an explicit memory cell population
– Plasma cells and a memory cell population (under the assumption that memory
cells must be antigenically stimulated to maintain the plasma cell population)
– An upper limit is placed on the number of memory cells, as the model includes
direct antigen-driven (exponential) expansion of the memory cell population,
which can lead to an infinite population of memory cells; no limit is placed upon
the size of the plasma cell population, since their expansion is independent of the
plasma cell population size in these models.
3.2 Methods
A mathematical model consisting of a set of differential equations was developed, building upon
previous models of schistosome immunity (Woolhouse 1992b, 1993) and of immune memory
development (Wilson & Nokes 1999; Wilson et al. 2007). Two main immune model structures

















Figure 3.1: Schematic diagram of the baseline model, showing the main state variables, worm
burden (P ) and plasma cells (A), with production of eggs (E). The model is shown with a
single worm compartment (n = 1), which gives exponential worm survival, for clarity. Multiple
worm compartments are shown in figure 3.2. The antibody response shown here is triggered by
live adult worms, but can also be triggered by cercariae, dying worms or eggs. All three possible
antibody targets are shown, although only one will be active at a time. θ and η determine the
strength of the anti-reinfection and anti-fecundity responses via an exponential function, and ψ
governs the rate of immune-induced death of adult worms. All parameters are defined in table
















ψΑ ψΑ ψΑ ψΑ 
nµ nµ nµ 
Immune-mediated worm death 
Infection 
Λ(a) 
Figure 3.2: Schematic diagram of the multi-compartment worm model, used to alter the natural
worm survival curve. n individual compartments are shown, with worms moving through these
at a constant rate, nµ, and dying as they leave the last compartment. When the immune
response increases the rate of worm death, worms leave each compartment at a rate ψA. All
parameters are defined in table 3.1, with parameter values given.
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plasma and memory B cell populations. The main antigenic stimulus for an immune response
was assumed to be provided by one of four different stages of the worm life cycle: cercariae, live
worms, dying worms or eggs. The antibody response was assumed to target a single part of the
worm life cycle: reducing re-infection, increasing worm death rate or reducing worm fecundity.
The full baseline model is presented first, with modifications for explicit memory responses,
fixed worm survival, suppression and antigen thresholds described in subsequent sections. The
models are shown schematically in figures 3.1, 3.2 and 3.3 and the equations describing the
model are given in the following text. Parameters are defined in detail in table 3.1.
3.2.1 Baseline model
The structure of the baseline model is shown schematically in figure 3.1. The model describes a
homogeneous endemic population all experiencing the same age-related rate of infection, which
changes with age according to equation 3.1. Contact rates are assumed to increase linearly from
zero at birth up to a maximum level (Λm), reached at age ac. Above this age, contact rates
remain constant. Individual worm burden (P ) is modelled using n compartments (equation 3.2),
where i is the compartment number (i = 1, ..., n), shown in figure 3.2. Worm burden changes
with host age according to an immigration-death process, with age-related infection rate, Λ(a),
and worm death rate, µ, modified by the immune response. Worms enter the first worm
compartment at a rate Λ(a), which is reduced if an anti-larval antibody response is present.
The level of protection against re-infection is modelled as a decreasing exponential function
of the number of plasma cells. It is assumed that antibody levels are directly proportional to
the size of the plasma cell population, and that the level of protection is determined by the
antibody titre. The strength of the anti-larval response is determined by the parameter θ,
and this response reduces the rate of infection by a factor of e−θA(a), which scales between 0
and 1 (equation 3.2). Models with exponential worm life span have a single worm compartment
(n = 1), and have a constant per-capita rate of natural worm death, µ, following the equation for
i = 1 (equation 3.2). Where multiple worm compartments are used to model non-exponential
worm life span (n > 1), the first part of equation 3.2, for i = 1, describes the first worm
compartment and the second part of the equation (for 1 < i ≤ n) describes all subsequent
worm compartments. Worms are assumed to pass through the compartments at a constant
rate, nµ, dying naturally (in the absence of an immune response) when they leave the final (nth)
compartment, so that the rate of natural death is given by nµPn(a). Anti-worm immunity is
modelled here as a separate additional worm per-capita death rate, directly proportional to the
number of plasma cells, scaled by a factor ψ, which applies equally to all worm compartments
(equation 3.2). The number of eggs exiting the body in urine (E) is assumed to be directly
proportional to the total worm burden (equation 3.3). Anti-fecundity immunity is modelled as
a decreasing exponential function of the number of plasma cells, with strength η, and reduces
the number of eggs produced by the total worm population by a factor of e−ηA(a) (equation
3.3). The effector response is modelled as a single compartment (A) representing a population
of plasma cells, which secrete antibody at a constant rate (equivalently this compartment may
represent a memory B cell population with constant antigen-independent production of very
short-lived plasma cells)(equation 3.4). This population is assumed to increase at a rate directly
proportional to antigen exposure (G), with relative strength of increase κ, and is assumed to
decay at a constant per-cell rate γ. Antigen (G) comes from cercariae, live adult worms,
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dying adult worms or eggs (equation 3.5). Note that, in the case where dying worms stimulate
protective antibody and this antibody increases worm death, there is a direct positive feedback
term (equation 3.5). The antibody response is assumed to have a single antigen and a single
target in this model.
Λ(a) =
Λm aac if a < ac,Λm if a ≥ ac. (3.1)
dPi(a)/da =






dA(a)/da = κG(a)− γA(a) (3.4)
G(a) =

Λ(a) for cercarial antigen,
n∑
i=1




Pi(a)ψA(a) for dying adult worm antigen,
























Figure 3.3: Schematic diagram of the memory model, showing the main state variables, worm
burden (P ), memory cell population (M) and plasma cells (A), with production of eggs (E).
The memory and antibody responses shown here are triggered by live adult worms, but can also
be triggered by cercariae, dying worms or eggs (with the same antigen triggering both memory
and antibody). Plasma cells are produced by activation of memory cells by antigen, at a rate
governed by the parameter δ. Antigen-driven memory expansion occurs at a rate ζ. Other
details are as in figure 3.1. All parameters are defined in table 3.1, with parameter values given.
3.2.2 Memory model
The structure of the memory model is shown schematically in figure 3.3. For models with
an explicit memory response, the memory cell population (M) changes with age as described
by equation 3.6 and the plasma cell population (A) now changes with age as described in
equation 3.7. The memory cell population is assumed to grow in two ways, firstly through
antigen-dependent activation of näıve cells (at a rate directly proportional to antigen exposure,
with relative strength σ), and secondly through antigen-dependent proliferation of the memory
compartment (at a rate proportional to both the level of antigen and the current level of memory,
with relative strength ζ). As before, antigen exposure refers to one single antigen source, with
the same source for both the memory and antibody responses (equation 3.5). A maximum limit
(KM ) is placed upon the size of the memory cell population, with the overall rate of memory
cell expansion through either route limited via the density dependent function (1−M(a)/KM ).
The memory cell population decays at a constant per-cell rate ω. The plasma cell population
is now assumed to grow principally through antigen-dependent activation of the memory cell
population, and decays at a rate proportional to the plasma cell population size (equation 3.7).
As before, the effects of immunity on the infection process are directly mediated by the plasma
cell population (with no direct effect of memory), and the equations describing the infection
processes are the same as for the earlier model (equations 3.1, 3.2, 3.3 and 3.5).
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dA(a)/da = δG(a)M(a)− γA(a) (3.7)
3.2.3 Fixed worm survival
An alternative model with fixed worm survival was developed. This model uses a single
compartment for worms, with worms leaving this compartment a fixed time interval (1/µ) –
equivalent to the worm life span – after they enter (equation 3.8). The number of dying worms
is now calculated as the death rate under this new formulation (equation 3.9). Infection rates,
egg output, exposure to other antigens and the development of antibody are all calculated as
before (3.1, 3.3, 3.4 and 3.5). Note that with fixed worm survival represented in this way there
is no straightforward way to include immune-mediated worm death, and so only anti-larval and
anti-fecundity responses are considered in this version of the model.
dP (a)/da = Λ(a)e−θA(a) − Λ(a− (1/µ))e−θA(a−(1/µ))H(a− (1/µ)) (3.8)
G(a) = Λ(a− (1/µ))e−θA(a−(1/µ))H(a− (1/µ)) for dying worm antigen (3.9)
where H is the Heaviside step function (H = 0 when (a− (1/µ)) < 0 , H = 1 when (a− (1/µ) ≥
0).
3.2.4 Suppression
The level of suppression is assumed to be directly proportional to either current worm burden
or cercarial exposure (equation 3.10), and is then assumed to reduce the rate at which a
protective antibody response is made through an exponential function which scales the effect
of suppression to between 0 and 1, with strength ν (equation 3.11). The equations describing
infection levels and the different antigens remain the same (3.1, 3.2, 3.3 and 3.5). Alternative
versions of the suppression model are also considered, allowing suppression to reduce the effects
of protective antibody (rather than reducing its production), and using alternative functions
to the exponential to scale both the strength of the antibody response and the strength of
suppression (Mitchell et al. 2008). In order to assess the likely outcomes if worms only suppress
anti-worm responses (enhancing their own survival but not suppressing responses to incoming
larvae), the antibody response is allowed to have two simultaneous targets (anti-reinfection and
increased worm death), with suppression of only the anti-worm activity (Mitchell et al. 2008).
S(a) =

Λ(a) for cercarial-related suppression
n∑
i=1
Pi(a) for adult worm-related suppression
(3.10)
dA(a)/da = κG(a)e−νS(a) − γA(a) (3.11)
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3.2.5 Antigen thresholds
Antigen thresholds are introduced as levels of antigen exposure (either current or cumulative)
which must be exceeded before an antibody response can be mounted. Antigen thresholds are
included in three different ways. Firstly, a ‘fixed current’ antigen threshold based upon the
current level of antigen exposure and remaining at a constant level (T1) is introduced (3.12
and 3.13). For this version of the antigen threshold model, any antigen experienced over and
above the antigen threshold level (T1) is able to stimulate a protective antibody response, as
before. Secondly a ‘dropping current’ antigen threshold (T2) is used, for which again the antigen
threshold is based upon the current level of antigen exposure (equation 3.12), but as soon as
an antibody response has been stimulated, the antigen threshold is removed (set to 0), so that
any antigen encountered subsequently can stimulate a protective response (equation 3.14).
dA(a)/da =
κ(G(a)− T )− γA(a) if G(a) ≥ T,−γA(a) if G(a) < T. (3.12)
For a fixed current antigen threshold T = T1 (3.13)
For a dropping current antigen threshold T =
T2 if A(a) = 0,0 if A(a) > 0. (3.14)
where T1 and T2 are constants.
Finally, a cumulative antigen threshold is used, where a separate equation is added to the
model to record cumulative exposure to antigen (C), with this cumulative exposure building up
at a rate directly proportional to the level of antigen, with relative strength β (equation 3.15).
If the level of cumulative exposure exceeds the antigen threshold, antibody is made at a rate
proportional to current antigen levels (equation 3.16).
C(a) = βG(a) (3.15)
dA(a)/da =
κG(a)− γA(a) if C(a) ≥ T3,−γA(a) if C(a) < T3. (3.16)
where T3 is a constant.
3.2.6 Model analysis
For all models, all of the possible pairwise combinations of antigen stimulus (cercariae, live
worms, dying worms or eggs) and target (reduced re-infection, increased worm death or
reduced fecundity) were used in turn. Worm survival was varied (varying the number of worm
compartments or using the fixed survival equation) to assess its effects on the age-intensity curve
and the level of protective antibody, and the rate of infection was varied to assess the robustness
of the peak shift in these models. Parameters governing the strength and decay rates of the
immune responses and worm survival were varied to see whether the infection criteria identified
in chapter 2 could be met (with the peak occurring between ages 6 and 20, and the level of





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































simulations were first run using variable memory survival and short-lived plasma cells (with a
mean life span of 5 days), without antigen-driven memory expansion, then also allowing variable
plasma cell survival, with and without antigen-driven memory expansion. For the suppression
models, the strength of suppression was varied to assess the effects upon the age-intensity curve,
and in antigen threshold models, the level of the antigen threshold was varied. For models with
immune-mediated worm death, the impact of immunity upon average worm life span was also












Equations were solved numerically using a variable time step embedded fifth-order Runge-
Kutta algorithm with Cash-Karp parameters (Press et al. 2002), using either Berkeley Madonna




For the baseline model (without explicit memory responses, suppression or antigen threshold
included), the peaked infection curve and the peak shift could both be reproduced for every
combination of antigen and antibody target. Examples are shown for two combinations in figure
3.4. The curves shown fit within all of the infection criteria identified in field data in chapter 2:
the age of peak infection intensity was between 6 and 20 years, the level of infection in adults
(aged 34) was less than 40% of the peak level of infection, and a peak shift was seen when the
rate of infection was changed – as the rate of infection increased, the level of peak intensity was
raised and occured at an earlier age. These patterns could all be replicated for some parameter
values (within the ranges in table 3.1) for all combinations of antigen and target for the antibody
response for the baseline model, regardless of which worm survival curve was used.
3.3.2 Memory models
For the memory models, it was found that the peaked infection curve and peak shift could be
reproduced for each combination of antigen and antibody target. Using a stricter requirement,
that these models reproduce an age-infection curve with the peak occurring between the ages
of 6–20 years old and infection level at age 34 < 40% of the peak level, it was found that
plasma cell decay rates determined whether or not this was possible for all antigen:antibody
target combinations. With memory cell decay rates allowed to vary over their full range
(given in table 3.1), but plasma cell decay rates fixed at a rapid rate of 80 year-1, models
with cercariae-triggered anti-fecundity, live worms-triggered anti-worm and eggs-triggered anti-
fecundity responses were unable to meet this stricter requirement. If plasma cell decay rates































Figure 3.4: Age-infection profiles and peak shift in two permutations of the baseline model
without explicit memory cells, suppression or antigen thresholds included. Egg output is shown
changing with age for the following values of Λm (maximum rate of infection) from bottom to
top (with arrow): 12.5, 25, 50, 100, 200. (a) Antigen: live worms; antibody target: increased
worm death. n = 9, 1/µ = 10, ψ = 0.001, κ = 1, γ = 0.008. (b) Antigen: dying worms;
antibody target: reduced re-infection. n = 1, 1/µ = 6.5, θ = 0.016, κ = 1, γ = 0.008. (All
parameters fully defined with units in table 3.1.)
3.3.3 Suppression
When suppression was included, then increasing the strength of suppression (by increasing ν)
raised the level of the peak parasite burden and delayed the age at which the peak occurred
until, when suppression was sufficiently strong, the age-intensity curve tended towards the
monotonically increasing immigration-death curve seen when there was no resistance at all
(figure 3.5a). The simultaneous effect that increasing suppression had upon the level of
protective antibody is shown in figure 3.5b. Increasing suppression delayed the development
of a protective antibody response and also reduced the final level of antibody produced. At
the higher levels of suppression explored, the protective response did not develop at all. These
patterns seen in both infection and antibody profiles with increasing suppression remained the
same regardless of the antigen and target of the protective immune response. Suppression also
affected the peak shift. For a constant strength of worm-induced suppression, the peak shift
could still be observed at the lowest rates of infection, but as the rate of infection increased,
the peak shift was reversed, before complete loss of the peaks occurred at the highest infection
intensity levels (figure 3.6). Removal of the peak at the highest infection intensity corresponded
with almost complete prevention of acquired immunity developing. The same qualitative
patterns were seen if suppression was assumed to reduce the effects of protective immunity,
rather than reduce its production (Mitchell et al. 2008).
If suppression was assumed to be mediated by cercariae rather than adult worms, similar
results were seen – suppression delayed the development of protective antibody, but with high
strength of suppression or high infection rates, suppression overwhelmed the protective response,
removing the infection peak. If the antibody response was assumed to have two targets, with
suppression of only one part of the response, then increasing the strength of suppression raised
the height and delayed the age of the peak, but could not remove it altogether. The peak
shift did not always remain if the suppressed response had a much greater strength than the
unsuppressed response, but so long as part of the protective response was not suppressed, some
degree of infection control was still achieved in adults.
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Figure 3.5: The effect of increasingly severe worm-induced suppression upon (a) egg output
and (b) levels of protective antibody. Changing levels with age are shown for both. Antigen:
live worms; antibody target: increased worm death. n = 9, Λm = 50, 1/µ = 10, ψ = 0.001, κ =
1, γ = 0.008. Bold lines indicate no suppression (S = 0) and no antibody response (A = 0) as
marked. Lines in between are for increasing strength of suppression, ν (in direction of arrow):


























Figure 3.6: The effect of suppression on the peak shift. Egg output is shown changing with age
with increasing Λm, which increases with the direction of the arrow. Bold infection curves are
for Λm = 12.5, 25, 50, 100, 200, for comparison with figure 3.4a. Remaining infection curves
are for increasing Λm from 12.5 to 200 in steps of 12.5. Antigen: live worms; antibody target:
increased worm death. n = 9, 1/µ = 10, ψ = 0.001, κ = 1, γ = 0.008, ν = 0.0125. (All
parameters fully defined with units in table 3.1.) The trend of the peak shift is highlighted in
white squares joined by a grey line.
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Figure 3.7: The effect of changing the worm survival curve upon (a) egg output and (b) levels
of protective antibody. Changing levels with age are shown for both. Antigen: dying worms;
antibody target: reduced re-infection, 1/µ = 6.5, θ = 0.016, κ = 1, γ = 0.008. (All parameters
fully defined with units in table 3.1.) Different worm survival curves: dashed line: n = 1
(exponential worm survival), bold line: n = 9 (approximately Gaussian distributed survival),
dotted line: n = 100 (approaching fixed worm survival); solid narrow line: fixed worm survival.
Using alternative functions (linear or a Gumbel function) to scale the strength of protective
antibody or suppression did not change any of the predicted trends for this model (Mitchell
et al. 2008).
3.3.4 Dying worms and worm survival
Dying worms were included as one possible source of antigen in the model, to see whether
they gave predicted patterns of infection and antibody which were distinct from other potential
antigen sources (cercariae, live worms or eggs). Since the antigenic stimulus was assumed to be
directly proportional to the current rate of worm death, in the case where worm survival was
assumed to be exponentially distributed and there was no immune-mediated worm killing, the
rate of worm death was directly proportional to the current number of live worms and there was
no mathematical difference between live or dying worms as an antigenic stimulus. However, if
other worm survival curves were used, or there was immune-mediated worm death, then worm
death was no longer directly proportional to the number of live worms and exposure to dying
worms had a different distribution with host age.
Figure 3.7 shows how different worm survival curves altered the age-intensity profiles for both
infection and protective antibody when the protective response was assumed to be triggered
by dying adult worms. As the survival curve was changed progressively from exponential to
fixed (increasing the number of worm compartments and then using the alternative equation
for fixed worm survival), the peak occurred at a later age and a higher level, with the final level
of infection in adults always settling to the same level regardless of worm survival (note that
this level is reached some time after the age of 34 for the curves shown in figure 3.7a). For
models with antibody stimulated by dying worm antigen, as the survival curve was changed
progressively from exponential to fixed, the development of the protective antibody response
was delayed (figure 3.7b), although antibody levels eventually settled at the same stable level
regardless of worm survival if the models were run for long enough. Different worm survival
curves did not remove the peak shift, but could change its relative ‘shape’ (figure 3.8). Keeping
all other parameters constant, moving from exponential to fixed worm survival increased the
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Figure 3.8: The effect of altering the worm survival curve upon the peak shift. (a) Exponential
worm survival (n = 1) (same data as in figure 3.4b), (b) fixed worm survival. For both panels,
antigen: dying worms; antibody target: reduced re-infection, 1/µ = 6.5, θ = 0.016, κ = 1, γ =
0.008. Egg output is shown changing with age for the following values of Λm (maximum rate
of infection) from bottom to top (with arrow): 12.5, 25, 50, 100, 200. (All parameters fully
defined with units in table 3.1.)
range of peak infection levels seen over the same range of infection rates, but reduced the range
of ages over which peaks occurred.
Changing the worm survival curve could also affect the age-infection curve for models with
antigen sources other than dying worms. In particular, models in which protective antibody
reduced re-infection (with either cercarial or live worm antigen) tended to have later and higher
infection intensity peaks with increasing numbers of worm compartments. This was not due to a
delay in the development of protective antibody, which developed earlier (for live worm antigen)
or at the same rate (for cercarial antigen) with increasing numbers of worm compartments (data
not shown).
3.3.5 Antigen thresholds
Inclusion of an antigen threshold on the protective antibody response had different effects upon
the age-intensity profile depending upon which type of antigen threshold was used (figure 3.9a-
c). For all of the types of antigen threshold explored, inclusion of an antigen threshold delayed
the development of protective antibody (figure 3.9d-f). For a fixed antigen threshold based upon
current antigen exposure level (T1), increasing the level of this antigen threshold delayed the age
at which infection peaked and raised the height of the infection peak, but also raised the level
of infection in adults (figure 3.9a). For a sufficiently high antigen threshold level, the antigen
threshold could not be passed, an antibody response could not be made, and there was no
control of infection. For an antigen threshold based upon current exposure which was removed
(set to 0) once an antibody response has been initiated (T2), increasing the antigen threshold
level also delayed the age and raised the height of the peak, but lower levels of infection could be
achieved in adults. Once an antibody response had been initiated, infection intensity settled to
the same level in adults regardless of the antigen threshold level, provided the antigen threshold
was passed (figure 3.9b). Again, at sufficiently high antigen threshold levels, it was sometimes
impossible for the antigen threshold to be passed, and there was no control of infection.
For a cumulative antigen threshold without any decay in cumulative exposure (T3),
increasing the antigen threshold level also delayed and raised the height of the infection peak,
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Figure 3.9: The effect of increasing the level of different types of antigen threshold upon egg
output (a,b,c) and levels of protective antibody (d,e,f). For all panels, antigen: live worms;
antibody target: increased worm death, n = 9, Λ = 50, 1/µ = 6.5, ψ = 0.001, κ = 1, γ = 0.008.
Type of antigen threshold: (a, d) Fixed current; (b, e) dropping current; (c, f) cumulative.
Bold lines indicate what happens when there is no antigen threshold (threshold = 0). Other
lines show what happens with increasing antigen threshold levels: for (a, d) values for antigen
threshold level (T1) (increasing in direction of arrow) 100, 200, 300, 400; for (b, e) values for
T2 (increasing in direction of arrow) 100, 200, 300, 400; for (c, f) values for T3 (increasing in













































Figure 3.10: The impact of antigen thresholds upon the peak shift. (a) Fixed current antigen
threshold, (b) dropping current antigen threshold, (c) cumulative antigen threshold. Egg output
is shown changing with age with increasing Λm (infection rate) from bottom to top (with the
direction of the arrow) 12.5, 25, 50, 100, 200. For all panels, antigen: live worms; antibody
target: increased worm death, n = 9, Λm = 50, natural mean worm life span 1/µ = 6.5,
ψ = 0.001, κ = 1, γ = 0.008. For (a) T1 (current antigen threshold) = 200, for (b) T2 (initial
antigen threshold) = 200 (with threshold falling to 0 once antibody begins to be made) and for
(c) T3 (cumulative antigen threshold) = 1000. (All parameters fully defined with units in table
3.1.)
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but did not affect the level of infection in adults if the antigen threshold was passed. For this
model, the peak could be shifted to a later age than with current antigen thresholds, as a
cumulative threshold could be exceeded after current antigen exposure has plateaued (figure
3.9c). At a sufficiently high antigen threshold level (T3), this threshold could not be exceeded
within the simulated time period (not shown).
Both types of current antigen threshold failed to replicate the peak shift at low levels of
infection (figure 3.10a,b), as at low levels of infection the antigen threshold was never passed
and control was never achieved. The cumulative antigen threshold allowed a very strong peak
shift to be maintained across populations with varying infection rates (figure 3.10c), although
it was possible to find combinations of antigen threshold level (T3) and infection rate (Λm) for
which the threshold was not passed during the 34 years simulated and control was not achieved
(data not shown).
3.3.6 Average worm life span
For models where the protective immune response increased worm death rate, this could have
a large impact upon the average worm life span, which decreased both with host age and with
increasing infection rate (figure 3.11). For models which achieved levels of control in line with
field estimates (the level of infection in adults is less than 40% of the peak level), worm life
span was reduced substantially (as for all of the curves in figure 3.11).



















Figure 3.11: Effect of anti-adult worm immune responses on worm life span at different host
ages. Results shown for baseline model without explicit memory cells, suppression or antigen
thresholds included. The average worm life span is calculated using equation 3.17 and is shown
for different values of infection rate (Λm) from top to bottom (with the direction of the arrow)
12.5, 25, 50, 100, 200. Antigen: live worms; antibody target: increased worm death, n = 9, 1/µ
= 10, ψ = 0.001, κ = 1, γ = 0.008. (Infection curves for these same populations are shown in
figure 3.4a.) (All parameters fully defined with units in table 3.1.)
3.4 Discussion
This analysis showed that a wide range of models were able to reproduce age-intensity
curves consistent with field data. These included models with varying representations of
the pathways leading to antibody production, different antigens and antibody targets, and
different mechanisms for delaying the development of protective antibody responses. Using
a mathematical modelling approach to investigate these questions is useful because it allows
findings from laboratory and field studies to be applied to a hypothetical population setting
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under a set of explicit and verifiable assumptions, producing outputs that can be compared with
field data. Previous work by Woolhouse (1992b, 1993, 1994a), using a simple representation
of immunity similar to the baseline model here, showed that the qualitative patterns of a
peaked age-intensity curve and a peak shift could be reproduced by all of the possible different
combinations of cercariae, live adult worms and eggs as antigen and target for antibody
responses. The analysis here was more quantitative, using infection rates which varied with
age in accordance with field observations (Chan et al. 2000), and testing whether age-intensity
profile characteristics fell within ranges identified from field data, in particular the age of the
infection peak and the height of the peak relative to adult levels of infection.
Basic models, with the immune response represented as a single population of plasma cells,
were able to reproduce these patterns for all possible combinations of antigen and target for the
protective response. Most (although not all) of these models required very slow decay rates of
the plasma cell population to achieve this – constant per cell decay rates of 0.08–0.008 year-1,
equivalent to a half-life of 9–90 years. Antibody-secreting or plasma cells do not divide (Kalia
et al. 2006), which implies that individual cells would have to have half-lives of 9–90 years if
this model were true. Several studies in both mice and humans have suggested that antibody
levels can be maintained for months or years by long-lived plasma cells (which constitutively
produce antibody)(Ahuja et al. 2008; Kalia et al. 2006; Radbruch et al. 2006). Radbruch
et al. (2006) suggest that these plasma cells may have a half-life of roughly 23 years, and
Amanna et al. (2007) demonstrated a half-life of 92 years for the antibody response to vaccinia
vaccination (in the absence of re-exposure), which they implied may be maintained by long-lived
plasma cells. Others have suggested that antibody can be maintained in an antigen-independent
manner through non-specific activation of memory B cells to produce short-lived plasma cells
(Bernasconi et al. 2002; Kalia et al. 2006; Lanzavecchia et al. 2006). The baseline model used
here could equally represent this mechanism (provided plasma cells have a relatively short half-
life), and in this case it would not need to be assumed that individual memory cells can survive
for decades, as memory cells can proliferate and maintain their populations (Macallan et al.
2005; Wirths & Lanzavecchia 2005).
As some studies suggest that antigen is needed to drive plasma cell production from memory
populations (Ochsenbein et al. 2000), an alternative model structure was considered including
an explicit memory cell population, with antigen-dependent production of plasma cells from this
memory population. These memory models were also able to reproduce age-intensity profiles
consistent with those seen in the field; for some antigen:target combinations, the plasma cells
as well as the memory cell populations needed to have fairly long half-lives (which is not
inconsistent with experimental findings, as discussed above).
The models suggested that suppression could delay and reduce the development of protective
immune response in humans, but may have complex effects upon population patterns of infection
(Mitchell et al. 2008). The suppression models showed that very strong immunosuppression
of the entire protective response could completely overwhelm it, removing all evidence of
acquired immunity and removing the ‘peak’ in infection intensity altogether, while very weak
immunosuppression had little or no effect on the age and intensity of peak infection, as
protective immunity was scarcely affected. For a given level of suppression, the impact
upon the age-intensity curve was also predicted to vary with the rate of infection, with the
peak shift remaining at low rates of infection, but at increasingly high rates of infection the
suppressive effect reversed the peak shift and then removed the peaks altogether. Alternatively,
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if immunosuppression only acted against part of the immune response, leaving another part
intact, then suppression was unable to remove the peaks and had a much more modest effect
upon the peak shift.
It has been questioned whether the level of suppression is really likely to be proportional
to infection intensity; a recent study of regulatory T cells in a Zimbabwean population with
endemic S. haematobium found no clear relationship between the percentage of T cells which had
a regulatory phenotype and level of infection intensity (N. Nausch, in prep). If suppression was
assumed in this model to have a constant level regardless of infection level, this was equivalent
to assuming that antibody production was induced at a slower rate and did not affect the overall
behaviour of the baseline model at all.
Parasite-induced immunosuppression has previously been included in other models of macro-
parasite infection. Duerr et al. (2003b) modelled parasite-associated suppression as an increasing
rate of parasite establishment (equivalent to infection rate in this model) with increasing parasite
burden. Their null model (without suppression) was equivalent to the full suppression model
here (in which resistance never developed). Their model predicted sigmoidal age-intensity
curves, consistent with onchocerciasis data (Basáñez & Boussinesq 1999; Duerr et al. 2003b),
and their model could not generate peaks or a peak shift, as was seen with very high suppression
in our model. Schweitzer & Anderson (1991) included parasite-induced suppression of T cell
responses in their more mechanistic models of parasite immunology. Removal of activated
T cells by parasites permitted a stable state with high parasite burden and low numbers of
activated T cells, with high levels of repeated exposure tending to move the system towards
this state. In a more complex model where parasites suppressed IL-2-driven T cell proliferation,
progression from an immunosuppressed to an immune state was increasingly delayed at higher
infective doses. This is in general agreement with the findings reported here.
In contrast to the predictions from the suppression model, existing field data on S. mansoni
and S. haematobium demonstrates a definite peak in infection intensities in childhood, which is
increasingly strongly convex at higher infection intensities (Anderson & May 1991b), and a clear
peak shift towards younger individuals is seen in more heavily infected populations (Fulford et al.
1992). Similar peak shifts have also been demonstrated for filarial and hookworm infections in
human populations (Woolhouse 1998). This suggests that significant intensity-related parasite-
specific suppression of all immune responses is inconsistent with observed population patterns
of schistosome infection intensity.
The models showed that while having dying worms as the principal antigen stimulating a
protective antibody response could give rise to age-intensity profiles consistent with field data,
other life-cycle stages could also act as the principal antigen. For an individual’s exposure
to dying worms to have a distinct profile from their exposure to live worms, it was necessary
to either have protective antibody increasing worm death, or to have non-exponential worm
survival. The models showed that the assumed worm survival curve could make an appreciable
difference to the age-intensity profile. If dying worms were the principal antigen, then changing
worm survival from an exponential distribution towards distributions with less variation in
worm life span (approximately Gaussian-distributed and fixed worm survival) always delayed
the timing of initial exposure to dying worms, delaying development of protective antibody, and
leading to higher and later infection peaks. The worm survival curve also affected models with
other antigenic stimuli, where protective antibody reduced rates of re-infection. Since worm
death and egg production were not affected by the immune response in these models, the decline
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in infection levels came from natural worm death after the reduction of new worm arrivals. This
decline was affected by worm survival, again leading to higher and later infection peaks with
reduced worm life span variation, although in this case there was no delay in the generation
of protective antibody. In all of these models, the peak shift was maintained regardless of the
worm survival curve used. While a fixed worm life span is a deliberate extreme case which
is unlikely to occur in reality, using approximately Gaussian distributed worm survival also
made a considerable difference to age-intensity patterns. Data from human and animal studies
gives limited information about what the true distribution of natural worm survival might be.
Maximum life span estimates for schistosomes, based upon finding individuals passing eggs
some time after their last possible exposure, go up to 29 years for S. haematobium and 33 years
for S. mansoni (Berberian et al. 1953; Christopherson 1924; Fairley 1931; Harris et al. 1984),
considerably longer than the usual average worm life span estimates of 3–10 years (Goddard
& Jordan 1980; Vermund et al. 1983; Warren et al. 1974; Wilkins et al. 1984), which suggests
that there is considerable variation but does not support any particular distribution.
The models indicated that the requirement for a threshold level of antigen exposure to
be reached before a protective antibody response was mounted could substantially delay the
development of a protective response, but the effects upon the age-infection profile varied
depending upon the way in which such an antigen threshold was assumed to operate. Problems
arose particularly for populations with low levels of infection which never reached the antigen
threshold and thus never controlled infection at all. This is not consistent with field studies
of populations with endemic S. haematobium, which consistently demonstrate lower levels of
infection in adults than children, suggestive of protective immunity developing. While this
occurred to a certain extent in all of the threshold models, it happened much more frequently
in models with antigen thresholds based on current antigen levels. In models with a threshold
based upon cumulative antigen exposure, this threshold could be passed over a much broader
range of population infection rates.
When the protective immune response was assumed to increase the rate of worm death,
worm life span was shortened considerably – for models in which the ratio of infection in adults
to the peak level was less than 40% (in line with field estimates; see chapter 2), worm life
span in adults was shortened to less than 2 years, and usually less than 1 year, in contrast
to the estimates of 3–10 years previously calculated from field data (Goddard & Jordan 1980;
Vermund et al. 1983; Wilkins et al. 1984). The prediction arising from these models that if
there is significant immune attrition of adult worms then worm life expectancy will be shorter
in adults than in children, has been previously tested in two field studies of S. mansoni. One
study using transmission control in St. Lucia, showed some evidence of a longer worm life span
in children, although the life span in adults was still estimated to be between 2 and 4 years
(Goddard & Jordan 1980). Another study analysing pre- and post-treatment data from Kenya
failed to find evidence of a significant difference in worm life span with host age (Fulford et al.
1995). Field estimates of worm life span have all used the assumption that worm life span is
exponentially distributed, for which the evidence (discussed earlier) is equivocal, and this may
bias these estimates. Since the interruption of transmission (often used to estimate worm life
span) will also alter the levels of exposure to all of the different schistosome life stages, it may
also alter the strength of anti-worm immune responses, so that these life span estimates may
not fully take into account the effect of immunity upon worm survival.
The results presented here have shown that different representations of the immune system
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can give age-intensity profiles consistent with those seen in endemic communities. They also
demonstrated that a variety of combinations of different life cycle stages as the principal source
of protective antigen, and as the target of protective antibody, could also reproduce plausible
age-intensity profiles. The models indicated that antigen thresholds, worm- or cercariae-induced
immunosuppression, or having dying worms as the source of protective antigen (with non-
exponential worm survival) were all able to delay the development of protective immunity.
However, antigen thresholds, particularly those based upon current antigen exposure, prevented
the peaked age-intensity curve and peak shift being replicated across all levels of infection
rate. Immunosuppression had effects on population levels of infection intensity which have not
been reported in field data, in particular reducing the convexity of the age-intensity curve,
and reversing the peak shift. This suggests that intensity-related immunosuppression of the
specific protective immune response does not occur to a significant extent during schistosome
infection. The other proposed mechanisms (dying worms or a cumulative antigen threshold)
were consistent with observed field patterns, as were results from baseline models without any
additional mechanisms included. Additional patterns from field data, including age-antibody
profiles, and infection and antibody distributions and co-distributions, will be considered as
extra filters to further discriminate between these proposed hypotheses for the slow development
of protective immunity in human schistosome infection.
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Chapter 4
Exploration of factors underlying
the antibody switch
4.1 Introduction
Infection intensities in populations with endemic urinary schistosomiasis consistently follow a
‘peaked’ (or convex) curve with age, with infection levels peaking between the ages of 6–20
years old, and lower infection intensities found in older adults (Clarke 1966). In areas with
higher overall levels of infection, the peak in infection intensity tends to be higher and occur at
an earlier age than in areas with lower infection levels. This pattern is described as a peak shift
(Woolhouse 1998). Previous modelling work has demonstrated that the peak shift is consistent
with the development of acquired protective immunity as a function of cumulative exposure
to schistosome antigens (Woolhouse 1992b). Age-related changes in the nature of the immune
response generated against schistosomes have also been reported. Two studies in Zimbabwe
have identified different groups of schistosome-specific antibody sub-classes (isotypes) which
display contrasting age profiles. One group of isotypes was shown to rise with host age while
a second group declined in older individuals (Mutapi et al. 1997; Ndhlovu et al. 1996b). Both
studies reported negative correlations between antibodies from the two different groups. The
‘switch’ between the different antibody responses occurred after the peak in infection intensity
for both populations. Some of the isotypes which increased with age in these populations have
been associated with protection against re-infection in other studies, particularly IgE specific
for adult worm antigen preparations (Hagan et al. 1991), but these protective responses tend to
develop slowly with age, despite frequent exposure to infection from an early age (Woolhouse
et al. 2000).
In this chapter, two hypotheses were explored for the slow development of protective
immunity. The first hypothesis was that dying worms are the main source of protective antigen.
It has been observed that praziquantel treatment, which kills adult worms, induces an antibody
switch in young children similar to the switch seen occurring naturally in older children (Mutapi
et al. 1998). It is hypothesised that the long life span of schistosome worms delays exposure
to protective antigens, delaying the development of natural protective immunity (Woolhouse
& Hagan 1999). Second, it has been proposed that exposure to a certain threshold level of
antigen is needed before protective responses can be stimulated (Mutapi et al. 2008; Woolhouse
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& Hagan 1999). This is supported by the finding that, in a S. haematobium endemic area,
older or more heavily infected groups produced detectable antibody against a wider range of
schistosome antigens (Mutapi et al. 2008). Both of these hypotheses were discussed in more
detail in chapters 1 and 3.
These hypotheses were tested using deterministic models which describe changing levels of
infection and two separate antibody responses with age in a homogeneously exposed population.
These models were tested for their ability to reproduce key patterns in infection and antibody
observed in field studies of S. haematobium, extending the list of patterns to include the
antibody switch as well as the age-infection intensity profile and the peak shift. A pattern-
oriented modelling approach was taken. This systematically tested the ability of a range of
different model structures and parameter sets to simultaneously reproduce several different
patterns identified from population-level field data (Grimm et al. 2005; Janssen et al. 2009;
Rossmanith et al. 2007). The models were used to test whether one or more of the following
factors was necessary to reproduce these patterns: dying worms as the principal antigen (versus
other life cycle stages), non-exponential worm survival distribution (expected to affect the
timing of exposure to dying worms), an antigen threshold, or cross-regulation between the two
antibody responses. Cross-regulation was included specifically to see whether this was necessary
to generate the antibody ‘switch’, in line with the antagonism known to exist between different
cytokine responses, which are involved in determining which antibody isotypes are made (Abbas
et al. 1996; Jeannin et al. 1998). It was found that each of these factors enhanced the ability of
the models to reproduce the required patterns, but none of them were necessary for the models
to be able to reproduce patterns of infection and antibody consistent with field data. The
combination of the stage of the schistosome life cycle which stimulated each antibody response,
and the stage of the life cycle targeted by the antibodies, was found to be informative.
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Analysis framework for chapter 4
• The aim of the analysis in this chapter is to explore different hypotheses to explain




– Cross-regulation (representing antagonism between different branches of the
immune response)
• Models are tested for their ability to pass both the infection intensity and the antibody
switch criteria:
– Peaked age infection curve (peaking in the right age range) with sufficient
reduction of infection in adults relative to the peak
– Peak shift between areas with different rates of infection
– Sufficiently long mean worm life span in adult hosts (in line with field estimates)
– Antibody switch, after the age of the peak in infection
• Deterministic models are used which describe mean population infection intensity and
two independent protective antibody responses, enabling the model to be tested against
all of the above criteria
• In this model, it is assumed that the antibody switch occurs when one group of B cell
clones supersedes a separate group of B cell clones. The two groups of B cells may
have the same or different sources of stimulating antigen, antigen targets and survival
times - all possible combinations are considered. An alternative approach which was
not followed might be to model a single clone of B cells undergoing a true isotype
switch.
• Different worm survival distributions are used, since these can affect the timing of
exposure to dying worms and the dynamics of a protective response, as shown in chapter
3. Two distributions are used - exponential and approximately Gaussian, using one and
nine adult worm compartments respectively to alter the worm survival curve. Fixed
worm survival is not considered, as it gave little additional impact over the Gaussian
distribution in chapter 3, and cannot be used in models with immune-mediated worm
death.
• A cumulative antigen threshold is used, as the analysis in chapter 3 demonstrated that
this could give infection profiles consistent with field data over a wide range of infection
rates.
• The threshold is only applied to one of the two antibody responses, since only one
response is thought to be delayed in this model of the antibody switch; it is applied
to the longer-lived response, as previous work suggests that this is likely to be the
late-developing response.
• Cross-regulation between the two antibody responses is included as a reduction in the
production rate of each plasma cell population, proportional to the level of antigen
stimulating the other response. An alternative approach would be use a more detailed





















Figure 4.1: Schematic diagram of the plasma cell model. This shows the main state variables,
worm burden (P ) and two populations of plasma cells (A1 and A2), with production of eggs (E).
A single worm compartment (n = 1), corresponding to exponential worm survival, is shown for
clarity. The first antibody response shown here (A1) receives its antigenic stimulus from the
live worm population, and the second (A2) is stimulated by dying worms, but each response
could be stimulated by any one of cercariae, live worms, dying worms or eggs. In the figure,
the first antibody response (A1) is shown reducing re-infection, with relative strength θ1, and
the second antibody response (A2) is reducing worm fecundity with relative strength η2, but
each response could target any one of re-infection, worm death or fecundity (immune-mediated
worm death is shown in figure 2). Cross-regulation between the two responses is shown using
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Figure 4.2: Schematic diagram of the multi-compartment worm model, used to alter the natural
worm survival curve. The first three and the final (nth) compartments are shown for a model
with multiple worm compartments, with worms moving between these compartments at a
constant rate, nµ, dying as they leave the final compartment. When either antibody response
increases the rate at which worms die, worms additionally leave each compartment at a rate
(ψ1A1 + ψ2A2). All parameters are defined in table 4.1 with parameter values given.
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4.2 Methods
Age-related development of schistosome infection and antibody responses were modelled using a
set of differential equations, using a similar framework to earlier models of helminth immunity
(Mitchell et al. 2008; Woolhouse 1992b, 1993) and immune memory development (Wilson &
Nokes 1999; Wilson et al. 2007). Two different structures for the immune response were
explored: one with only plasma cells, and the other including both plasma cell and memory
B cell populations. Different stages of the worm life cycle were allowed to provide the main
antigenic stimulus for, and different stages of the life cycle were assumed to be the principle
target of, each protective antibody response. The model with plasma cells only is presented first,
followed by the memory model and the models including antigen thresholds. The equations are
given below, and the model is represented schematically in figures 4.1, 4.2 and 4.3. Parameters
are defined, and parameter ranges given, in table 4.1.
4.2.1 Plasma cell model
The plasma cell-only model (figure 4.1) describes the development of infection and two antibody
responses (modelled as populations of plasma cells) with age in a homogeneous population
with endemic schistosome infection. Each antibody response is stimulated by antigen from a
single stage of the schistosome life cycle, and each antibody response targets a single life cycle
stage in this model. It is assumed that antibody levels are directly proportional to the size of
their respective plasma cell populations. This is reasonable, since plasma cells are constitutive
producers of antibody, and antibody has a relatively short plasma half-life in humans, of the
order of days to weeks (Morell et al. 1970; Waldmann & Strober 1969).
Infection rates are assumed to be the same for all individuals within the population, and to be
constant with time, but vary with age as described by equation 4.1. The age-related contact rate
(Λ) is zero at birth, increases linearly with age up to age ac, when it reaches its maximum level
(Λm), and remains at this maximum level for all subsequent ages. Worm burden (P ) is modelled
using n compartments (equation 4.2), shown schematically in figure 2. New worms enter the first
compartment at a rate Λ(a), which can be reduced by anti-reinfection antibody responses as a
decreasing exponential function of the number of relevant plasma cells (A1 or A2 or both), with
relative strength θj (θ1 or θ2 as appropriate for the 1
st or 2nd (jth) antibody response) (equation
4.2). Worms move between compartments at a constant rate nµ, dying naturally when they
leave the final (nth) compartment, giving a natural death rate nµPn(a) and an overall mean
natural worm life span (in the absence of immunity) of 1/µ. Increased immune-induced worm
death is included as an additional per-worm death rate, directly proportional to the number
of plasma cells and scaled by a factor ψj (figure 4.2 and equation 4.2). This additional worm
death rate applies equally to all worm compartments (meaning that the ability of the immune
response to kill adult worms is not affected by worm age). For exponentially distributed worm
life span, a single worm compartment is used (n = 1), using the equation for i = 1 (where
i is the compartment number) (equation 4.2). For an approximately Gaussian distribution of
worm life spans, nine worm compartments are used (n = 9), with the first compartment
described by the first line of equation 4.2, for i = 1, and all other compartments described by
the second line (for 1 < i ≤ n). The number of eggs measured in urine (E) is assumed to be
directly proportional to total worm burden (summed over all worm compartments), and can
be reduced by anti-fecundity antibody responses as a decreasing exponential function of the
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number of plasma cells, with relative strength ηj (equation 4.3).
The antibody responses are modelled as two separate compartments of plasma cells, A1
and A2 (equations 4.4, 4.5). Each plasma cell population grows at a rate directly proportional
to the level of antigen (Gj) exposure (with the rate governed by parameter κj). The antigen
stimulating each cell population (Gj) comes from a single stage of the schistosome life cycle
(Sj): cercariae, live adult worms, dying adult worms or eggs (equation 4.6). Each plasma cell
population decays at a constant per-cell rate γj . Cross-regulation between the two different
antibody responses is modelled as a reduction in the production rate of each plasma cell
population, proportional to the level of antigen stimulating the other response. This is scaled
using a decreasing exponential function, with the strength of cross-regulation governed by the
parameter ρj .
Λ(a) =
Λm aac if a < ac,Λm if a ≥ ac. (4.1)
dPi(a)/da =








−ρ1G2(a) − γ1A1(a) (4.4)
dA2(a)/da = κ2G2(a)e
−ρ2G1(a) − γ2A2(a) (4.5)
where γ1 ≥ γ2
Gj(a) =

Λ(a) for Sj = cercarial antigen,
n∑
i=1




Pi(a)(ψ1A1(a) + ψ2A2(a)) for Sj = dying adult worm antigen,
E(a) for Sj = egg antigen.
(4.6)
4.2.2 Memory cell model
The memory models include memory B cell populations as well as plasma cells (figure 4.3). The
memory cell populations are assumed to grow through antigen-dependent activation of näıve
cells, at a rate directly proportional to antigen exposure, with relative strength σj (equations
4.7,4.8). The antigenic source comes from a single life cycle stage (equation 4.6), and the
same stage stimulates the production of both memory cells and plasma cells for each antibody
response. A density dependent function with strength KM is used to restrict memory cell
population growth. The memory cell populations each decay at a constant per cell rate ωj . In
the memory models, the plasma cell populations expand through antigen-dependent activation
of their respective memory cell populations, governed by the parameter δj , and decay at a



























Figure 4.3: Schematic diagram of the memory model. This model has state variables for worm
burden (P ), two populations of memory cells (M1 and M2) and two corresponding populations
of plasma cells (A1 and A2). Worms produce eggs (E). The first memory response (with
associated antibody) shown here (M1 and A1) receives its antigenic stimulus from the live
worm population, and the second (M2 and A2) is stimulated by dying worms, but each response
could be stimulated by any one of cercariae, live worms, dying worms or eggs (with the same
antigen stimulating both memory cells and plasma cells for each response). Plasma cells are
generated through activation of memory cells by antigen, at a rate governed by the parameter
δj . Protection is mediated by the plasma cell population, as in the plasma cell-only models.
Cross-regulation is shown using dashed lines – it is shown acting in one direction (reducing
production of M2 and A2) for clarity, but may also act to reduce production of M1 and A1.
Cross-regulation between the two responses affects both memory and plasma cell production.
All parameters are defined in table 4.1, with parameter values given.
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schistosome life stages are mediated by the plasma cells, with no direct effect of memory cells.
The infection processes and the impact of antibody upon the parasite life cycle stages are
identical to those in the plasma cell-only model (equations 4.1,4.2,4.3,4.6). Cross-regulation
affects the rate of production of both memory and plasma cell populations in these models









where ω1 ≥ ω2
dA1(a)/da = δ1G1(a)M1(a)e
−ρ1G2(a) − γ1A1(a) (4.9)
dA2(a)/da = δ2G2(a)M2(a)e
−ρ2G1(a) − γ2A2(a) (4.10)
4.2.3 Antigen threshold
For models which include an antigen threshold, a separate equation records cumulative exposure
(C) to one of the antigens (G2). Cumulative antigen exposure builds up at a rate directly
proportional to the level of antigen (with relative strength β), and does not decay over time
(equation 4.11).
It is assumed that this cumulative antigenic exposure has to exceed a certain threshold level
for one of the two immune responses to be stimulated. As shown in chapter 3, an antigenic
threshold can delay the development of an antibody response. In antibody responses which show
an age-related ‘switch’, only one of these responses is delayed, and so an antigen threshold is
only applied to one of the responses in this analysis. As different decay rates are used for
the two responses (see section 4.2.4), the threshold is applied to the response with less rapid
decay (A2 in this analysis), which is likely to develop later than the more rapidly decaying
response (Woolhouse 1994b). For the plasma cell-only model, A2 is not produced if the level
of cumulative exposure is below the set threshold. Once this threshold has been exceeded, the
plasma cell population grows at a rate proportional to current antigen level (equation 4.12). At
all times, these plasma cells decay at a constant per cell rate γ1. The other antibody response,
A1, is not affected by the antigen threshold, and its production and decay is the same as in the
earlier model (equation 4.4).
C(a) = βG2(a) (4.11)
dA2(a)/da =
−γ2A2(a) if C(a) < T,κ2G2(a)− γ2A2(a) if C(a) ≥ T. (4.12)
where T is a constant.
For the memory model, cumulative exposure is calculated in the same way (equation 4.11),
but the threshold now applies to the more slowly decaying memory response (M2 in this
analysis). M2 is only made when the level of cumulative exposure to the relevant antigen exceeds
the threshold, and is then made at a rate proportional to current antigen levels (equation 4.13),
at all times decaying at a rate ω2. The equations describing the dynamics of the other memory
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response and the two antibody responses are the same as previously (equations 4.7,4.9,4.10).
dM2(a)/da =





− ω2M2(a) if C(a) ≥ T.
(4.13)
where T is a constant.
4.2.4 Model analysis
For both plasma cell-only and memory models, every possible pairwise combination of antigen
stimulus (cercariae, live worms, dying worms or eggs) and antibody target (reduced re-infection,
increased worm death or reduced fecundity) were used in turn for each of the two antibody
responses. All models were run using two different worm survival curves, with worm life
spans following exponential or approximately Gaussian distributions (using n = 1 or n = 9
respectively). Cross-regulation between the two antibody responses was included, operating in
one or two directions. An antigen threshold was included in separate models (without cross-
regulation). The average worm life span (L), taking into account both natural and immune-









nµ+ ψ1A1(a) + ψ2A2(a)
)i−1
(4.14)
Models were run for values of age from 0 to 34 years old (in line with field data showing
stable contact rates in adults up to the age of 34, see chapter 2). The parameters determining
infection rate, antibody strength, antibody and memory decay rates, average worm life span,
strength of cross-regulation and threshold level were each varied across plausible ranges, mostly
in geometric series (values used are given in table 4.1), and all possible combinations of these
parameters were used in turn. For the plasma cell models, the combinations of plasma cell
decay rates used were restricted to those in which A1 decayed at the same or a faster rate
than A2 (γ1 ≥ γ2). For the memory models, it was assumed that both plasma cell populations
decayed very rapidly (γ1 = γ2 = 80 year
-1), with different combinations of memory cell decay
rates, again restricted to combinations where M1 decayed at the same or a faster rate than
M2 (ω1 ≥ ω2). As detailed in chapter 2, published and unpublished data from field studies of
endemic S. haematobium were analysed and criteria were drawn up for testing whether models
could replicate the following patterns: a peaked age intensity curve with control of infection
in adults, a peak shift, reasonable mean worm life span and an antibody switch after peak
infection intensity. Full details of the criteria and data used are given in table 4.2. For each
model, parameter combinations were identified which allowed the model to simultaneously meet
all of these criteria over a two-fold change in the infection rate (Λm).
The differential equations were solved numerically using a variable time step embedded
fifth-order Runge-Kutta algorithm with Cash-Karp parameters, adapted from the rkqs routine





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(a) exponential (n = 1) (b) approximately Gaussian (n = 9)
ANTIBODY 2 ANTIBODY 2
cercariae live worms dying worms eggs antigen/ cercariae live worms dying worms eggs antigen/
c w e c w e c w e c w e target c w e c w e c w e c w e target
cercariae c 0 0 0 0 0 0 0 0 0 0 0 0 cercariae c 0 0 0 0 0 0 0 0 0 0 0 0
w 0 0 0 0 0 0 0 0 0 0 0 0 w 0 0 0 0 0 0 0 0 0 0 0 0
e 0 0 0 0 0 0 0 0 0 0 0 0 e 0 0 0 0 0 0 0 0 0 0 0 0
live c 0 0 0 0 0 0 0 0 0 0 0 0 live c 0 0 0 0 0 0 0 0 0 0 0 0
worms w 0 0 0 0 0 0 0 0 0 0 0 0 worms w 0 0 0 0 0 0 0 0 0 0 0 0
e 0 0 0 0 0 0 0 0 0 0 0 0 e 0 0 0 0 0 0 0 0 0 0 0 0
dying c 0 0 0 0 0 0 0 0 0 0 0 0 dying c 0 0 0 0 0 0 0 0 0 0 0 0
worms w 0 0 0 0 0 0 0 0 0 0 0 0 worms w 0 0 0 0 0 0 0 0 0 0 0 0
e 0 0 0 0 0 0 0 0 0 0 0 0 e 0 0 0 0 0 0 0 0 0 2.4 0 2.9
eggs c 0 0 0 0 0 6.3 0 0 11 0 0 0 eggs c 0 0 0 0 0 10 0 0 74 0 0 0
w 0 0 0 0 0 3.6 0 0 3.3 0 0 0 w 0 0 0 0 0 7.4 0 0 28 0 0 0


















Figure 4.4: Relative success of plasma cell models without cross-regulation or thresholds in
reproducing infection and antibody profiles seen in field data. Individual entries give the number
of parameter sets per 1000 tested for which all of the criteria (as laid out in table 4.2) are met,
for each different antigen:target combination for the two antibody responses. The total number
of parameter combinations tested for each antigen:target combination was 11,025. Antigens
and targets for A2 (which has equal or slower decay than A1) are given along the x -axis of
the table, antigens and targets for A1 are given along the y-axis. Targets: c = cercariae
(reduced re-infection); w = worms (increased worm death); e = eggs (reduced fecundity). Red
squares indicate that no parameter combinations were ever found for which all criteria were
met; orange that fewer than 1 in 1000 parameter combinations were found that could meet all
criteria, and yellow that more than 1 in 1000 parameter combinations were able to meet all
criteria. No cross-regulation or thresholds are included in these models. In panel (a) models
used exponentially-distributed worm survival (n = 1). In panel (b) models used approximately
Gaussian-distributed worm survival (n = 9).
4.3 Results
The combination of both the parasite life cycle stage providing the main antigenic stimulus for
each antibody response, and the stage being targeted by the antibody responses (“antigen:target
combination”), was critical in determining whether or not the models were able to reproduce all
of the patterns identified from field data. For this reason, results are presented and analysed by
antigen:target combination within each model structure. For each model structure (described
in the subsections below), the main outputs of interest were the number and consistent features
of antigen:target combinations for which all of the model criteria could ever be met, and the
proportion of total parameter space explored for which all of the criteria were met. Proportions
rather than absolute numbers were used because different numbers of parameter sets were
explored for each model.
4.3.1 Plasma cell models without cross-regulation or thresholds
Figure 4.4 shows results for the plasma cell-only models without cross-regulation or antigen
thresholds. For each of the possible antigen:target combinations of the two antibody responses,
the proportion of parameter sets tested over which models were able to simultaneously reproduce
all of the required patterns is shown. Results are shown separately for models with exponentially
distributed worm life span (n = 1; figure 4.4a), and with approximately Gaussian-distributed
worm life span (n = 9; figure 4.4b). In the absence of either cross-regulation or an antigen


















(a) exponential (n = 1) (b) approximately Gaussian (n = 9)
ANTIBODY 2 ANTIBODY 2
cercariae live worms dying worms eggs antigen/ cercariae live worms dying worms eggs antigen/
c w e c w e c w e c w e target c w e c w e c w e c w e target
cercariae c 0 0 0 0 0 0 0 0 0 0 0 0 cercariae c 0 0 0 0 0 0 0 0.9 0 0 0 0
w 0 0 0 0 0 0 0 0 0 0 0 0 w 0 0 0 0 0 0 0 0 0 0 0 0
e 0 0 0 0 0 0 0 0 0 0 0 0 e 0 0 0 0 0 0 0 0 0 0 0 0
live c 0 0 0 0 0 0 0 0 0 0 0 0 live c 0 0 0 0 0 0 0 0 0 0 0 0
worms w 0 0 0 0 0 0 0 0 0 0 0 0 worms w 0 0 0 0 0 0 0 0 0 0 0 0
e 0 0 0 0 0 0 0 0 0 0.4 0 0 e 0 0 0 0 0 0 0 0 0 0 0 0
dying c 0 0 0 0 0 0 0 0 0 0 0 0 dying c 0 0 0 0 0 0 0 0 0 0 0 0
worms w 0.2 0 0 0 0 0 0 0 0 0 0 0 worms w 3.2 0 0 0 0 0 0 0 0 0 0 0
e 0 0 0 0 0 0 0 0 0 0.7 0.2 0.5 e 0 0 0 0 0 0 0 0 0 28 3 37
eggs c 0 0 0 0 0 5.5 0 0 30 0 0 0 eggs c 0 0 0 0 0 4.6 0 0 129 0 0 0
w 0 0 0 0 0 6.3 0 0 11 0 0 0 w 0 0 0 0 0 7.7 0 0 47 0 0 0
e 0 0 0 0 0 2 0 0 20 0 0 0 e 0 0 0 0 0 2.2 0 0 155 0 0 0
antigen/target antigen/target
Figure 4.5: Relative success of memory models without cross-regulation or thresholds in
reproducing infection and antibody-profiles seen in field data. See legend for figure 4.4. In
this model, it is the memory cell populations for each antibody response which differ in their
decay rates – M2 has equal or slower decay than M1.
patterns for any part of the parameter space tested, 6/144 for n = 1 and 8/144 for n = 9. These
models all had one antibody response stimulated by antigens from live or dying worms, which
reduced worm fecundity, with the other antibody response stimulated by egg antigens. In all
cases, the antibody response stimulated by eggs peaked early and was replaced by the other,
worm-stimulated, response. Usually the egg-stimulated response decayed more rapidly than
the worm-stimulated response (models with egg-stimulated A1 and worm-stimulated A2), but
for some of the models with Gaussian-distributed worm life span and dying worm antigen, this
was reversed (models with worm-stimulated A1 and egg-stimulated A2). For the antigen:target
combinations which were ever able to reproduce the required field patterns, a very restricted
part of parameter space (≤8.3% of combinations tested) gave results which passed all of the
criteria. Using approximately Gaussian distributed worm survival (figure 4.4b) increased the
range of parameters for which it was possible to pass all of the criteria when compared with
exponentially distributed worm survival (figure 4.4a). Across the whole parameter space tested,
only 0.25 parameter sets per 1000 tested were able to meet all of the criteria for models with
exponentially distributed worm survival, compared with 1.5 per 1000 tested for approximately
Gaussian distributed worm survival.
4.3.2 Memory models without cross-regulation or thresholds
Figure 4.5 shows the same results for memory models without cross-regulation or an antigen
threshold. As in the plasma cell-only models, a small number of antigen:target combinations
were able to reproduce all of the field patterns (11/144 for both n = 1 and n = 9). Most
of these, like the plasma cell-only models, had one fecundity-reducing worm-induced antibody
response while the other response was stimulated by egg antigen. A small number of models
had a different combination of antigens and targets, with one response stimulated by antigens
from dying worms, which reduced worm survival, and the other stimulated by cercarial antigens
and reducing reinfection.
For the antigen:target combinations which were ever able to reproduce the required field
patterns, only a limited range of the parameter space (≤15% of combinations tested) gave
results which passed all of the criteria. As with the plasma cell models, using approximately
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Gaussian distributed worm survival (figures 4.5b) increased the range of parameters for which
it was possible to pass all of the criteria when compared with exponentially distributed worm
survival (figures 4.5a). Across the whole parameter space tested, only 0.54 parameter sets
per 1000 tested were able to meet all of the criteria for models with exponentially distributed
worm survival, compared with 2.9 per 1000 tested for approximately Gaussian distributed worm
survival.
4.3.3 Plasma cell models with cross-regulation
Figure 4.6 shows the impact of cross-regulation in plasma cell-only models, acting in one or both
directions. Inclusion of cross-regulation increased the number of antigen:target combinations
which could meet the criteria. Across all of the cross-regulation models (figure 4.6), 57/144
(40%) of the different antigen:target combinations tested were ever able to reproduce the
infection and antibody patterns. For the models that were able to reproduce these field patterns,
one of the antibody responses always fell into one of two broad groupings of antigen:target
combinations: (i) antigen cercariae/live worms/dying worms, target fecundity; or (ii) antigen
cercariae/dying worms, target re-infection. Models with cross-regulation of both responses
enabled the greatest number of different antigen and target combinations to reproduce field
patterns at least once (figure 4.6e,f). Models with approximately Gaussian-distributed worm
survival were able to replicate field patterns for a greater number of antigen:target combinations
than equivalent models with exponential worm survival.
Models with cross-regulation of the more rapidly decaying response (A1) were able to
reproduce patterns seen in the field over the greatest proportion of parameter space (figure
4.6c,d), with 0.69 parameter sets per 1000 tested able to meet all of the criteria for models with
exponentially distributed worm survival, and 3.6 per 1000 tested for approximately Gaussian
distributed worm survival. Similarly, for both models with cross-regulation of the more slowly
decaying response (A2) and models with cross-regulation of both responses, using approximately
Gaussian distributed worm survival increased the range of parameters for which it was possible
to pass all of the criteria when compared with exponentially distributed worm survival.
4.3.4 Memory models with cross-regulation
Similar overall patterns were seen for memory models with cross-regulation (figure 4.7).
Inclusion of cross-regulation increased the number of antigen:target combinations which could
meet the criteria. Across all of the cross-regulation models tested, 87/144 (60%) of the different
antigen:target combinations tested were ever able to reproduce all of the field patterns. For the
models that were able to reproduce these field patterns, one of the antibody responses always fell
into one of the three following broad groupings: (i) antigen cercariae/live worms/dying worms,
target fecundity; (ii) antigen cercariae/dying worms, target re-infection; or (iii) antigen dying
worms; target worm survival (unique to the memory models). Models with cross-regulation
of both responses enabled the greatest number of different antigen and target combinations
to reproduce field patterns at least once (figure 4.7e,f). Models with approximately Gaussian-
distributed worm survival were again able to replicate field patterns for a greater number of
antigen:target combinations than equivalent models with exponential worm survival.
Models with cross-regulation of the more rapidly decaying response (M1) were able to




















































(a) exponential (n = 1) (b) approximately Gaussian (n = 9)
ANTIBODY 2 ANTIBODY 2
cercariae live worms dying worms eggs antigen/ cercariae live worms dying worms eggs antigen/
c w e c w e c w e c w e target c w e c w e c w e c w e target
cercariae c 0 0 0 0 0 0 0 0 0 0 0 0 cercariae c 0 0 0 0 0 0 0 0 0 0 0 0
w 0 0 0 0 0 0 0 0 0 0 0 0 w 0 0 0 0 0 0 0 0 0 0 0 0
e 0 0 0 0 0 0 0 0 0 0 0 0 e 0 0 0 0 0 0 0 0 0 0 0 0
live c 0.7 0 0 0 0 0 0 0 0 0 0 0 live c 3.7 0 0 0 0 0 0 0 0 0 0 0
worms w 1 0 0 0 0 0 0 0 0 0 0 0 worms w 2.9 0 0 0 0 0 0 0 0 0 0 0
e 0.9 0 0 0 0 0 0 0 0 0.6 0.1 0 e 4.1 0.2 0 0 0 0 0 0 0 0.1 0.1 0
dying c 0.4 0 0 0 0 0 0 0 0 0 0 0 dying c 0.2 0 0 0 0 0 0.2 0 0 0 0 0
worms w 0.1 0 0 0 0 0 0 0 0 0 0 0 worms w 0.1 0 0 0 0 0 0 0 0 0 0 0
e 0.2 0 0 0.1 0 0 0 0 0 0.4 0 0 e 3.1 1.2 3.1 2.5 1 2.4 3.5 2.2 3.4 5.2 1.5 6.6
eggs c 0.7 0 0.5 0 0 6 0 0 4.9 0 0 0 eggs c 3.7 0 1.5 0 0 6.6 0 0 20 0 0 0
w 1 0 0.6 0 0 5.7 0 0 3.3 0 0 0 w 2.9 0 1.3 0 0 6 0 0 9.7 0 0 0
e 0.8 0 0.5 0 0 6.7 0 0 6.1 0 0 0 e 3.4 0 1.6 0 0 7.1 0 0 29 0 0 0
antigen/target antigen/target
(c) (d)
ANTIBODY 2 ANTIBODY 2
cercariae live worms dying worms eggs antigen/ cercariae live worms dying worms eggs antigen/
c w e c w e c w e c w e target c w e c w e c w e c w e target
cercariae c 0 0 0 0 0 4.7 0 0 2.4 0 0 0 cercariae c 0 0 0 0 0 3.7 0 0 32 0 0 0
w 0 0 0 0 0 4.5 0 0 1 0 0 0 w 0 0 0 0 0 2.5 0 0 17 0 0 0
e 0 0 0 0 0 4.4 0 0 2.3 0 0 0 e 0 0 0 0 0 2.3 0 0 32 0 0 0
live c 0 0 0 0 0 2.7 0 0 1.7 0 0 0 live c 0.1 0 0 0 0 2.5 9.9 0 27 0 0 0
worms w 0.2 0 0 0 0 2.1 0 0 0.8 0 0 0 worms w 0.1 0 0 0 0 2.2 5.6 0 15 0 0 0
e 0.1 0 0 0 0 2.3 0 0 1.8 0.1 0 0 e 0.3 0 0 0 0 2.4 5.7 0 25 0 0 0
dying c 0 0 0 0 0 2.6 0 0 1.9 0 0 0 dying c 0.1 0 0 0 0 2.7 0 0 38 0 0 0
worms w 0 0 0 0 0 2 0 0 1.1 0 0 0 worms w 0.1 0 0 0 0 2.1 0 0 28 0 0 0
e 0 0 0 0 0 2.4 0 0 2 0 0 0 e 0 0 0 0 0 2.9 0 0 37 0.6 0.1 1
eggs c 0 0 0 0 0 9.3 0 0 13 0 0 0 eggs c 0.1 0 0 0 0 5.5 9.9 0 70 0 0 0
w 0.2 0 0 0 0 8.2 0 0 5.7 0 0 0 w 0.1 0 0 0 0 5.7 5.6 0 34 0 0 0
e 0.1 0 0 0 0 8.8 0 0 12 0 0 0 e 0.1 0 0 0 0 5.8 5.8 0 81 0 0 0
antigen/target antigen/target
(e) (f)
ANTIBODY 2 ANTIBODY 2
cercariae live worms dying worms eggs antigen/ cercariae live worms dying worms eggs antigen/
c w e c w e c w e c w e target c w e c w e c w e c w e target
cercariae c 0 0 0 0 0 0.9 0 0 0.2 0 0 0 cercariae c 0 0 0 0 0 0.8 0.2 0.2 8.1 0 0 0
w 0 0 0 0 0 0.7 0 0 0.1 0 0 0 w 0 0 0 0 0 0.6 0 0 4.8 0 0 0
e 0 0 0 0 0 0.9 0 0 0.1 0 0 0 e 0 0 0 0 0 0.6 0 0 7.7 0 0 0
live c 0.6 0 0 0 0 0 0 0 0 0 0 0 live c 2.2 0 0 0 0 0 0.8 0 1.9 0 0 0
worms w 0.6 0 0 0 0 0 0 0 0 0 0 0 worms w 1.9 0 0 0 0 0 0.6 0 0.7 0 0 0
e 0.8 0 0 0 0 0 0 0 0 0.3 0 0 e 2.6 0 0 0 0 0.1 0.4 0 1.3 0.1 0 0
dying c 0.1 0 0 0 0 0.4 0 0 0.4 0 0 0 dying c 0.3 0 0 0 0 0.9 0 0 13 0 0 0
worms w 0.1 0 0 0 0 0.3 0 0 0.3 0 0 0 worms w 0.4 0 0 0 0 0.8 0 0 9.6 0 0 0
e 0.1 0 0 0 0 0.4 0 0 0.5 0.3 0 0 e 0.7 0.2 0.4 0 0 0.9 0.9 0.6 13 0.9 0.2 1.2
eggs c 0.6 0 0.4 0 0 3.7 0 0 4.7 0 0 0 eggs c 2.2 0 1 0 0 2.8 0.8 0 16 0 0 0
w 0.6 0 0.4 0 0 3.5 0 0 3 0 0 0 w 1.9 0 0.9 0 0 3.1 0.6 0 7.8 0 0 0





Figure 4.6: Relative success of plasma cell models with cross-regulation in reproducing infection
and antibody profiles seen in field data. See legend for figure 4.4. For panels (a) and (b), there is
one-way down-regulation of the less rapidly decaying antibody response (A2), in panels (c) and
(d) there is one-way down-regulation of the more rapidly decaying antibody response (A1) and
in panels (e) and (f) there is two-way cross-regulation of both antibody responses. The total
number of parameter combinations tested for each antigen:target combination was 33,075 for
models with one-way regulation (a,b,c,d) and 99,225 for models with two-way cross-regulation
(e,f). The left-hand set of panels are for models with exponentially-distributed worm life span
(n = 1) (a,c,e), the right-hand set are for models with approximately Gaussian-distributed























































(a) exponential (n = 1) (b) approximately Gaussian (n = 9)
ANTIBODY 2 ANTIBODY 2
cercariae live worms dying worms eggs antigen/ cercariae live worms dying worms eggs antigen/
c w e c w e c w e c w e target c w e c w e c w e c w e target
cercariae c 0 0 0 0 0 0 0 0 0 0 0 0 cercariae c 0 0 0 0 0 0 0 0.3 0 0 0 0
w 0 0 0 0 0 0 0 0 0 0 0 0 w 0 0 0 0 0 0 0 0 0 0 0 0
e 0 0 0 0 0 0 0 0 0 0 0 0 e 0 0 0 0 0 0 0 0 0 0 0 0
live c 1.5 0 0 0 0 0 0 0 0 0 0 0 live c 3.8 0 0 0 0 0 0 0 0 0 0 0
worms w 3.3 0 0 0 0 0 0 0 0 0 0 0 worms w 3.5 0 0 0 0 0 0.1 0 0 0 0 0
e 2.6 0.2 0.1 1.2 0.7 0.7 1 0.8 0.9 1.3 0.2 0.1 e 0.8 0.5 0 0.5 0.3 0.2 2.5 2.5 2.5 0.8 0.4 0.2
dying c 0.5 0 0 0 0 0 0 0 0 0 0 0 dying c 2.3 1.2 4.2 0.1 0 0 2 2.3 1.7 0.1 0 0.1
worms w 1.3 0 0.1 0 0 0.2 0 0 0 0 0 0 worms w 7.9 0.1 0 0.3 0.1 0.3 5.6 0.4 0 0.3 0.1 0
e 2.1 1.5 1.6 0.7 0.1 0.5 0.5 0 0.2 3.8 1.9 4.4 e 11 8.5 11 10 7.3 5.4 31 25 30 26 13 42
eggs c 1.5 0 0.7 0 0 17 0 0 18 0 0 0 eggs c 3.8 0 1.5 0 0 9.9 0 0 24 0 0 0
w 3.3 0 1.2 0 0 17 0 0 13 0 0 0 w 3.5 0 1.4 0 0 11 0.1 0 17 0 0 0
e 1.1 0 0.5 0 0 17 0 0 23 0 0 0 e 2.1 0 0.6 0 0 12 0 0 44 0 0 0
antigen/target antigen/target
(c) (d)
ANTIBODY 2 ANTIBODY 2
cercariae live worms dying worms eggs antigen/ cercariae live worms dying worms eggs antigen/
c w e c w e c w e c w e target c w e c w e c w e c w e target
cercariae c 0 0 0 0.3 0.8 2.7 0.2 0 7.3 0.3 0.8 0.1 cercariae c 0 0 0 1.4 0.7 1.8 4.3 1.1 41 1.4 0.7 0.6
w 0 0 0 0 0 2 0 0 6.7 0 0 0 w 0 0 0 0 0 1.6 2.8 0 31 0 0 0
e 0 0 0 0 0 1.9 0 0 6.9 0.5 0.4 0.2 e 0 0 0 0 0 1.7 7.3 0 40 1.5 0.5 0.5
live c 0 0 0 0 0 0.7 0 0 2.2 0 0 0 live c 0 0 0 0 0 1 0.5 0 31 0 0 0
worms w 0 0 0 0 0 0.4 0 0 1.6 0 0 0 worms w 0 0 0 0 0 1 1.1 0 22 0 0 0
e 0 0 0 0 0 0.4 0 0 1.4 4.5 3.1 8 e 0.1 0 0 0 0 0.8 0.2 0 20 2.7 1.4 5.7
dying c 0 0 0 0 0 0.4 0 0 2.3 0 0 0 dying c 0 0 0 0 0 3 2.1 3.7 52 0 0 0
worms w 0 0 0 0 0 0.4 0 0 1.5 0 0 0 worms w 0.9 0 0 0 0 3 2.9 0 46 0 0 0
e 0 0 0 0 0 0.5 0 0 2 3.4 2.5 5.2 e 0 0 0 0 0 3 2.1 0 53 5.7 3.6 13
eggs c 0 0 0 0 0 5.3 0 0 29 0 0 0 eggs c 0 0 0 0 0 5.8 0.5 0 94 0 0 0
w 0 0 0 0 0 4.7 0 0 17 0 0 0 w 0 0 0 0 0 5.6 1.1 0 56 0 0 0
e 0 0 0 0 0 2.7 0 0 26 0 0 0 e 0 0 0 0 0 3.9 0.4 0 116 0 0 0
antigen/target antigen/target
(e) (f)
ANTIBODY 2 ANTIBODY 2
cercariae live worms dying worms eggs antigen/ cercariae live worms dying worms eggs antigen/
c w e c w e c w e c w e target c w e c w e c w e c w e target
cercariae c 0 0 0 0.2 0.3 1.1 0 0 1.5 0.2 0.3 0.1 cercariae c 0 0 0 0.5 0.2 0.2 0.1 0.5 7.7 0.5 0.2 0.1
w 0 0 0 0 0 0.8 0 0 1.2 0 0 0 w 0 0 0 0 0 0.2 0 0 6.8 0 0 0
e 0 0 0 0 0 0.8 0 0 1.6 0.3 0.1 0.2 e 0 0 0 0 0 0.1 0.1 0 7.5 0.3 0.2 0.2
live c 1.2 0 0 0 0 0 0 0 0 0 0 0 live c 1.1 0 0 0 0 0 0 0 0.1 0 0 0
worms w 1.3 0 0 0 0 0 0 0 0 0 0 0 worms w 0.8 0 0 0 0 0 0 0 0 0 0 0
e 1.3 0 0 0 0 0 0 0 0 3 2.2 2.4 e 0.5 0 0 0 0 0 0.6 0.6 0.6 1.3 0.8 0.7
dying c 0.1 0 0 0 0 0 0 0 0.8 0 0 0 dying c 0.1 0 0.1 0 0 0.8 1 0.6 13 0 0 0
worms w 0.4 0 0 0 0 0 0 0 0.7 0 0 0 worms w 1.5 0.1 0.1 0 0 0.8 0.7 0 11 0 0 0
e 0.2 0 0.2 0 0 0 0 0 0.8 2.3 1.4 3.4 e 2 1.2 2.1 0 0 0.8 4.6 3.1 16 3.1 2.2 7
eggs c 1.2 0 0.2 0 0 6.9 0 0 11 0 0 0 eggs c 1.1 0 0.4 0 0 3.5 0 0 12 0 0 0
w 1.3 0 0.2 0 0 6.4 0 0 7.1 0 0 0 w 0.8 0 0.4 0 0 3.5 0 0 9.8 0 0 0
e 1 0 0.2 0 0 6 0 0 12 0 0 0 e 0.7 0 0.2 0 0 2.8 0 0 18 0 0 0
antigen/target antigen/target
Figure 4.7: Relative success of memory models with cross-regulation in reproducing infection
and antibody profiles seen in field data. See legends for figures 4.4 and 4.6. In this model, it is
the memory cell populations for each antibody response which differ in their decay rates – M2


















(a) exponential (n = 1) (b) approximately Gaussian (n = 9)
ANTIBODY 2 ANTIBODY 2
cercariae live worms dying worms eggs antigen/ cercariae live worms dying worms eggs antigen/
c w e c w e c w e c w e target c w e c w e c w e c w e target
cercariae c 0 0 0 0 0 0 0 0 0 0 0 0 cercariae c 0 0 0 0 0 0 0 0 0 0 0 0
w 0 0 0 0 0 0 0 0 0 0 0 0 w 0 0 0 0 0 0 0 0 0 0 0 0
e 0 0 0 0 0 0 0 0 0 0 0 0 e 0 0 0 0 0 0 0 0 0 0 0 0
live c 10 0 0 0 0 0 0 0 0 0 0 0 live c 25 0 0 0 0 0 0 0 0 0 0 0
worms w 35 0 0 0 0 0 0 0 0 0 0 0 worms w 43 0 0 0 0 0 0 0 0 0 0 0
e 7.7 0 0 0 0 0 0 0 0 0 0 0 e 18 0 0 0 0 0 0 0 0 0 0 0
dying c 11 0 0 0 0 0 0 0 0 0 0 0 dying c 10 0 0 0 0 0 0 0 0 0 0 0
worms w 21 0 0 0.9 0 0 0 0 0 0.9 0 0 worms w 14 0 0 0 0 0 0 0 0 0 0 0
e 9 0 0 0 0 0 0 0 0 0 0 0 e 10 0 0 0 0 0 0 0 0 1.6 0 1.8
eggs c 10 0 74 0 0 115 0 0 130 0 0 16 eggs c 25 0 82 0 0 111 0 0 177 0 0 15
w 35 0 79 0 0 119 0 0 120 0 0 16 w 43 0 88 0 0 123 0 0 150 0 0 16
e 8.1 0 74 0 0 101 0 0 149 0 0 11 e 22 0 76 0 0 104 0 0 199 0 0 11
antigen/target antigen/target
Figure 4.8: Relative success of plasma cell models with an antigen threshold in reproducing
infection and antibody profiles seen in field data. See legend for figure 4.4. A threshold is
included for the less rapidly decaying antibody response (A2). The total number of parameter
combinations tested for each antigen:target combination was 22,050.
4.7c,d), with 1.1 parameter sets per 1000 tested able to meet all of the criteria for models
with exponentially distributed worm survival, and 4.9 per 1000 tested for approximately
Gaussian distributed worm survival. Similarly, for both models with cross-regulation of the
more slowly decaying response (M2) and models with cross-regulation of both responses, using
approximately Gaussian distributed worm survival increased the range of parameters for which
it was possible to pass all of the criteria when compared with exponentially distributed worm
survival.
Memory models were able to reproduce field patterns for a greater number of possible
antigen:target combinations and over a greater overall portion of parameter space than were
equivalent plasma cell models (figure 4.7 cf. figure 4.6).
4.3.5 Plasma cell models with an antigen threshold
The inclusion of an antigen threshold also influenced whether models could reproduce field
patterns. For plasma cell models, inclusion of an antigen threshold on the more gradually
decaying response (A2) increased the number of antigen:target combinations which could
meet the criteria (figure 4.8). The number of antigen:target combinations which were able
to reproduce all of the patterns for any part of the parameter space tested was increased to
23/144 (17%) for both n = 1 and n = 9. For the models that were able to reproduce these
field patterns, one of the antibody responses always fell into one of the two following broad
groupings: (i) antigen cercariae/live worms/dying worms/eggs, target fecundity; or (ii) antigen
cercariae, target re-infection. Note that the anti-fecundity response stimulated by egg antigens
is unique to the threshold models.
For the antigen:target combinations which were ever able to reproduce the required field
patterns, up to 20% of combinations tested now gave results which passed all of the criteria.
Using approximately Gaussian distributed worm survival (figure 4.8b) slightly increased the
range of parameters for which it was possible to pass all of the criteria when compared
with exponentially distributed worm survival (figure 4.8a). Across the whole parameter space
tested, 8 parameter sets per 1000 tested were able to meet all of the criteria for models with
exponentially distributed worm survival, compared with 9.5 per 1000 tested for approximately
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(a) exponential (n = 1) (b) approximately Gaussian (n = 9)
ANTIBODY 2 ANTIBODY 2
cercariae live worms dying worms eggs antigen/ cercariae live worms dying worms eggs antigen/
c w e c w e c w e c w e target c w e c w e c w e c w e target
cercariae c 0 0 0 0 0 0 0 0.4 0 0 0 0 cercariae c 0 0 0 0 0 0 0 0.1 0 0 0 0
w 0 0 0 0 0 0 0 0 0 0 0 0 w 0 0 0 0 0 0 0 0 0 0 0 0
e 0 0 0 0 0 0 0 0 0 0 0 0 e 0 0 0 0 0 0 0 0 0 0 0 0
live c 16 0 0 0 0 0 0 0 0 0 0 0 live c 23 0 0 0 0 0 0 0 0 0 0 0
worms w 41 0 0 0 0 0 0 0 0 0 0 0 worms w 41 0 0 0 0 0 0 0 0 0 0 0
e 10 0 0 0 0 0 0 0 0 0.2 0 0 e 13 0 0 0 0 0 0 0 0 0 0 0
dying c 17 0 0 0 0 0 0 0 0 0 0 0 dying c 8.2 0 0 0 0 0 0 0 0 0 0 0
worms w 23 0 0 0.4 0.1 0 0.2 0 0 0.4 0.1 0 worms w 35 0.1 0.6 0.9 0.3 0 5.3 0 0 0.9 0.3 0
e 14 0 0 0 0 0 0 0 0 0.3 0.1 0.3 e 7.3 0 0 0 0 0 0 0 0 30 11 33
eggs c 16 0 97 0 0 156 0 0 140 0 0 25 eggs c 23 0 102 0 0 145 0 0 194 0 0 23
w 41 0 96 0 0 159 0 0 133 0 0 24 w 41 0 98 0 0 155 0 0 158 0 0 21
e 9.1 0 91 0 0 143 0 0 173 0 0 15 e 18 0 91 0 0 142 0 0 233 0 0 12
antigen/target antigen/target
Figure 4.9: Relative success of memory models with an antigen threshold in reproducing
infection and antibody profiles seen in field data. See legend for figure 4.8. In this model,
it is the memory cell populations for each antibody response which differ in their decay rates –
M2 has equal or slower decay than M1.
4.3.6 Memory cell models with an antigen threshold
Similar patterns were seen for memory models with an antigen threshold on the more gradually
decaying response (M2) (figure 4.9). The number of antigen:target combinations which were
able to reproduce all of the patterns for any part of the parameter space tested was increased
to 31/144 (22%) for n = 1 and 32/144 (22%) for n = 9. For the models that were able
to reproduce these field patterns, one of the antibody responses always fell into one of the
three following broad groupings: (i) antigen cercariae/live worms/dying worms/eggs, target
fecundity; (ii) antigen cercariae, target re-infection; or (iii) antigen dying worms, target worm
survival (unique to the memory models). The anti-fecundity response stimulated by egg antigens
is unique to the threshold models.
For the antigen:target combinations which were ever able to reproduce the required field
patterns, up to 23% of parameter combinations tested now gave results which passed all of
the criteria. Using approximately Gaussian distributed worm survival (figure 4.9b) slightly
increased the range of parameters for which it was possible to pass all of the criteria when
compared with exponentially distributed worm survival (figure 4.9a). Across the whole
parameter space tested, 10 parameter sets per 1000 tested were able to meet all of the criteria
for models with exponentially distributed worm survival, compared with 11.6 per 1000 tested
for approximately Gaussian distributed worm survival.
For models including an antigen threshold, memory models (figure 4.9) were able to
reproduce field patterns for a greater number of possible antigen:target combinations and over
a greater overall portion of parameter space than were equivalent plasma cell models (figure
4.8).
4.3.7 Models which never meet all criteria
Analysing the results by antigen:target combination, it was found that some of these were never
able to reproduce all of the field patterns in any of the different models tested. Altogether,
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Table 4.3: Combinations of life cycle stage providing the main source of antigens for, and life
cycle stage targeted by, each antibody response, for which the model criteria were never met
for any parameter combination
Life cycle stage
Antigen for A2 Targeted by A2 Antigen for A1 Targeted by A1
cercariae cercariae cercariae cercariae
cercariae cercariae cercariae worm survival
cercariae cercariae cercariae eggs
cercariae worm survival cercariae cercariae
cercariae worm survival cercariae worm survival
cercariae worm survival cercariae eggs
cercariae worm survival live worms cercariae
cercariae worm survival live worms worm survival
cercariae worm survival eggs cercariae
cercariae worm survival eggs worm survival
cercariae worm survival eggs eggs
cercariae eggs cercariae cercariae
cercariae eggs cercariae worm survival
cercariae eggs cercariae eggs
cercariae eggs live worms cercariae
cercariae eggs live worms worm survival
live worms cercariae cercariae worm survival
live worms cercariae cercariae eggs
live worms cercariae live worms cercariae
live worms cercariae live worms worm survival
live worms cercariae eggs cercariae
live worms cercariae eggs worm survival
live worms cercariae eggs eggs
live worms worm survival cercariae worm survival
live worms worm survival cercariae eggs
live worms worm survival live worms cercariae
live worms worm survival live worms worm survival
live worms worm survival dying worms cercariae
live worms worm survival eggs cercariae
live worms worm survival eggs worm survival
live worms worm survival eggs eggs
dying worms worm survival cercariae eggs
dying worms worm survival live worms cercariae
dying worms worm survival live worms worm survival
dying worms worm survival eggs cercariae
dying worms worm survival eggs worm survival
dying worms worm survival eggs eggs
eggs cercariae cercariae worm survival
eggs cercariae live worms cercariae
eggs cercariae live worms worm survival
eggs cercariae eggs cercariae
eggs cercariae eggs worm survival
eggs cercariae eggs eggs
eggs worm survival cercariae worm survival
eggs worm survival live worms cercariae
eggs worm survival live worms worm survival
eggs worm survival dying worms cercariae
eggs worm survival eggs cercariae
eggs worm survival eggs worm survival
eggs worm survival eggs eggs
eggs eggs cercariae worm survival
eggs eggs live worms cercariae
eggs eggs live worms worm survival
eggs eggs dying worms worm survival
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54 of the 144 different antigen:target combinations tested failed to ever pass all of the criteria
simultaneously. These combinations are listed in table 4.3. These models are ordered by the
A2 response, which tended to be the stronger determinant of model success. Within this set
of antigen:target combinations, dying worms were less likely to be the antigenic stimulus for
either response than other stages of the life cycle, and for more than half of them, the target
of the longer-lived A2 response was reduced worm survival.
4.3.8 Immune cell decay rates in successful models
Due to the balanced study design, which used every potential parameter combination, it was
possible to identify preferred parameter values from their relative frequencies in models which
met all of the criteria. Results are presented for the decay rates for the immune cells (plasma
cells and memory B cells), which are estimable (at least in principle). The relative rates of
decay for the two antibody responses are of interest as well as absolute values.
For plasma cell-only models with exponential worm life span and without cross-regulation
or an antigen threshold, distinct combinations of antibody survival were found to work (figure
4.10a). For these models to meet all of criteria, it was necessary to have one antibody response
with very slow decay (A2 decay of 0.008 or 0.08 year
-1, equivalent to a half-life of 9–90 years) with
very rapid decay of the other response (A1 decay of at least 0.8 year
-1, or a half-life of 10 months
or less), with at least a 100-fold difference between decay rates for the two responses. Inclusion
of one or more of Gaussian-distributed worm survival (figure 4.10b,d,f), cross-regulation (figure
4.10c,d) or an antigen threshold (figure 4.10e,f) in the plasma cell-only models increased the
range of survival rates which were seen for the ‘longer-lived’ A2 response, and allowed field
patterns to be reproduced when the two antibody responses had equal decay rates. In all of
these models there was still an overall preference for having a disparity between the decay rates
of the two plasma cell populations.
For the memory models, plasma cell decay rates were kept constant at 80 year-1 (half-life
of 3 days) for both responses, and decay rates for memory cell populations were varied. Less
clear patterns were seen in memory decay rates (graphs displayed in appendix C). There was
a consistent preference for slower decay rates of M2, but preferred values of M1 varied widely
by model. For all of the models, it was possible to reproduce all of the field patterns when the
two memory responses had equal decay rates.
4.3.9 Natural mean worm life span in successful models
The distribution of natural mean worm life span (not taking into account anti-worm immunity)
was also investigated in successful models, to see what influence this had upon the ability of the
models to reproduce field patterns. These results are shown in appendix C. The preferred worm
life span varied with the antigen stimulating A2, the worm survival distribution and whether or
not an antigen threshold was included. For example, in models with cross-regulation, if live or
dying worms stimulated A2, there was a preference for longer-lived worms, but with cercarial
antigen, there was a preference for a short worm life span if worm survival was exponentially
distributed. Since all of these models were able to pass all of the criteria, it is not possible to
conclude from this that any particular value for worm life span is more consistent with patterns
























































































































































exponential (n = 1) approximately Gaussian (n = 9)
Figure 4.10: Antibody decay rates for plasma cell models which pass all criteria. Plots show
the total number of times parameter combinations including the different possible combinations
of decay rates for the two plasma cell populations pass all criteria. (a,b) Models without
cross-regulation or thresholds, (c,d) cross-regulation models (total frequencies summed over
all of them), (e,f) models with a threshold on A2. The left-hand panels are for models with
exponentially-distributed worm life span (n = 1) (a, c,e), the right-hand ones are for models
with approximately Gaussian-distributed worm life span (n = 9) (b,d,f). All of the different
combinations of decay rates that were used have a bar on the chart; black bars indicate that no
successful parameter combination had this combination of antibody decay rates, blue bars that
at least one successful parameter combination had this combination of antibody decay rates.
Note that different maximum values are used on the z (frequency)-axis.
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4.3.10 Importance of different criteria
The relative importance of the different criteria used was assessed by looking at how frequently
they were responsible for excluding parameter combinations. This was done by summing up
the number of times each criterion was the only one to be failed by any of the parameter sets
tested. It was found that most parameter combinations failed on multiple criteria, with only
6% failing to pass only a single criterion. Each of the six criteria excluded some parameter sets
single-handedly, demonstrating that they were all discriminatory in this analysis. Parameter
sets that failed only a single criterion were most likely to fail to pass the antibody switch
criterion, or the requirement for the age of the infection peak to fall between 6 and 20 years
old. They were least likely to fail on either the peak shift criterion or the criterion stipulating
the level of infection in adults relative to the peak.
4.4 Discussion
It was shown that testing models for their ability to simultaneously reproduce multiple patterns
seen in both infection and antibody data enabled a large number of potential model structures
and parameter combinations to be rejected. These results give insight into the likely mechanisms
giving rise to these patterns. It was found that both the stage of the life cycle which provided
the main antigenic stimuli for each antibody response, and the stage of the life cycle which was
targeted by a protective antibody response were critical in determining whether the models
could reproduce infection and antibody profiles consistent with field data. Some of the models
which had dying worms as the main source of protective antigen were able to reproduce all of the
required patterns. However, some models which had other stages of the life cycle acting as the
principle antigen source could also meet all of the criteria, suggesting that it is not necessary for
dying worms to provide the main source of protective antigen to explain the patterns explored
here. Inclusion of cross-regulation, an antigen threshold or using approximately Gaussian-
distributed worm survival each increased the number of antibody antigen-target combinations,
and the range of parameter space for which it was possible to reproduce patterns seen in the
field, but none of these were essential for enabling all of the field patterns to be replicated.
From this analysis it is possible to exclude some combinations of life cycle stage providing the
main antigenic stimulus for, and life cycle stage targeted by, each antibody response, and these
combinations are listed in table 4.3.
The approach used here has similarities to pattern-oriented modelling, testing multiple
different model structures and parameter values for their ability to simultaneously reproduce
multiple patterns seen in population data (Grimm et al. 2005). Previous modelling studies have
shown that individual patterns in macroparasite infection data can frequently be reproduced by
more than one mechanism or combinations of mechanisms, particularly the peaked age-intensity
curve and the peak shift (Duerr et al. 2003a; Fulford et al. 1992; Woolhouse 1992b). In this study,
‘successful’ models had to simultaneously pass six different criteria for infection and antibody
profiles, including the peaked age-intensity curve (within limits identified from field data), the
peak shift, an antibody ‘switch’, and realistic mean worm survival, making it much more likely
that these models incorporate the ‘true’ mechanisms determining field patterns. It was shown
that all of the criteria used were informative in rejecting particularly parameter sets tested, as
they were all able to exclude some parameters single-handedly. Thorough sensitivity analysis,
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using a balanced design where all possible combinations of levels of different parameters were
investigated, increases confidence that all of the model structures which can possibly reproduce
these patterns have been identified here. Although the immune responses are represented in a
simplistic fashion in these models, they should capture the important features of the antibody
response, being based upon well characterised B cell maturation pathways (Gray 2002), and
covering the main alternative theories for the persistence of antibody: (i) antigen-independent
mechanisms either through persistence of long-lived plasma cells or continual non-specific
activation of memory cells to form short-lived plasma cells (both represented by the plasma
cell-only models), and (ii) antigen-dependent mechanisms, with specific antigenic activation of
memory cells to form short-lived plasma cells (memory models) (Kalia et al. 2006; Ochsenbein
et al. 2000).
This approach was intended to identify the essential mechanisms underlying universal
patterns of schistosome infection and antibody, by selecting models that give outputs consistent
with a wide range of studies of endemic S. haematobium, rather than trying to accurately
replicate patterns seen in individual studies. To this end, patterns were chosen that were
seen across multiple different studies. However, some of these patterns are more robust than
others; the age of the peak and the peak shift have been well characterised across numerous
different studies, but although lower infection levels are always reported in adults for endemic
S. haematobium, the level relative to the peak can vary considerably in some studies depending
upon which age groupings are used. For this reason, a wide range was permitted for this
criterion. In this analysis, it was rarely the only criterion on which individual parameter sets
were excluded, and so the uncertainty in this pattern will have very little impact upon the
results reported here.
The antibody switch has been clearly identified in three Zimbabwean populations (Mutapi
et al. 1998, 1997; Ndhlovu et al. 1996b), but was not seen in a fourth study (Mutapi et al., unpub.
data; see results for Mutoko-Rusike in chapter 2.). This pattern has not been specifically looked
for in other published studies, meaning that it may not be universal. However, it was seen across
a number of different isotypes in all three of these populations (see analysis in chapter 2 and
Ndhlovu et al. (1996b)), making it a robust and striking pattern within these populations which
deserves exploration.
One potentially important factor which may vary between different populations is the shape
of the age-contact profile. The contact data used to define the age-infection rate in these
models came from the same area as two of the populations we used to identify the infection and
antibody criteria (Chan et al. 2000; Mutapi et al. 1997), meaning that the models should be
able to explain the patterns seen in these particular populations. Additionally, the pattern of
increasing water contact with age in young children which was included in this model has been
widely reported, but relative contact levels in older children and adults can vary widely between
studies (Kabatereine et al. 1999). Although the level of infection was varied in these models,
no attempt was made to investigate the effect of changing the shape of the age-contact profile,
due to sparse data and substantial study-to-study variation where such data is collected.
A potential limitation of these models is that they describe population averages without
taking into account distributions of infection or antibody. The assumption that all individuals
within a certain population are exposed at the same rate is unlikely to be true, as most studies
of water contact (which is the usually best proxy for infection rate) show highly over-dispersed
contact patterns between individuals over set periods of time (Chandiwana 1987; Chandiwana
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& Woolhouse 1991). Previous models have shown that introducing heterogeneity in contact
rates into similar deterministic models gives an earlier and lower infection peak for the same
mean contact rate (Woolhouse 1992b), and it would also be expected to affect mean antibody
profiles. The best way to look at the effects of heterogeneous contact rates for these types of
models is through the use of fully stochastic individual based models (Chan et al. 2000), but
it was not feasible in this study to cover the same breadth of model structures and parameter
ranges with stochastic simulation models, which take longer to run and need to be repeated
many times to account for stochastic variation in individual simulations.
Previous analyses looking at the age-intensity profiles generated by models with different
stages of the life cycle providing the principal antigen source and being targeted by protective
antibody found differences in the shapes of these profiles but did not exclude any combinations
as being inconsistent with field data (Woolhouse 1992b). In this analysis, using more
quantitative criteria based on field data, and additionally requiring models to reproduce the
antibody switch, a large number of potential antigen:target combinations were excluded. This
analysis suggests that the antibody switch may arise when one antibody response, which is
stimulated by a life cycle stage that is continually present, reduces the level of antigen inducing
another response. In many of the models, one of the antibody responses was stimulated by
worms or cercariae and reduced worm fecundity, which reduced host exposure to eggs which were
the antigen for the other antibody response. While this process may be enhanced by unequal
natural survival of the cells responsible for the two antibody responses, active down-regulation
of the second antibody response via responses to the persisting life stage, or an antigen threshold
giving a more rapid change between the two responses, none of these were necessary to reproduce
a switch under the definition used here. These results suggest that gradual acquisition of
exposure to protective antigens is sufficient to explain the slow development of protective
immunity, without it being necessary to invoke a major role for dying worms or an antigen
threshold, but do suggest that continual exposure to the relevant antigen is most likely to
induce such a protective response. These models have suggested that protective immunity
may primarily target worm fecundity, which was not routinely considered in earlier immuno-
epidemiological models. They have also shown that the assumed worm survival curve can make
a considerable difference to the outcome, challenging the usual assumption of exponential worm
survival, which is mathematically convenient but has not been empirically demonstrated.
This analysis has confirmed that dying worms or an antigen threshold can both affect
the patterns of immune responses to schistosomes, but has not excluded the other alternative
explanations explored. To further distinguish between the different potential explanations for
the slow development of protective immunity discussed here, additional robust data patterns
are considered in the next chapter, including infection and antibody distributions and co-
distributions. Using a similar model framework to that used here, stochastic individual-based
models are developed, which not only enable the impact of heterogeneity in contact rates to be
taken into account, but also allow patterns of aggregation and co-distribution to be simulated
and compared with field data. This extra layer of criteria is used to further distinguish some of
the key mechanisms underlying the observed dynamics and distributions of both infection and




co-distributions of infection and
antibody
5.1 Introduction
Like other helminth infections, schistosomes are highly aggregated among their human hosts,
such that many individuals in an endemic population will harbour few or no schistosome worms,
whilst a small proportion carry very heavy parasite loads (Guyatt et al. 1994; Woolhouse
1994a). Previous modelling work has suggested that the level of aggregation observed in human
schistosome infection is likely to arise mainly from aggregation between individuals in their
relative contact rates, rather than inter-individual differences in immune competence (Chan
& Isham 1998). Several observational studies have demonstrated that there is considerable
heterogeneity between individuals in the number of water contacts they make over a fixed
time period (Chandiwana et al. 1991; Etard et al. 1995). For practical reasons, these studies
have generally been conducted over a fairly short time period, so that the extent to which an
individual maintains the same level of contact over their lifetime is unknown. Individuals tend
to be predisposed to heavy or light infections (Etard et al. 1995), which is likely to be at least
partially mediated through contact rates. Mathematical models with varying predisposition
have demonstrated that this can have a substantial impact upon the distribution of infection
across a population (Quinnell et al. 1995). Models have also shown that aggregation in worm
burden can occur as a result of ‘clumped’ infection, with aggregation in the number of worms
acquired per contact (Duerr et al. 2003a; Quinnell et al. 1995). Acquired immunity which is
generated as a function of infection level is expected to reduce aggregation in worm burden,
with modelling work by Galvani (2003) suggesting that parasite aggregation is reduced to a
greater extent by immunity affecting susceptibility to re-infection than by immunity which
reduces worm fecundity.
Levels of specific antibody against schistosome antigen preparations also tend to be highly
aggregated (Mutapi 1997; Mutapi & Roddam 2002), as was discussed in chapter 2, but this
has received much less attention in immuno-epidemiological modelling of schistosome infection.
Antibody isotypes which demonstrate an age-related ‘switch’ (Mutapi et al. 1997; Ndhlovu
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et al. 1996b) show a dichotomous relationship with each other (Mutapi et al. 1998), which was
characterised in chapter 2. As well as occurring naturally with age, this antibody switch has
been observed in younger children following praziquantel treatment (Grogan et al. 1996; Mutapi
et al. 1998). Other studies have also reported that praziquantel treatment alters the level of
different antibody isotypes (Butterworth et al. 1996; Corrêa-Oliveira et al. 2000; Gomes et al.
2002), with several studies showing that treatment increases levels of isotypes associated with
protection against re-infection (Fitzsimmons et al. 2007; Satti et al. 1996; Webster et al. 1997).
In chapter 4, deterministic models describing mean levels of infection and antibody responses
in homogeneously exposed populations showed that the age-related antibody switch, as well as
peaked age-intensity profiles consistent with field data, could be reproduced by a variety of
models. It was shown that the combination of the stage of the life cycle which was assumed
to provide the main antigenic stimulus for each antibody response, and the stage of the life
cycle which was targeted by each antibody response, was critical in determining whether or
not these patterns could be reproduced. Cross-regulation between the two antibody responses
and the inclusion of an antigen threshold for one of the responses both enhanced the ability of
these models to reproduce these patterns, but neither mechanism was essential for the models
to do so. To further distinguish between these mechanisms, and to test the hypothesis that
exposure to dying worms is necessary to stimulate a protective antibody response, a different
modelling approach was undertaken to see whether these different mechanisms could explain the
observed distributions of infection and antibody as well as age-related mean levels. Stochastic
individual-based models were used, which made it straightforward to incorporate heterogeneity
in individual exposure rates and to measure distributions of simulated infection and antibody
levels as well as mean levels. Additionally, these models were tested for their ability to reproduce
the observed treatment-induced antibody switch in younger children.
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Analysis framework for chapter 5
• The aim of the analysis in this chapter is to further explore different hypotheses
to explain both the switch seen in the antibody response to S. haematobium and
population-level infection profiles, using an increased panel of criteria looking at
distributions as well as mean levels of infection and antibody, and post-treatment




• Models are tested for their ability to pass an extended list of infection intensity and
antibody switch criteria:
– Peaked age infection curve (peaking in the right age range) with sufficient
reduction of infection in adults relative to the peak
– Peak shift between areas with different rates of infection
– Aggregated egg output
– Infection prevalence within criterion range
– Sufficiently long mean worm life span in adult hosts (in line with field estimates)
– Antibody switch with age, occurring after the age of the peak in infection
– Antibody switch occurring after treatment
• Stochastic individual-based models are used which describe infection intensity and
levels of two independent antibody responses in a population of individuals, with model
outputs being sampled and analysed in the same way as the population data in chapter
2.
• Water contact is assumed to be aggregated, in line with field data, to test whether this
is adequate to explain the aggregation seen in infection and antibody responses.
• Worm lifespan is assumed to follow a Gaussian distribution, as this gave the most fits
in chapter 4
• Only one antibody response is assumed to be protective, in line with results from
chapter 4.
• Cross-regulation is assumed to down-regulate the shorter-lived response, as this gave
the most fits in chapter 4.
• The effects of a single round of treatment are modelled as a decline in worm burden
(with an increase in exposure to dying worms), with or without a reduction in
transmission over the following 36 weeks.
• The following are changed separately to assess their impact upon the results:
– aggregation of water contacts
– aggregation of cercariae acquired per contact
– aggregation of egg output per worm
– relative number of eggs output per worm
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Table 5.1: Model structures used
Immune mechanism Life cycle stage
Antigen for A2 Targeted by A2 Antigen for A1
Cross-regulation
cercariae cercariae live worms
cercariae cercariae dying worms
cercariae cercariae eggs
live worms eggs cercariae
live worms eggs live worms
live worms eggs dying worms
live worms eggs eggs
dying worms cercariae live worms
dying worms cercariae eggs
dying worms eggs cercariae
dying worms eggs live worms
dying worms eggs dying worms
dying worms eggs eggs
Antigen threshold
cercariae cercariae live worms
cercariae cercariae dying worms
cercariae cercariae eggs
cercariae eggs eggs
live worms eggs eggs
dying worms eggs eggs
eggs eggs eggs
5.2 Methods
An individual-based stochastic discrete-time model was used to describe changes in worm
burden and the level of two separate antibody responses with age for people living in an area
with stably transmitted endemic schistosome infection. The model was based upon one of the
frameworks used for the deterministic population-level models in chapter 4, with the immune
response modelled as populations of plasma cells (without memory cell populations) and worm
survival assumed to be approximately Gaussian distributed. The model structures used for
analysis in this chapter were those that looked most promising (were able to pass all of the
criteria over the greatest region of parameter space tested) in the deterministic analysis. The
selected models were those with cross-regulation of the short-lived antibody response, and
those with an antigen threshold for the longer-lived antibody response. In the deterministic
framework, it was found that for the vast majority of successful permutations of these models
the shorter-lived antibody response (A1) had little or no protective effect. Therefore, for
the stochastic models it was assumed that only the longer-lived antibody response (A2) had
any protective effect. From now on A2 is referred to as the ‘protective’ antibody response,
and A1 as the non-protective response. Only the combinations of life cycle stage providing
the main antigenic stimulus for the two antibody responses, and target for the protective
antibody response which were successful in the deterministic analysis were explored further
in the stochastic models. These combinations are listed in table 5.1.
For each population, separate simulations were run for 161 individuals, with infection and
antibody levels recorded at a single age for each individual to give simulated cross-sectional data
sets for comparison with field data (chapter 2). Overall infection rates were assumed to stay
constant over time. At birth (day 0), the worm burden and antibody levels for each person were
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set to 0. For each individual, the simulation started at age (a) = 1 day old and was updated at
daily time steps up until the age of sampling. For 136 of these individuals, the sampling ages,
which varied between 6–34 years old, were taken from one of the field populations analysed in
chapter 2 (Valhalla). An additional group of 25 individuals aged 3–5 years old were simulated
to check that the peak of infection did not occur below the age of 6, but were not included
in any other part of the analysis. Antibody correlations were calculated for a subset of 101
individuals, chosen to match those with real antibody data available (chapter 2).
Water contact, worm acquisition and death, and measured egg output were all modelled
as stochastic processes, with number of contacts, worms and sampled eggs taking only integer
values. Antibody development and immune stimulation by egg antigens were modelled as
deterministic processes, with antibody level and number of eggs within the host both being
continuous variables. The model is described below, with all parameters defined in detail in
table 5.2. For consistency with the analysis in chapter 4, parameters in the deterministic models
which were yearly rates are kept as yearly rates here, but are converted into probabilities within




Whereas in the deterministic framework the same water contact age-profile is assumed for all
individuals in a population, in the stochastic individual-based models individuals are assumed
to differ in their contact rates. Each individual in these models has an underlying maximum
yearly contact rate Λm, drawn from a gamma distribution which has a mean equal to the







is the shape parameter of the gamma distribution). Λm is selected in this way at the start of the
simulation (when a = 0), and is reselected in the same way with a yearly probability φ, so at each
(daily) time step there is a probability φ/dpy that an individual’s underlying maximum contact
rate will be recalculated (where dpy = 365). If φ is 0, this assumes perfect predisposition, with
individuals maintaining the same relative level of exposure for life. Positive values of φ represent
individuals making sudden changes in their contact rate, which might happen if they move
house or change school or occupation. Here, φ is based upon rates at which people reported
moving house in a Zimbabwean study population. In this population, a positive correlation
was found between infection intensity and distance lived from the nearest water-contact site in
young children, suggesting that location of residence is a strong determinant of exposure level
(appendix D). A correlation between distance lived from water contact site and infection levels
has also been reported in schoolchildren in Tanzania (Rudge et al. 2008).
As in chapters 2–4, and based upon field observations from Zimbabwe (Chan et al. 2000), an
individual’s contact rate is assumed to increase linearly with age up to age ac and then remain
constant at a yearly rate Λm:
Λ(a) =
Λm aac if a < ac,Λm if a ≥ ac. (5.1)
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On each day, the number of contacts, r, that an individual makes is drawn from a Poisson
distribution with mean Λ(a)/dpy (r ∼ Pois(Λ(a)/dpy)). It is assumed that, on average,
an individual acquires one schistosome cercariae per contact. To incorporate aggregation in
cercarial infection, it is assumed that an individual acquires d cercariae with a probability 1/d
per contact. tq is the number of cercariae acquired on the q
th contact (q = 1, ..., r) on each day
such that
tq =
d if s < 1/d, where s ∼ U(0, 1)0 otherwise. (5.2)





New cercariae may be killed upon entry into the host by an anti-reinfection antibody
response. It is assumed that cercariae are killed as a decreasing exponential function of antibody
level (A2), in the same way as in the deterministic models, such that the probability of a
cercariae surviving is e−θA2(a−1) . The number of surviving cercariae acquired on a given
day, f , is binomially distributed, f ∼ Binom(b, e−θA2(a−1)). The schistosomulum stage is not
explicitly represented here; in reality, the larval stages take about 4–6 weeks to reach maturity
(becoming adult, egg-laying worms), but this is a relatively short period in comparison with
the simulation time for these models (6–34 years), and is not included.
Live worms are modelled passing through nine compartments (n = 9) to give approximately
Gaussian distributed worm survival (as used in chapters 3 and 4). Newly acquired worms (f)
enter the first worm compartment (i = 1). The rate at which a worm moves from compartment i
to compartment i+1 is nµ per year where 1/µ is the average worm life span in years (see chapters
3 and 4). Therefore the daily probability of a worm moving from compartment i to compartment
i + 1 is 1 − e−nµ/dpy. If compartment i contains Pi(a − 1) worms at age a − 1 the number of
worms leaving it at age a, mi, is binomially distributed (mi ∼ Binom(Pi(a− 1), 1− e−nµ/dpy)).
Therefore the number of worms in compartment i at age a is given by
Pi(a) =
Pi(a− 1) + f −mi for i = 1,Pi(a− 1) +mi−1 −mi for 1 < i ≤ n. (5.4)
Worms die as they leave the final (nth) compartment. The number of eggs stimulating an
immune response (E) is assumed to be proportional to current worm burden, but reduced by
anti-fecundity antibody. An anti-fecundity response is assumed to reduce E deterministically
via a decreasing exponential function of antibody level (in the same way as in the deterministic







Mean egg output (analogous to egg counts measured in urine) is calculated on a single day
for each individual (sampling day), as the arithmetic mean of three separate ‘samples’ (uy for
y = 1,2,3). Each sample is drawn from a negative binomial distribution (implemented as a
Poisson distribution with a gamma-distributed mean), with mean εE(a) (where ε is the mean
number of eggs output in 10ml urine per worm per day) and aggregation parameter kE :












The aggregation parameter for egg output (kE) is taken from values calculated for
S. mansoni (de Vlas 1996).
Antibody responses
Two antibody responses (A1 and A2) are modelled as separate populations of plasma cells. It is
assumed that antibody levels are directly proportional to the number of plasma cells at a given
time. Plasma cell population dynamics are modelled deterministically. Each antibody response
(the jth antibody response (where j = 1,2)) has a single life stage (Sj) as its principal source
of antigen, either cercariae, live worms, dying worms or eggs (within the host). The level of
antigen (Gj) stimulating the j
th antibody response at age a is calculated as follows:
Gj(a) =






/dpy for Sj = live adult worm antigen,
mn for Sj = dying adult worm antigen,
E(a)/dpy for Sj = internal egg antigen.
(5.7)
Levels of live worms and internal eggs are divided by the number of days per year (dpy) to
give a direct comparison with the deterministic model output (chapter 4).
Two separate types of models are considered: those with cross-regulation of the non-
protective antibody response, and those with an antigen threshold for the protective antibody
response. These are described in turn below.
Each plasma cell population (Aj) expands at a rate proportional to the level of antigen
stimulating that response (Gj), multiplied by a constant, κj . In models with cross-regulation,
this rate of growth is down-regulated for the non-protective antibody response, A1, via a
decreasing exponential function of the level of antigen stimulating the protective antibody
response (G2), with relative strength ρ. There is no cross-regulation of the protective antibody
response in these models. Each plasma cell population decays with a yearly per cell rate γj ,
giving a daily cell loss of 1− e−γj/dpy.
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A1(a) = A1(a− 1) + κ1G1(a)e−ρG2(a) −A1(a− 1)(1− e−γ1/dpy) (5.8)
A2(a) = A2(a− 1) + κ2G2(a)−A2(a− 1)(1− e−γ2/dpy) (5.9)
where γ1 ≥ γ2
For models with an antigen threshold, a cumulative tally of exposure to antigen is kept
(equation 5.10). The non-protective plasma cell compartment (A1) is unaffected by the
threshold and grows at a rate proportional to the level of its antigen, G1 (equation 5.11). The
protective antibody response (A2) is only made if the antigen cumulative exposure exceeds a
threshold level, T (equation 5.12). Once this antigen threshold has been exceeded, the protective
plasma cell compartment (A2) grows at a rate proportional to the level of relevant antigen
present (G2), in the same way as in the cross-regulation model. Both plasma cell populations
decay with a yearly per cell rate γj , as before.
C(a) = C(a− 1) + βG1(a) (5.10)
A1(a) = A1(a− 1) + κ1G1(a)−A1(a− 1)(1− e−γ1/dpy) (5.11)
A2(a) =
A2(a− 1)−A2(a− 1)(1− e−γ2/dpy) if C(a) < T,A2(a− 1) + κ2G2(a)−A2(a− 1)(1− e−γ2/dpy) if C(a) ≥ T. (5.12)
Including treatment
The impact of treatment is assessed in the model by introducing treatment on a single day
(the day after sampling) for all individuals aged 6–15 years old. The effects of treatment are
assumed to be (i) a decline in worm burden, (ii) a boost to the level of dying worm antigen
(equal to the number of worms killed by treatment) and (iii) a reduction in transmission after
treatment, modelled as a reduction in the probability of infection per contact on all subsequent
days. The simulation is continued for a further 36 weeks after treatment, with egg output and
antibody levels recorded at 12, 18, 24, 30 and 36 weeks post-treatment for individuals aged
6–15 years old.
With a given treatment efficacy (probability that a worm is killed by a single round of
treatment), x, the number of worms removed from compartment i at age a is binomially
distributed (wi ∼ Binom(Pi(a − 1), x)). The total number of worms killed across all





If either antibody response is stimulated by antigens from dying worms, this level is increased
by z worms on the day of treatment, such that
Gj(a) = z +mn for Sj = dying adult worm antigen (5.14)
The decrease in infection rates after treatment is assumed to apply from the day after
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treatment, and to affect all individuals equally. This is included as a reduction in the probability
of infection per contact. The number of cercariae acquired on a ‘successful’ contact, d, is
multiplied by a factor ϕ, such that for any contacts made in the 36 weeks after treatment, the
number of new cercariae acquired in a single contact (tq), is given by
tq =
ϕd if s < 1/d, where s ∼ U(0, 1)0 otherwise. (5.15)
5.2.2 Model criteria
Criteria were drawn up to test whether models could reproduce the required patterns of
infection and antibody seen in field data. Most of the criteria relate to patterns seen in cross-
sectional data, with an additional criterion for the effect of treatment on antibody. As for
the deterministic models (chapter 4), there were criteria to test for the following patterns: a
peaked age intensity curve with lower levels of infection in adults, a peak shift and an antibody
switch occurring after the peak in infection intensity. These were assessed using grouped means
for the infection criteria, and Spearman’s correlation for the antibody switch (as was used for
the original data analysis in chapter 2). Additionally for the stochastic models there were
criteria to test whether measured infection prevalence and aggregation in egg output fell within
ranges identified from field data, in each of two age groups (6–14 year olds and 15–34 year
olds). There was also a criterion for infection aggregation in the whole population, but the
equivalent criterion for prevalence was found to be uninformative and was not used. Finally
there was a criterion to test whether the antibody switch occurred after treatment. These
criteria are listed and defined in full in table 5.3. The peak shift was assessed on the average
values of peak age group and peak infection level over all repeat simulations for different values
of maximum infection rate; all other criteria were assessed for individual simulations. Initially
I had hoped to use formal criteria to test whether the models were able to reproduce observed
aggregated distributions of antibody, but it was found that the range of standardized variances
for the different antibody isotypes obtained from field data (chapter 2) was too broad to be
informative. Antibody aggregation and co-distributions were assessed visually for a subset of
the models which passed all of the criteria for qualitative comparison with the field data.
5.2.3 Model analysis
Simulations were run for each of the successful combinations of antigen and antibody target
identified from deterministic analysis (listed in table 5.4). In the initial baseline analysis, the
parameters governing the stochastic processes were kept constant at the values given in table
5.2. The parameters determining mean population infection rate, worm life span, antibody
strength, strength of cross-regulation/antigen threshold level and plasma cell decay rates were
each varied across plausible ranges (given in table 5.2). Note that these parameters were the
same as those used in the deterministic analysis, with the exception of A1 strength (assumed
to be 0 for all stochastic models), and the inclusion of an additional higher antigen threshold
level (T = 2500). All possible combinations of these parameters were used in turn, giving 3150














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































was analysed in the same way as the field data in chapter 2. Mean levels of infection and
antibody were calculated for five separate age classes (6–8, 9–10, 11–12, 13–23 and 24–34 year
olds) and the prevalence and standardized variance of infection were calculated for two larger
age groups (6–14 and 15–34 year olds). The Spearman’s correlation coefficient between the
two antibody responses was calculated across the whole population. These were used to see
whether the model could meet all of the cross-sectional criteria described above. These criteria
are set out in full in table 5.3. Successful parameter combinations had to meet these criteria
over a two-fold change in contact rate (Λpmax). Performance curves were drawn for a selection
of parameter sets which preliminary analysis indicated were able to meet the model criteria,
to determine the optimal number of replicate simulations which needed to be performed for
each set of parameter values. Parameter sets for which all of the cross-sectional criteria were
met were then tested for their ability to reproduce the treatment-induced antibody switch in
the subset of the simulated population aged 6–15 years old. The predicted egg reduction rate
(ERR) was calculated by comparing geometric means of infection intensity before and 12 weeks
after treatment using the following formula (Saathoff et al. 2004):
ERR =
(
1− geometric mean egg count after treatment
geometric mean egg count before treatment
)
× 100% (5.16)
The ERR is calculated using geometric means in the vast majority of studies which report
it for S. haematobium (Danso-Appiah et al. 2008).
Univariate sensitivity analysis was carried out on models which were able to reproduce
both the cross-sectional and post-treatment patterns satisfactorily, varying separately in turn
the aggregation of the underlying population contact rate distribution (k1), the rate at which
individual underlying contact rates are re-sampled (φ), the aggregation of cercariae acquired
per contact (d), the aggregation of eggs per worm (kE), and the number of eggs excreted in
10ml urine per worm (ε), while varying all other parameters across their full range, as above.
The different parameter values used in the sensitivity analysis are given in table 5.2. These
models were tested for their ability to reproduce both the cross-sectional and post-treatment
patterns.
All simulations were run in C++.
5.3 Results
5.3.1 Identification of successful models
Performance curves were constructed for nine parameter sets which frequently passed all of the
criteria. A variable number of repeat simulations, between 20 and 1000, were run ten times
for each parameter set to determine how many repeat simulations were needed to give a stable
estimate of the proportion of repeat simulations passing all criteria. The performance curves
are shown in appendix E. It was found that 400 repeat simulations were sufficient to give a
stable estimate of the proportion of repeat simulations passing all criteria. On the basis of these
results, which showed quite low proportions of simulations passing all criteria, a threshold of
50% of simulations (i.e. 200 out of 400) passing all criteria was used to identify successful
parameter combinations in all subsequent analyses.
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5.3.2 Baseline analysis: cross-sectional criteria
The initial analysis used only the baseline parameters for the stochastic processes in the model,
but covered the full range of all the other parameters (parameters listed in the ‘baseline analysis’
column in table 5.2). In the initial analysis, only the cross-sectional criteria were used (all of
the criteria listed in table 5.3 apart from the post-treatment antibody switch). In line with
field observations and the deterministic analysis in chapter 4, models were assessed for their
ability to meet all of the cross-sectional criteria over a two-fold difference in population contact
rate. The number of parameter sets which successfully did this are given for each model in
table 5.4 (column headed ‘cross-sectional’). Only three of the different model structures tested
were ever able to meet all of the cross-sectional criteria over a two-fold change in population
contact rate (highlighted in bold in table 5.4). These models all had an antigen threshold for
the protective antibody response, and all had the protective antibody response reducing worm
fecundity. The non-protective antibody response was stimulated by antigens from the egg stage
and the protective antibody response could be stimulated by antigen from cercariae, live worms
or dying worms.
It was also seen that one of the cross-regulation models (as indicated in table 5.4) was able
to meet all of the cross-sectional criteria for some individual parameter sets, although not over
a two-fold difference in population contact rate. This model also had the protective antibody
response reducing worm fecundity and the non-protective antibody response stimulated by
antigens from the egg stage. In this model, the protective antibody response was stimulated by
antigen from dying worms.
5.3.3 Importance of different criteria
The criteria used to judge whether model output adequately replicated patterns seen in infection
and antibody field data are listed in table 5.3. The relative importance of different criteria in
excluding parameter combinations was assessed in detail for the baseline analysis using only the
cross-sectional criteria. The number of individual simulations passing each criterion and passing
each possible combination of criteria was counted. The criteria which were consistently passed
by the fewest number of simulations were the requirement for infection prevalence to lie between
5–80%, particularly in the younger age group (aged 6–14 years old), and the requirement for a
negative correlation between the two antibody responses. The majority of simulations failed on
multiple criteria, with only 5% failing on a single criterion alone. Simulations that failed on a
single criterion were most likely to fail to pass the criteria relating to the age of peak infection
intensity, infection prevalence levels in 6–14 year olds or the antibody switch. All of the criteria
were at some point the only filter to not be passed, indicating that all of these criteria were
informative.
5.3.4 Inclusion of treatment
The parameter sets which were able to meet all of the criteria over a two-fold change in
population contact rate (the three antigen threshold models highlighted in table 5.4) were
further analysed for their ability to reproduce the observed antibody switch after treatment of
children aged 6–15 years old. A range of different treatment efficacies and post-treatment levels




















































































































































































































































































































































































































































































































































































































































































































































































Figure 5.1: Egg reduction rate (ERR) at 12 weeks post treatment in different models. ERR
(calculated using the formula given in section 5.2.3) is shown for each of the three antigen
threshold models tested. The three panels show results for models with different life cycle
stages providing the main antigenic stimulus for the protective antibody response (a) cercariae,
(b) live worms, (c) dying worms. For each of these models, A2 reduces worm fecundity, and A1
is stimulated by antigen from eggs. The graphs show the mean ERR across all of the parameter
sets tested for each value of treatment efficacy and transmission reduction used. For (c) they
are additionally split by antigen threshold (T ). In all graphs, transmission reduction is shown
as squares for 100%, crosses for 50% and diamonds for 0%. In panel (c), open symbols denote
antigen threshold (T ) = 250, filled symbols denote antigen threshold (T ) = 25.
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observed egg reduction rate (ERR) at 12 weeks post-treatment (figure 5.1). ERR increased
with increased treatment efficacy and with increased reduction of transmission after treatment
(figure 5.1), and was also affected by the nature of the immune response. For the two models
with antigen from cercariae or live worms stimulating the protective antibody response (A1),
ERR tended to be lower than the actual treatment efficacy, due to new infections acquired
during the 12 weeks after treatment (including those acquired on the day of treatment itself)
(figure 5.1a,b). For the model with dying worms providing the antigen for the protective
antibody response, ERR was often higher than the treatment efficacy, and was affected by the
level of the antigen threshold for the protective antibody response, with a greater ERR seen
for parameter sets with a lower antigen threshold (figure 5.1c).
Only the models with dying worm antigens stimulating the protective antibody response
were able to reproduce the post-treatment antibody switch (table 5.4). This was only possible
for a subset of the parameters which reproduced all of the cross-sectional data patterns. The
number of parameter sets reproducing the post-treatment antibody switch was robust to the
level of treatment efficacy and reduction in transmission post-treatment across all of the levels
explored.
Exploratory analysis of the cross-regulation model which was able to reproduce all of the
cross-sectional data patterns for individual parameter sets indicated that this model could also
reproduce the antibody switch after treatment. This was investigated further in the sensitivity
analysis.
5.3.5 Sensitivity analysis
Sensitivity analysis was carried out on the two model structures which were able to reproduce
the antibody switch after treatment: one with cross-regulation of the non-protective antibody
response, and one with an antigen threshold for the protective antibody response, which both
had the protective antibody stimulated by antigens from dying worms, with protective antibody
reducing worm fecundity, and the non-protective antibody stimulated by eggs. Each of the
parameters governing the stochastic processes in the model was varied separately in turn, using
the alternative values given in table 5.2 (column headed ‘Values used in sensitivity analysis’),
whilst varying all other parameters over the full ranges used in the baseline analysis. These
models were assessed for their ability to pass both the cross-sectional and the post-treatment
criteria (all criteria listed in table 5.3). Figure 5.2 shows the number of parameter sets which
were able to pass all of the criteria for both cross-sectional and post-treatment criteria over a
two-fold change in maximum contact rate when each of the stochastic process parameters was
varied in turn. For the cross-regulation model (figure 5.2a), this was only possible for models
with moderate cercarial aggregation (d = 10) or with fewer eggs output in urine per worm (ε =
0.1). In the antigen threshold model, it was found that both the aggregation of the underlying
contact rates between individuals and the rate at which this contact level was re-sampled
affected whether or not the models were able to meet all of the criteria. Poisson distributed
contacts (k1 = ∞) and frequent re-sampling of contact rates (φ = 0.5 year-1) both prevented
the models from reproducing field patterns (figure 5.2b). Note that more frequent re-sampling
of contact rates reduces the overall aggregation of contact between individuals, so that these
results are not independent. Making more modest changes to these parameters – increasing
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Figure 5.2: Results of univariate sensitivity analysis. Panels show the number of parameter
combinations tested which meet all criteria (cross-sectional and post-treatment) over a two-
fold change in maximal contact rate when the following parameters are changed individually
as shown: the scale parameter for the underlying gamma distribution from which individual
maximal contact rates are drawn (k1), the yearly probability with which the individual maximal
contact rate is resampled (φ), the parameter governing the aggregation of cercariae acquired
per contact (d), the mean number of eggs per worm output in a 10ml urine sample (ε), and the
scale parameter for the gamma distribution from which the number of eggs per worm is drawn
(kE). Baseline values for these parameters are: k1 = 0.5, φ = 0.05 year
-1, d = 1, ε = 1, kE =
1. Results are shown for the two model structures for which cross-sectional and post-treatment
criteria were ever met: (a) with cross-regulation of the non-protective antibody response, (b)
with an antigen threshold for the protective antibody response. For both of these models, the
stage of the schistosome life cycle which provides the main antigenic stimulus for A2 is dying
worms, A2 reduces worm fecundity, and A1 is stimulated by antigen from eggs.
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(1998) (k1 = 0.4), or using perfect predisposition (φ = 0) – both increased the number of
parameter sets which were able to meet all of the criteria. As in the cross-regulation model,
varying cercarial aggregation and egg output in urine per worm both made a large difference to
the ability of the model to reproduce field patterns. Either level of cercarial aggregation used
in this analysis (d = 10, d = 100) increased the number of parameter sets meeting all criteria
to a similar level, and reducing egg output in urine to 0.1 also greatly increased the area of
parameter space over which the criteria were passed. Increasing egg output per worm (ε = 10)
made little difference in these models, and reducing the aggregation of eggs per worm found
in urine (using a Poisson distribution, kE =∞) reduced the number of parameter sets able to
meet all of the criteria.
5.3.6 Parameter distributions
The ranges of decay rates for the two plasma cell populations in successful parameter sets were
plotted for the two different model structures (figure 5.3). These are summed across the baseline
and sensitivity analysis results. Similar patterns were seen for both the cross-regulation model
(figure 5.3a) and the antigen threshold model (figure 5.3b). For all of the successful parameter
sets, there was relatively rapid decay of the initial antibody response (A1) of 8–80 year
-1 (half-
life 3–30 days), with slower decay of the protective antibody response (A2) of 0.008–0.8 year
-1
(half-life of 10 months–90 years) for all except four parameter combinations in the antigen
threshold models which had more rapid A2 decay of 8 year
-1 (half-life 30 days). Within these
ranges there was little apparent preference for particular values or combinations of the two
decay rates.
5.3.7 Antibody aggregation and codistributions
The level of antibody aggregation was not used as a criterion in these models since the great
majority of simulations gave standardized variances for antibody which fell within the broad
range calculated from field data in chapter 2, meaning that this was not an informative criterion.
All of the models which passed all of the other criteria gave aggregated distributions for both
antibody responses. These are plotted for two randomly selected parameter sets in figure
5.4. Although it was not formally tested for, standardized variance tended to change between
the two age groups in the same direction seen in the field data (in the opposite direction
to the change in mean level, chapter 2). Visual inspection of antibody codistributions for
randomly selected parameter sets (figure 5.4c,f) confirmed that the models had reproduced the
dichotomous relationship between the two antibodies which was seen in field data (chapter 2),


















































Figure 5.3: Distribution of plasma cell decay rates in successful parameter combinations. The
frequency of different combinations of decay rates for the two plasma cell populations are
shown for models which were able to meet all of the cross-sectional and post-treatment criteria,
in either the baseline or the univariate sensitivity analysis. (a) Models with cross-regulation
of the initial antibody response (A1). (b) Models with an antigen threshold for the protective
antibody response (A2). Bars are drawn for all combinations of plasma cell decay rates which































































































































































































































SV = 4.5 SV = 3.6
SV = 5.2 SV = 3.9
Figure 5.4: Antibody aggregation and co-distributions in the model outputs, shown for two
example parameter sets. (a,b,c) Cross-regulation model, parameters used: Λpmax = 25, 1/µ =
10, γ1 = 80, γ2 = 0.008, η = 0.256, ρ = 0.1, k1 = 0.5, φ = 0.05, kE = 1, d = 10. (d,e,f) Antigen
threshold model, parameters used: Λpmax = 100, 1/µ = 6.5, γ1 = 80, γ2 = 0.08, η = 1.024,
T = 250, k1 = 0.5, φ = 0.05, kE = 1, d = 100. In (a) and (d) the distribution of the initial
antibody response is shown, in (b) and (e) the distribution of the protective antibody response
is shown, and in (c) and (f) the co-distribution of the two antibodies is shown. In (c) and (f)
data points are coloured by age: grey circles 0–14 years old, black circles 15–34 years old. SV
= standardized variance (σ2/x2).
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5.4 Discussion
Stochastic individual-based models were used to identify model structures that could simulta-
neously reproduce field patterns of schistosome infection and antibody, including aggregation
of infection and age-related and treatment-induced antibody switches. As hypothesised, it was
found that dying worms had to provide the main antigenic stimulus for a protective antibody
response in order to reproduce these patterns. Additionally, it was found that the protective
antibody response had to reduce worm fecundity, and the non-protective antibody response
had to be stimulated by eggs. Models including either cross-regulation or an antigen threshold
were able to reproduce all of the pre- and post-treatment infection and antibody patterns.
The analysis suggested that the plasma cell populations that produce the switching antibody
isotypes have different intrinsic decay rates, with the plasma cells producing the initial antibody
response decaying more rapidly than those producing protective antibody. It also showed that
some aggregation in the number of cercariae acquired per contact or a low number of eggs
output in urine per worm both enhanced the ability of the models to reproduce the observed
data patterns.
The finding that dying worms provide the main source of protective antigen is in line with
several studies showing that praziquantel treatment, which kills adult schistosomes, can boost
antibody responses associated with protection against re-infection (Butterworth et al. 1996;
Fitzsimmons et al. 2007; Gomes et al. 2002; Grogan et al. 1996; Mutapi et al. 1998). Models
with dying worms providing protective antigen demonstrated immune-enhanced reduction in egg
output following treatment, which is known to occur in praziquantel treatment of schistosomes
(Nyazema et al. 1995; Utzinger et al. 2003b). The finding that protective immunity is likely
to principally target fecundity is supported by the findings of Agnew et al. (1996) that for
S. haematobium, lower levels of egg output were found relative to levels of circulating anodic
antigen (CAA, a marker for worm burden) in adults than in children, and that S. haematobium
fecundity is reduced by the immune response in murine infections (Agnew et al. 1992). The
models assume that immune stimulation by eggs (found to be the principal source of antigen
for the non-protective antibody response) is primarily by very recently laid eggs, since the
number of eggs stimulating the immune response is related to current worm burden in these
models. This is likely to correspond to secreted egg antigens. If eggs become trapped within the
host tissues, secreted antigen has been shown to be sequestered by the granulomatous response
within a few days of egg deposition (von Lichtenberg 1964).
For virtually all of the successful models, the plasma cell population producing protective
antibody had a slower natural decay rate than the plasma cell population producing the initial
(non-protective) response, this being necessary in these simulations to generate and sustain the
antibody switch over 36 weeks post treatment. A similar conclusion was reached in a modelling
study of the epidemiological patterns of so-called ‘blocking’ antibodies (Woolhouse 1994b),
which could be explained by different decay rates of the two supposedly antagonistic antibody
responses. The differences in decay rates suggested in the current analysis cannot be attributed
to different intrinsic decay rates of the antibody molecules themselves, since natural antibody
decay rates in humans are of the order of days to weeks (Morell et al. 1970; Waldmann & Strober
1969) which is too rapid to fully explain the differences seen here. One possible explanation
is that the different antigens are stimulating different populations of plasma cells belonging to
the short- and long-lived subsets, which have differing reported decay rates (Lanzavecchia et al.
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2006; Ochsenbein et al. 2000; Radbruch et al. 2006). It is also possible that the cells producing
different antibody isotypes have varying dynamics, as different rates of cell turnover have been
reported for IgA, IgG and IgM switched memory cell populations (Wirths & Lanzavecchia
2005).
Many of the parameter combinations tested here failed to generate levels of infection
prevalence (which is related to parasite aggregation) consistent with field data, frequently giving
prevalence levels above 80% in the younger age group. Previous stochastic models of schistosome
infection have also given very high prevalence levels (Chan & Isham 1998). It was found that
relatively high levels of aggregation of individual contact rates had to be maintained, with fairly
high predisposition (infrequent resampling of individual contact rates), in order to reproduce
field patterns. The values used in the baseline analysis, of k1 = 0.5 and φ = 0.05 year
-1, which
were both estimated from field data, were sufficient to reproduce all of the required patterns.
Aggregation of cercarial acquisition increased the number of parameter sets for which models
met all of the criteria but was not essential, and both reduced mean egg output per worm
and increased aggregation of egg output also enhanced the ability of the models to meet the
criteria, through the increased occurrence of egg-negative individuals (decreasing the measured
prevalence of infection). The level of aggregation of egg output used in most of the models was
estimated from S. mansoni data, and seems plausible for S. haematobium, for which substantial
day-to-day variation in urine egg counts is also observed (van Etten et al. 1997; Warren et al.
1978). The reduced level of mean egg output per worm (0.1 per worm per 10ml urine) which
improved model performance is slightly lower than previous estimates (Cheever et al. 1977;
Woolhouse et al. 1996), but plausible given the considerable uncertainty in egg production
rates for S. haematobium and variation in urine output. Woolhouse et al. (1996) assumed that
0.64 eggs were excreted daily per female worm per 10ml urine (assuming 1400ml urine were
passed per day and 90 eggs excreted per mated female daily (Hairston 1965)), and Cheever
et al. (1977) estimated that 1.28 mature eggs were passed per female worm per 10ml urine from
autopsy studies. In a small study of live human patients, an average of 200 eggs per mated
female were passed in urine per day, but this was highly variable between subjects (range 3–560)
(Cheever et al. 1975).
Cercarial aggregation is more difficult to measure, with the evidence for aggregated exposure
to schistosome infection being sparse and equivocal (discussed by Quinnell et al. (1995)).
Although the degree of aggregation of the antibody responses in these models was not
formally tested for, due to the wide range in aggregation levels found in field data, the
models did give highly aggregated antibody output. This demonstrated that aggregation in
individual exposure levels was sufficient to explain antibody aggregation as well as aggregation in
infection intensities, without needing to additionally consider other potential sources of antibody
aggregation such as variability in individual immune competence.
This analysis used the pattern-oriented modelling (POM) approach which was introduced in
chapter 4, requiring models to pass an extended panel of different criteria simultaneously. Other
studies using POM have found that some criteria are non-discriminatory (Rossmanith et al.
2007). In this study, filters for antibody aggregation and prevalence in the whole population
were not used because of their poor discriminatory ability. However, the other ten filters used
all had individual discriminatory power, and the fact that successful models were able to pass
such a diverse set of filters lends strength to the conclusions drawn.
This analysis considered only models with plasma cell populations (with no explicit memory
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response). It would be interesting to extend the analysis to other immune models, starting
with the memory models which were successful in the deterministic analysis. Since only models
with Gaussian-distributed worm survival were considered here, it is not possible to draw any
conclusions about the probable shape of natural worm survival curves - it is possible that some
models with exponentially distributed worm life span would also be able to reproduce all of the
required patterns, but this would need to be formally tested.
This work has identified a single model structure and a relatively small range of parameter
values for which it is possible to reproduce both pre-treatment age-related patterns of infection
and antibody, and short-term post-treatment changes in the antibody response. This model can
now be used to investigate the longer-term implications of treatment of endemic populations,
in terms of its impact upon the development of acquired immunity and consequent effects









Recent attempts at schistosomiasis control have focussed upon mass drug administration
(MDA), using the antihelminthic drug praziquantel (Fenwick et al. 2009; WHO 2001, 2006).
The main aim of these mass treatment programmes has been to reduce morbidity rather than
to eliminate infection, although mass treatment can significantly reduce population levels of
infection (Kabatereine et al. 2007; King et al. 1991; Koukounari et al. 2007; Tohon et al. 2008)
and have a demonstrable effect upon transmission rates (French et al. 2009; King et al. 1991).
However, to keep infection levels low, treatments need to be administered repeatedly for an
indefinite time period (Chan et al. 1998; Utzinger et al. 2003a).
The main effect of treatment programmes on infection levels is through direct killing of
worms, with indirect effects through reduced transmission. Acquired immunity is also expected
to have some effect, enhancing the efficacy of treatment during control programmes, and playing
a major role in determining the dynamics of infection after treatment programmes cease (Chan
1996; Chan et al. 1996). Previous modelling work, in which it was assumed that protective
immunity was stimulated by live adult worms, has demonstrated that repeated population-
level treatment in this case disrupts the development of acquired immunity, through removal
of the antigenic stimulus (Anderson & May 1985; Chan et al. 1996). Chan et al. (1996) showed
that, if treatment was stopped, under some circumstances infection levels could ‘overshoot’ to
exceed pre-treatment levels.
Several studies have demonstrated that praziquantel treatment can induce changes in the
antibody response to schistosomes (S. mansoni or S. haematobium), boosting schistosome-
specific antibody responses including IgE and IgG1 (Butterworth et al. 1996; Fitzsimmons
et al. 2007; Gomes et al. 2002; Mutapi et al. 1998; Satti et al. 1996) and bringing about isotypic
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changes which occur more gradually with age in the same populations (Grogan et al. 1996;
Mutapi et al. 1998). Praziquantel treatment has also been shown to boost schistosome-specific
cytokine responses, including IL-4, IL-5, IL-10, IL-13 and TGF-β (Fitzsimmons et al. 2004;
Joseph et al. 2004b; van den Biggelaar et al. 2002). Praziquantel kills adult worms, and has
been shown to expose a number of antigens on the worm surface of S. mansoni in murine and in
vitro studies (Redman et al. 1996), and to allow or enhance serological recognition of a number
of S. haematobium antigens in humans (Mutapi et al. 2005). It is thought that this increased
exposure to antigens released from dying worms is responsible for stimulating the changes seen
in the immune responses following praziquantel treatment. Several of the responses which are
boosted by praziquantel treatment, including IgE, IgG1, IL-4 and IL-5, have been associated
with protection against re-infection in other studies (Dunne et al. 1992a; Hagan et al. 1991;
Medhat et al. 1998; Roberts et al. 1993; Satti et al. 1996). This implies that treatment may
enhance protective immunity and reduce subsequent re-infection, although this has not yet been
directly demonstrated in a field setting.
If protective immunity is assumed to be mainly stimulated by antigens from dying worms,
then treatment is expected to increase antigenic exposure and boost protective immune
responses in the short term through worm killing. However, since treatment causes worms to
die sooner than they would do under natural circumstances, it will result in reduced exposure
to dying worms for a period of time after the initial reduction in worm burden. This exposure
will be further reduced if population-wide treatment reduces transmission rates, leading to
decreased levels of re-infection. The long-term implications of treatment for the development
of protective immunity in this case are not fully clear.
The aim of the work described in this chapter was to assess the expected impact of long-
term treatment (repeated treatment over several years) upon the development of acquired
immunity, and resultant effects on infection, both during and after a mass treatment campaign.
Current MDA programmes, such as those carried out by the Schistosomiasis Control Initiative
(SCI), aim to implement sustainable long-term control (Fenwick et al. 2009). However, it is
important to assess the potential consequences of the cessation of these control programmes,
given that previous modelling work has shown that infection levels may overshoot and exceed
pre-treatment levels if control programmes are stopped (Chan et al. 1996).
In this chapter, the model structure and parameter sets that were able to reproduce all of the
required cross-sectional and post-treatment patterns in infection and antibody data (chapter
5) were used to predict the longer-term impact of repeated treatment upon the development of
protective immunity over a five year treatment period and eleven subsequent years of follow-
up. The effects upon infection intensity were also assessed, in particular whether these models,
which have dying worms providing the main antigenic stimulus, ever predicted infection levels
‘overshooting’ pre-treatment levels after treatment ceases, which would imply that cessation of
treatment programmes could temporarily impose a greater burden of infection upon populations
than they had before treatment started.
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Analysis framework for chapter 6
• The aim of the analysis in this chapter is to make predictions about the long-term
effects of large-scale mass treatment programmes upon the development of protective
antibody responses and the subsequent additional impact upon infection levels, both
during the treatment programme and after it stops.
• The same stochastic individual-based models which were used in chapter 5 are used
to make these predictions. These models describe infection intensity and levels of two
independent antibody responses in a population of individuals.
• Model structures and parameter sets which were able to meet all of the pre- and
post-treatment infection and antibody criteria in chapter 5 are used to make these
predictions.
• The models are run for a 5-year treatment programme and for a further 10 years after
the programme stops, using a constant-sized population with turnover
• Different treatment schedules are compared for their effects upon infection and
antibody dynamics:
– Biannual versus annual treatment
– 90% versus 75% coverage
– Treatment of all individuals aged 6-34 years old versus schoolchildren aged 6-34
years old
• Transmission is assumed to either not be affected at all treatment, or to be reduced by
50% or 100% throughout the intervention programme and for one year afterwards. A
preferable alternative for assessing the transmission-related effects of treatment would
be a full transmission model relating infection rates to egg output. However, there is
limited data available to parameterise such a model, as the effects of mass treatment
programmes on transmission (as distinct from infection intensity) are rarely measured.
6.2 Methods
6.2.1 The model
The stochastic individual-based model framework described in chapter 5 was also used in this
chapter. Treatment was modelled in the same way as in chapter 5, but in this analysis repeated
treatments were used, according to the schedules described in section 6.2.3.
6.2.2 Population structure
To maintain a constant size of population aged 6–34 years old over a time period of 15 years,
a different population structure from that used in chapter 5 was used here. A population of
175 individuals was simulated, with 5 individuals in each yearly age group from 1 to 34 years
old at the time of the baseline survey. Individuals were simulated up to their respective ages
before the initial population survey was taken and treatment applied. Individuals were then
simulated for a further 15 years after this initial survey, with treatment schedules applied as
described in the next section, and individual levels of egg output and antibody were recorded
at yearly intervals. When individuals reached the age of 34, they were replaced by 1 day old
infants with no infection or antibody responses, to maintain a constant population size. It was
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assumed that maternal antibodies play a negligible role in young children, who have very low
infection rates in these models.
6.2.3 Treatment schedules
Six different treatment schedules were used (listed in table 6.1). These were used to explore
the impact of treatment frequency, target population, coverage and effect of treatment upon
transmission. For the standard treatment schedule (schedule 1), treatment was given to school-
aged children in the population, defined as those aged 6–15 years old, as recommended by
the WHO and implemented by the SCI (Fenwick et al. 2009; WHO 2006). Treatment was
applied annually for five years (total of five treatments). Annual treatment is advised by the
WHO for high-prevalence communities (WHO 2006) and has been used by the SCI in Uganda,
Zanzibar and Zambia (Fenwick et al. 2009; Kabatereine et al. 2006a). In the standard treatment
schedule, coverage was assumed to be 75%, in line with WHO targets and coverage achieved by
SCI programmes in Uganda, Mali and Niger (Fenwick et al. 2009; Garba et al. 2006; Kabatereine
et al. 2006a; Tohon et al. 2008; WHO 2001). In the standard treatment schedule it was assumed
that treatment did not affect transmission.
In each of the other treatment schedules, one parameter was changed from the standard
schedule (table 6.1). In schedule 2, biannual treatment was given over a five year period (total
of three treatments). Biannual treatment is advised by the WHO for areas with moderate
prevalence, and has been used in SCI programmes in Burkina Faso and Niger (Fenwick et al.
2009; WHO 2006). In schedule 3, a treatment coverage of 90% was used (as achieved in some of
the countries targeted by the SCI (Gabrielli et al. 2006; Kabatereine et al. 2006b)). In schedule
4, the whole population over the age of 5 was treated, as recommended and implemented for
high risk populations (Fenwick et al. 2009; Garba et al. 2006; WHO 2006). In schedules 5 and 6,
it was assumed that treatment reduced transmission by 100% or 50% respectively. Treatment
was assumed to reduce transmission to a fixed level, from the day after the first treatment up
until one year after the final treatment. Transmission was then assumed to return to its original
level. The changes in transmission were assumed to occur as a step function with no gradual
transition between the two levels.
For all of the treatment schedules (1–6), treatment was applied over a five year period
(beginning the day after the initial baseline survey), and the population was sampled (infection
and antibody levels recorded) yearly throughout the treatment period and for a further 11 years
after the final round of treatment. When treatment was applied, this occurred on the day after
yearly sampling. Treatment was applied randomly across the eligible population at the required
coverage level (75% or 90%) at each round of treatment. It was assumed that an individual’s
chance of being treated at each treatment round did not depend upon whether or not they
had been treated in previous rounds. For all of the schedules, a treatment efficacy of 90% was
assumed, in line with field studies reporting egg reduction rates ((1 - geometric mean egg count
after treatment/geometric mean egg count before treatment) × 100%) for S. haematobium of
83-99.9% (Danso-Appiah et al. 2008; De Clercq et al. 2002; King et al. 2000; Midzi et al. 2008;
Saathoff et al. 2004; Sissoko et al. 2009; Tchuem Tchuente et al. 2004). The analysis in chapter 5
showed that the egg reduction rate in the model simulations will also be affected by re-infection
rates and the strength of the antibody response, but will fall within this reported range for the
model parameters used.
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1 Standard annual schoolchildren
(6–15 years old)
75% none
2 Biannual biannual schoolchildren
(6–15 years old)
75% none
3 90% coverage annual schoolchildren
(6–15 years old)
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The parameter sets identified in chapter 5, all of which were able to reproduce cross-sectional
and short-term post-treatment patterns of infection and antibody over a two-fold change in
maximum mean population infection rate, were used for simulations of the long-term impact
of treatment. For each parameter set, 200 repeat simulations of the whole population were
run, and mean levels of infection and antibody for the whole population aged 6–34 years old
were calculated pre-treatment and at yearly intervals during and after the simulated treatment
regime, for each individual simulation and averaged over the 200 repeats. Averages were
calculated over this age range in order to capture the changes in infection and antibody levels
in treated individuals as they aged over the long follow-up period. Infection and antibody
dynamics were studied to see how quickly they returned to pre-treatment levels. This was
studied for the mean values calculated over the 200 repeats, with infection levels analysed for
how quickly they returned to within 95% of pre-treatment levels, and antibody levels for when
they dropped below 100% of pre-treatment levels. The conditions (particular parameter values
or treatment schedules) under which protective antibody levels fell below pre-treatment levels,
or infection significantly overshot (exceeded 120% of) pre-treatment levels, were identified.
6.3 Results
6.3.1 Standard treatment schedule
The different factors affecting the speed with which antibody and infection levels returned to
pre-treatment levels were assessed first of all for the standard treatment schedule, for which it
was assumed that there was no reduction in transmission during or after the period of treatment.
Considerable variation was observed between individual simulations for each parameter set,
particularly for infection levels but also for antibody (figure 6.1). For all subsequent analyses,
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protective antibody infection intensity
Figure 6.1: The results of 200 separate simulations using a single parameter set from the antigen
threshold model. Dynamics of (a) antibody and (b) infection intensity averaged across the whole
population are shown for each simulation. The mean level across the 200 simulations is shown
by the heavy black line. The standard treatment regime was used, with treatment given at
yearly intervals for 5 years to school-aged children (6–15 years old) with 75% coverage. It was
assumed that there was no decrease in transmission after treatment. Treatment was applied
on the day after surveys marked *. (Parameters used: Λpmax = 25, 1/µ = 6.5, γ2 = 0.008, η
= 1.024, T = 25, k1 = 0.5, φ = 0.05, kE = 1, x = 0.9, d = 1; all parameters fully defined in
chapter 5).
parameter set, and the mean levels were then adjusted relative to the mean level at baseline.
For all of the results reported here, levels of the second (non-protective) antibody response
closely followed infection dynamics, so that their time-profiles were virtually identical to those
shown for infection (non-protective antibody results not shown).
For the 56 parameter sets with cross-regulation of the antibody response, three distinct
time-profiles of protective antibody and infection levels were seen, which segregated by the
decay rate of the plasma cells producing protective antibody. These are shown in figure 6.2,
for the standard treatment schedule (schedule 1), with yearly treatment of schoolchildren with
75% treatment coverage. For all of these models, the level of protective antibody increased after
the initial treatment, but the dynamics differed both during and after the five annual rounds of
treatment for parameter sets with different rates of plasma cell decay. The maximum relative
increase in the level of protective antibody was greatest for models with more rapid decay of the
plasma cells producing protective antibody. Models with relatively slow plasma cell decay (0.008
– 0.08 year-1) saw progressive increases in the average population level of protective antibody
over the five years of treatment (figure 6.2a,b), whereas in models with more rapid plasma cell
decay, antibody levels peaked one year after treatment began and declined during subsequent
treatment rounds (figure 6.2c). Both the time at which mean antibody levels fell below pre-
treatment levels, and the time at which infection levels returned to 95% of pre-treatment levels
varied between models with different rates of plasma cell decay. The level of protective antibody
returned to pre-treatment levels around 11 years after treatment ceased for parameter sets with
the slowest decay of plasma cells producing protective antibody (0.008 year-1) (figure 6.2a),
around 6 years after the final treatment for parameter sets with a medium plasma cell decay
rate of 0.08 year-1, with subsequent reduction below pre-treatment levels (figure 6.2b), and
within 2 years of the final treatment for models with a rapid plasma cell decay rate of 0.8 year-1,
and in every case remained below pre-treatment levels for the remaining 9 years of simulation
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γ2 = 0.008 γ2 = 0.008
γ2 = 0.08 γ2 = 0.08
γ2 = 0.8 γ2 = 0.8
protective antibody infection intensity
Figure 6.2: Dynamics of protective antibody and infection during and after treatment,
without any reduction in transmission, for parameter sets with cross-regulation of the antibody
responses. Treatment was applied at yearly intervals for 5 years to school-aged children (6-
15 years old) with 75% coverage. Treatment was applied the day after surveys marked *.
(a-c) Antibody levels and (d-f) infection levels are shown relative to pre-treatment levels for
all of the parameter sets with antibody cross-regulation which reproduced cross-sectional and
post-treatment patterns in chapter 5. Results are shown separately for parameter sets with
different rates of yearly antibody decay: (a,d) 0.008, (b,e) 0.08 and (c,f) 0.8 year-1. Numbers
of parameter sets drawn in each plot: (a,d) 16, (b,e) 24, (c,f) 16. The dashed line on each
plot shows the baseline level. The dotted line on the infection intensity plots is at 20% above
baseline.
125
decay rates, particularly after treatment stopped (figure 6.2d-f). With slow plasma cell decay,
infection levels returned to within 95% of pre-treatment levels between 5–11 years after the
final treatment (figure 6.2d), and 5–9 years after the final treatment for moderate plasma cell
decay rates (figure 6.2e), but with more rapid plasma cell decay, infection levels returned to
pre-treatment levels 3 years after the final treatment and then overshot pre-treatment levels
(by more than 60%) before re-approaching levels of infection seen before control (figure 6.2f).
There was no clear order in which infection intensity and protective antibody returned to
pre-treatment levels. This was partly obscured by the greater inherent variability in infection
levels, but a strong trend for protective antibody to return to pre-treatment levels after or
at the same time as infection levels did so for slow plasma cell decay (figure 6.2a,d) was not
seen for rapid antibody decay, where protective antibody fell below pre-treatment levels before
infection returned to pre-treatment intensities (figure 6.2c,f).
For the 573 parameter sets with a threshold on the protective antibody response, more
variable dynamics were observed under the standard treatment regime (figure 6.3). The
dynamics of the protective antibody response appeared to be mainly determined by the rate
of plasma cell decay and the mean worm life span. (Note that no effect of worm life span was
seen in the cross-regulation models, because all of the parameter sets had a mean worm life
span of 10 years.) As for the cross-regulation models, a bigger boost in antibody was seen for
models with more rapid plasma cell decay, apart from the four parameter sets with very rapid
plasma cell decay (8 year-1), where antibody levels had already decreased below pre-treatment
levels at one year after the first treatment (figure 6.3d). In these models, antibody was boosted
3 months after treatment, but declined rapidly before the next round of treatment (figure
6.4). For models with slower plasma cell decay, the extent of both the antibody boost during
treatment and the decline below pre-treatment levels differed with mean parasite life span.
While in most cases levels of protective antibody remained elevated above pre-treatment levels
throughout the period of treatment, for models with fairly rapid plasma cell decay (0.8 year-1)
and a short mean worm life span of 3 years, levels of protective antibody consistently dropped
below pre-treatment levels after only three or four out of five rounds of treatment (figure 6.3c).
Over the whole follow-up period, models with a longer parasite life span tended to show both
a higher antibody boost and a more substantial drop below pre-treatment levels than models
with a shorter parasite life span (figure 6.3a-c). As for the cross-regulation models, antibody
levels tended to drop below pre-treatment levels earlier for models with more rapid plasma cell
decay. Infection profiles varied, but still segregated by parasite life span (figure 6.3e-g), with
infection levels reduced to a lesser extent by treatment and returning to pre-treatment levels
earlier with progressively shorter worm life span. It should be noted that parameter sets with
a mean worm life span of 3 years had a higher antigen threshold than those with a longer worm
life span, as these parameters were not independently distributed among the parameter sets
which were successful in chapter 5. Only a few parameter sets, with specific combinations of
plasma cell decay rate, antibody strength and antigen threshold level, gave an ‘overshoot’ in
infection levels (figure 6.3g). For mean infection levels to ever exceed 120% of pre-treatment
levels after treatment ceased, it was necessary to have fairly rapid plasma cell decay (γ2) of 0.8
year-1), moderate antibody strength (η) of 0.256 per plasma cell and an antigen threshold (T )
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(c) γ2 = 0.8 γ2 = 0.8
γ2= 8 γ2 = 8
Figure 6.3: Dynamics of protective antibody and infection during and after treatment, without
any reduction in transmission, for parameter sets with an antigen threshold. Details as for
figure 6.2. An additional rate of plasma cell decay is included in these models, of 8 year-1 (d,h).
The parameter sets used are those with an antigen threshold which reproduced cross-sectional
and post-treatment patterns in chapter 5. Numbers of parameter sets drawn in each plot: (a,e)
195, (b,f) 195, (c,g) 179, (d,h) 4. Within each plot, profiles are distinguished by mean parasite
life span: squares, pale blue lines = 3 years; triangles, red lines = 6.5 years; diamonds, dark
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Figure 6.4: Dynamics of protective antibody in models with very rapid plasma cell decay.
Antibody levels are shown at 3-monthly intervals for 4 years after the baseline survey. The
same parameter sets and treatment regimes are used as in figure 6.3d. Treatment was applied
the day after surveys marked *.
6.3.2 Treatment schedules 2–4 – varying treatment frequency, cover-
age and targeting
The impacts of separately varying the frequency of treatment, coverage of the target population,
and age range of the population targeted were assessed by looking at the results of treatment
schedules 2–4. Results are shown for four single parameter combinations (figures 6.5 and 6.6),
but are qualitatively representative of what was seen across all of the different parameter sets.
For each type of model, cross-regulation or threshold, the results are shown for two parameter
sets that did or did not give an overshoot in infection in the standard treatment regimes.
For the cross-regulation models, none of the different treatment schedules used (schedules 2–
4) made a difference to whether or not particular parameter sets did or did not give an overshoot
in infection levels after treatment ceased, but for parameter sets that did, the magnitude of
the overshoot was altered by different treatment regimes. With biannual treatment (schedule
2), protective antibody declined and infection increased following non-treatment years during
the programmes, but levels of infection and antibody came close to those seen with annual
treatment at one year after the biannual treatments (figure 6.5). For parameter sets with an
infection overshoot, this overshoot was less pronounced for biannual versus yearly treatment
(figure 6.5d).
Changing the level of coverage of the school-aged population (90% coverage (schedule 3) vs.
75% (schedule 1)) made little difference to the dynamics of protective antibody and infection
levels during or after treatment; the higher coverage level gave a slightly greater increase in
antibody levels and greater reduction in infection during treatment (figure 6.5), with a more
pronounced overshoot in infection for the parameter set which had an overshoot with 75%
coverage (figure 6.5d).
Treating both adults and children (aged 6–34 years old, schedule 4) rather than just school-
aged children (6–15 years old, schedule 1) led to much larger increases in the antibody boost
for all parameter combinations (figure 6.5b,d), with a concomitant reduction in infection levels
during the treatment programme. In models with treatment of both school-aged children and
adults, an increased overshoot in infection levels was seen after treatment ceased for parameter
sets with rapid decay of plasma cells, to a greater extent than that seen with increased coverage
of the school-age population (figure 6.5d).
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treat all aged 6-34 years old
(a)
protective antibody infection intensity
Figure 6.5: Dynamics of protective antibody and infection under different treatment regimes,
for parameter sets with cross-regulation. No reduction of transmission occurred after treatment
in these models. Results are shown for two different parameter combinations: (a) infection and
(b) antibody with Λpmax = 25, 1/µ = 10, γ2 = 0.08, η = 0.256, k1 = 0.5, φ = 0.05, kE = 1, d =
1, ε = 0.1; (c) infection and (d) antibody with Λpmax = 12.5, 1/µ = 10, γ2 = 0.8, η = 1.024, k1 =
0.5, φ = 0.05, kE = 1, d = 1, ε = 0.1 (all parameters fully defined in chapter 5). Treatment was
applied over a five-year period, with treatment frequency, coverage and targeting in the following
combinations: blue diamonds – standard; yellow squares – biannual treatment; pink triangles –
90% coverage; green circles – treatment of 6–34 year olds. Treatment was applied the day after
surveys marked * for all except biannual treatment, where treatment was applied the day after
survey 0, 2 and 4. The dashed line on each plot shows the baseline level. The dotted line on
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Figure 6.6: Dynamics of protective antibody and infection under different treatment regimes,
for parameter sets with an antigen threshold. Details as for figure 6.5, but using the following
parameter sets: (a) infection and (b) antibody with Λpmax = 25, 1/µ = 3, γ2 = 0.008, η =
1.024, T = 250, k1 = 0.5, φ = 0.05, kE = 1, d = 10, ε = 1; (c) infection and (d) antibody with
Λpmax = 100, 1/µ = 10, γ2 = 0.8, η = 0.256, T = 25, k1 = 0.5, φ = 0.05, kE = 1, d = 100, ε = 1.
illustrated for two different parameter sets (figure 6.6). Because in the antigen threshold models
overshoots were more modest than in the cross-regulation models, the different treatment
schedules (2–4) did make some difference to how many parameter sets gave infection levels
exceeding 120% of pre-treatment levels. In terms of infection reduction and antibody boosting
during the period of treatment, and effect on the magnitude of any infection overshoot post-
treatment, biannual treatment (schedule 2) had a smaller impact than annual treatment
(schedule 1), and led to only one parameter set ever giving an overshoot of 20% over pre-
treatment levels. Increased coverage (schedule 3) and treating the whole population (schedule
4) had an increasingly greater impact on the extent of infection reduction, antibody boosting
and the magnitude of any infection overshoot for individual parameter sets (figure 6.6). These
schedules both increased the number of individual parameter sets for which an overshoot
(infection levels exceeding 120% of pre-treatment levels) in infection levels was seen. Treating
the whole population also increased the range of possible parameter values for which an
overshoot could occur. In addition to parameter sets with fairly rapid plasma cell decay (γ2)
of 0.8 year-1, moderate antibody strength (η) of 0.256 per plasma cell and a threshold (T ) of
25 antigen units, other possible parameter combinations now included those with plasma cell
decay (γ2) of 0.8 year
-1, antibody strength (η) 0.064 per plasma cell and a threshold (T ) of 250
antigen units, and those with plasma cell decay (γ2) of 8 year
-1, antibody strength (η) 1.024
per plasma cell and a threshold (T ) of 250 antigen units (data not shown).
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6.3.3 Treatment schedules 5 and 6 – reduction of transmission
When treatment was assumed to reduce transmission (treatment schedules 5 and 6), different
patterns were predicted. For the cross-regulation models, with 100% reduction of transmission
assumed (i.e. no transmission occurring until one year after treatment ceased, schedule 5),
infection was reduced to less than 5% of the pre-treatment level after five rounds of treatment.
Protective antibody was predicted to fall below pre-treatment levels at some point for all
parameter sets, regardless of plasma cell decay rate, but do so more rapidly for faster decaying
plasma cells (figure 6.7a-c). For parameter sets with rapid rates of plasma cell decay (0.8 year-1),
levels of protective antibody fell below pre-treatment levels after four rounds of treatment
(before treatment had ceased). An overshoot in infection level was predicted to occur for all
parameter sets regardless of plasma cell decay rate, with the overshoot predicted to be larger
and occur earlier for more rapid plasma cell decay (figure 6.7 d-f). The infection profiles also
segregated into three distinct groups by infection rate (Λpmax = 12.5, 25 and 50), as can be
seen in figure 6.7. In each panel, the group of parameter sets with the earliest and highest
overshoot in infection levels has the highest infection rate (Λpmax = 50), with the latest and
lowest overshoots occurring for the group of parameter sets with the lowest infection rate (Λpmax
= 12.5).
With 50% reduction of transmission up until one year after treatment ceased (schedule
6), the effects on antibody and infection in the cross-regulation models were still substantial,
but less severe than with 100% reduction in transmission (figure 6.8). In all cases, antibody
levels dropped below pre-treatment levels after treatment ceased, and with rapid plasma cell
decay (0.8 year-1) this occurred within a year of the final treatment. Infection levels consistently
exceeded pre-treatment levels, but with moderate or slow plasma cell decay (0.008–0.08 year-1),
only a quarter of the parameter sets had infection levels ever exceeding 120% of pre-treatment
levels. With rapid plasma cell decay (0.8 year-1), an overshoot was consistently seen, as was
also seen when there was no reduction in transmission (schedule 1, figure 6.2f).
Results for the antigen threshold models were similar (figures 6.9 and 6.10). With 100%
transmission reduction (schedule 5), antibody levels always declined below pre-treatment levels
at some point, with the precise timing and extent of this affected by the decay rate of the
antibody response and the mean parasite life span. With a short parasite life span of 3
years, antibody levels always declined below pre-treatment levels before treatment ceased,
regardless of the plasma cell decay rate, but increasingly earlier in the control programme
with increasingly rapid plasma cell decay (figure 6.9a-d). For fairly rapid plasma cell decay
(0.8 year-1), levels of protective antibody virtually always declined below pre-treatment during
the treatment programme, regardless of parasite life span (only two parameter sets with a long
parasite life span of 10 years did not decline below pre-treatment levels until after treatment
ceased). Infection levels always overshot after treatment stopped, with considerable variation
in when and by how much this occured. The timing and extent of the overshoot were affected
by plasma cell decay rates, parasite life span and population infection rates (figure 6.9e-h).
With more moderate reduction of transmission, to 50% of pre-treatment levels during and for
one year after the control programme (schedule 6), antibody levels still frequently fell below
precontrol levels during the treatment programme when parasites had a short life span of 3
years (figure 6.10a-c), or with more rapid plasma cell decay (0.08 year-1) and a parasite life
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protective antibody infection intensity
Figure 6.7: Dynamics of protective antibody and infection during and after treatment, with
100% transmission reduction for 1 year post-treatment, for parameter sets with cross-regulation.
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Figure 6.8: Dynamics of protective antibody and infection during and after treatment, with
50% transmission reduction for 1 year post-treatment, for parameter sets with cross-regulation.
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Figure 6.9: Dynamics of protective antibody and infection during and after treatment, with
100% transmission reduction for 1 year post-treatment, for parameter sets with an antigen
threshold. See legend for figure 6.3. Note that (g) has a different maximum value on the y-axis
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Figure 6.10: Dynamics of protective antibody and infection during and after treatment, with
50% transmission reduction for 1 year post-treatment, for parameter sets with an antigen
threshold. See legend for figure 6.3. Note that (g) has a different maximum value on the
y-axis from (e),(f) and (h).
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were still consistently seen to drop below pre-treatment levels after treatment ceased, although
not to the same extent as when transmission was stopped completely (figure 6.10). For models
with slow or moderate plasma cell decay rates (0.008–0.08 year-1), 58% of parameter sets had
an overshoot in infection levels (exceeding 120% of pre-treatment levels), and with more rapid
plasma cell decay (0.8 year-1), 83% of parameter sets had an overshoot in infection levels after
treatment ceased. The occurence, level and timing of the overshoot were also affected by mean
parasite life span, as shown in figure 6.10e-h.
6.4 Discussion
In these models, levels of infection were substantially reduced by repeated MDA, and levels of
protective antibody, stimulated by dying worms, were boosted by treatment. This replicates
patterns seen in the field. It was shown that levels of protective antibody could fall below
pre-treatment levels after the control programme ceased, and in some cases even before control
stopped. Levels of protective antibody fell below pre-treatment levels earlier in models with
increased treatment-related reduction of transmission, more rapid decay of plasma cells or a
shorter worm life span. The models showed that if treatment reduced transmission, it reduced
subsequent re-infection and therefore reduced antigen exposure, leading to more rapid decline of
protective antibody. Even if transmission was unaffected, the models suggested that treatment
temporarily reduced exposure to dying worms, as the worm burden was reduced, meaning that
plasma cell decay rates strongly influenced the rapidity of antibody decline.
Models with a longer worm life span gave increased antibody boosting after treatment than
those with a shorter worm life span, even when all other parameters were identical. This was
likely due to the fact that baseline levels of infection were higher in models with longer worm
life span than in those with shorter worm life span. Rates of antigenic exposure at baseline are
expected to be lower in models with longer worm life span, and so the reduction in antigenic
exposure after the initial reduction in worm burden brought about by treatment is likely to
have a more rapid relative effect in models with short worm life span, which would explain why
antibody levels fell below baseline levels earlier on in these models.
It was also found that infection could rebound to levels exceeding pre-treatment levels after
the cessation of MDA. This was relatively rare in the absence of treatment-related transmission
reduction, but more likely to occur with rapid plasma cell decay. If treatment substantially
reduced transmission, overshooting of infection levels after cessation of treatment became much
more likely. The strong impact of reduced transmission on infection levels after cessation of
MDA is likely to be due to the substantial effect this has in reducing levels of protective
antibody, as discussed above. When infection levels did overshoot pre-treatment levels, this
occurred earlier in models with a shorter parasite life span (due to reduced levels of protective
antibody), and also occurred earlier in models with higher rates of infection. Although models
in which antibody fell below pre-treatment levels earlier on also tended to see infection returning
to pre-treatment levels earlier, reduction in antibody levels below pre-treatment levels during
MDA did not necessarily correspond with overshooting of infection levels after treatment ceased.
This means that protective antibody falling below pre-treatment levels during a treatment
programme is neither a necessary nor a sufficient indicator that infection levels will overshoot
after treatment ceases.
The different treatment regimes investigated (schedules 2–4) had consistent but relatively
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small effects upon the development of protective antibody and on infection dynamics during and
after MDA. Increasing the coverage of treatment of school children from 75% to 90% increased
antibody levels and decreased infection levels but by a very small amount. The small effect
upon antibody levels is probably due to the fact that the mean antibody level across the whole
population was dominated by antibody responses in adults, who were not affected by changes in
coverage of children. Within the 6–15 year old cohort, much larger antibody boosts were seen
(data not shown). The effect of increased coverage on infection levels was smaller than expected.
The random allocation of treatment at each round meant that even at 75% coverage, the chances
of an individual never being treated over the five rounds of treatment were very small, and this
may account for the comparitively small effect of increasing coverage. In reality, there will
be individuals who are more likely to be consistently missed in repeat treatment rounds (i.e.
treatment is not applied randomly across the population), and so increased coverage is likely
to have a greater impact in the field than is suggested by these models.
In this analysis, biannual treatment gave fluctuating dynamics during the treatment
programme, with infection and antibody levels approaching those seen with annual treatment a
year after each treatment. Slightly less severe overshooting of infection was seen after treatment
ceased for biannual compared with annual treatment regimens. The finding that biannual
treatment made little difference to long-term infection and antibody dynamics when compared
with annual treatment is in agreement with two previous modelling studies – Chan et al. (1998)
reported that in their model of S. haematobium in Ghana, treating after missing a single annual
treatment could bring infection down to almost the same level as if two annual treatments had
been given, and Williams et al. (2002) modelling prevalence of S. japonicum in China found little
difference of biannual treatment of humans over annual treatment. However, other modelling
studies have reported differences in the impact of biannual versus annual treatment (Gurarie
& King 2005).
Treating the whole population rather than just school-aged children gave a more pronounced
boost to population-level protective antibody and a greater reduction in infection level during
MDA, but meant that any overshooting of infection after treatment ceased became more
pronounced. This indicated that in these simulated populations, there was significant boosting
of antibody in individuals over the age of 15. In general, treatment regimes which caused a
more substantial (although transient) increase in infection levels after treatment ceased had
caused a greater reduction in infection level during MDA. The reverse did not necessarily hold
true, however, as in many cases no such overshoot was ever seen, despite substantial reduction
of infection during MDA.
Previous modelling analyses have focussed upon the dynamics of infection during and
after MDA, rather than antibody. Modelling studies that have considered the effects of
acquired immunity upon infection levels during treatment campaigns have suggested that the
strength and duration of protective immune responses play an important role in determining
infection dynamics (Chan et al. 1996), and this was also found here. Without any reduction in
transmission post-treatment, it was found that an overshoot in infection levels was most likely
to occur when plasma cell decay rates were relatively rapid (half-life of 10 months); in contrast,
Chan et al. (1996) reported overshoots occurring only with slow immune decay rates (half-life
of 7 years), and not with more rapid decay. This discrepancy may arise because in the study
by Chan et al. (1996) slow immune decay rates were compensated for with a higher value of R0
(i.e. increased infection rates). In the current analysis, in models with reduced transmission
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after treatment, higher infection rates gave rise to more pronounced infection overshoots after
treatment ceased.
It should be noted that the analysis undertaken here was not a formal sensitivity analysis
– parameters were not varied systematically, but were chosen in combinations that were able
to reproduce all of the patterns of cross-sectional and post-treatment patterns in field data
in chapter 5. It was therefore not always possible to fully disentangle the effects of different
parameters, as they did not appear independently of one another (for example, antigen threshold
level and mean parasite life span). The aim here was rather to make long-term predictions
using parameter sets which had already been identified as being consistent with all of the
data at my disposal. The analysis was based upon mean yearly levels calculated across
multiple replicates of population simulations, rather than looking at the behaviour of individual
simulations. Variation was observed between individual simulations, both in terms of whether
or not antibody and infection levels returned to pre-treatment levels, and the timing of such
returns, so that the reported results do not capture the full possible variation in outcomes for
a single village. The advantage of using the mean levels was that it made it possible to assess
how the complex time-varying dynamics of infection and antibody varied between different
parameter sets and scenarios.
No field studies have yet conclusively demonstrated whether or not praziquantel treatment
reduces subsequent reinfection through enhancing protective immune responses. This is difficult
to test directly, because reinfection can only be studied after treatment, meaning that untreated
controls cannot be used. To overcome this, a different hypothesis has been suggested, that
repeated treatment should enhance protection against schistosome infection to a greater extent
than single treatment (van den Biggelaar et al. 2002). van den Biggelaar et al. (2002)
demonstrated that repeated treatment over a two-year period could enhance S. haematobium-
specific cytokine responses to a greater extent than a single treatment in Gabonese school
children, but their small sample size precluded any effect upon re-infection rates being detected.
In the models and treatment schedules used here, the greatest impact of treatment upon
protective immunity was seen after a single treatment rather than after repeated treatment,
suggesting that the comparison of the effects of repeated versus single treatments may not
allow the full effect of treatment to be evaluated. The models suggest that the extent to
which repeated treatment further enhances protective antibody responses will depend upon
plasma cell decay rates and subsequent levels of exposure to re-infection (since further parasites
must be killed to enhance protective responses). The levels of both existing infection and
immunity are also expected to affect the relative impact of treatment. Longitudinal studies
of S. mansoni infection in occupationally exposed adults in Kenya who were treated with
praziquantel whenever they became re-infected have shown resistance to reinfection developing
in some individuals after repeated re-infection and treatment (Black et al. 2010; Karanja et al.
2002). Adults in this study who showed evidence of increasing resistance developing after many
repeated rounds of reinfection and treatment had had little exposure to schistosomes before
beginning to work as car-washers in Lake Victoria. Another cohort within this study, who
worked as sand harvesters but had been exposed to schistosomes from a much earlier age,
demonstrated maximum protection against re-infection after only two rounds of re-infection
and treatment (Black et al. 2010). This suggests that the effects of repeated treatment may
be larger in previously unexposed populations. However, these studies do not demonstrate a
direct impact of treatment upon the development of protective immunity, since there are no
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untreated or singly-treated controls, and there is therefore no way of knowing whether the
repeatedly treated individuals would have developed resistance more quickly or more slowly in
the absence of treatment. Protection in this study could equally arise from increased exposure
to schistosome parasites.
A consistent prediction from the models analysed here is that if treatment significantly
reduces transmission, this will have adverse effects on antibody and infection levels after
treatment ceases and transmission returns to pre-treatment levels. The results suggest that,
if transmission is reduced by 50% or more, infection is very likely to overshoot pre-treatment
levels after treatment ceases. Although the effect of treatment on transmission was modelled in
a rather simplistic way in this analysis, with an abrupt change in the level of the transmission
at the beginning and end of the treatment programme, the overshoots in infection are unlikely
to have been caused by this, since they occur over a period of several years after the return
to normal transmission levels. While many field studies have assessed infection levels after
treatment, few have looked at the effects of treatment upon transmission although some have
shown reduced prevalence of infection over time in young children being recruited into their
study populaton (King et al. 1991). Recent studies of S. mansoni infections in Uganda following
repeated MDA (French et al. 2009) have shown that the force of infection (incorporating both
infection rate and the effects of protective immunity) decreases by as much as 70% after one or
two rounds of treatment (M. French, pers. comm), falling within the range explored here.
To improve the accuracy of the predictions made here, it would be helpful to include a more
realistic description of transmission, such as those used in previous modelling studies (Chan
1996; Chan et al. 1996; Woolhouse 1991). This would require a different model structure to
be used, with explicit transmission between individuals over time. Several assumptions about
transmission between human and snail hosts would need to be made. Formal fitting of predicted
levels of infection and antibody from these models to field data, at least for the few years of
MDA for which data is available, would also increase the confidence that could be placed in these
model predictions. The model has shown that both plasma cell decay rates and worm life span
can have distinct effects upon the dynamics of protective antibody and infection. To use this
modelling approach to determine likely values for these parameters, further data patterns will
be required to test models against, since the ranges used in this chapter were able to reproduce
all of the cross-sectional and post-treatment patterns tested in chapter 5. Data on longer-term
infection and antibody dynamics during MDA or smaller studies of repeated treatment may be
able to generate criteria which narrow down the range of these parameters, although it may not
be possible to simultaneously estimate worm life span and plasma cell decay rates, since the
models here suggest that they have interacting effects upon antibody and infection dynamics.
Overall, this work has demonstrated that, with protective immune responses stimulated
by dying worms, repeated MDA is expected to boost protective immunity, but that during
or after cessation of MDA antibody levels could decline below pre-treatment levels, and
after MDA ceases infection levels could exceed those seen before MDA commenced. These
predictions cannot be directly tested against current field data, as MDA programmes have
not routinely measured antibody levels, and other studies of the effects of repeated treatment
on S. haematobium responses have not yet been carried out on a sufficiently long time scale
or large enough population to detect the effects predicted here. However, these predictions
have been made using a range of parameter sets which best explain a number of different
robust patterns seen in cross-sectional and short-term post-treatment studies of S. haematobium
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infection, and so represent the most informed prediction that can be made based upon current
data. While MDA programmes have had substantial impact upon schistosomiasis infection





Urinary schistosomiasis remains a major public health problem, particularly in sub-Saharan
Africa. Current control efforts are primarily focussed upon vaccine development and mass
drug administration programmes, with the goal of reducing morbidity rather than eliminating
infection. Vaccine progress to date has been slow (McManus & Loukas 2008), with only one
candidate, the Sh28GST vaccine, having entered Phase III clinical trials (NIH 2009). A greater
understanding of how naturally acquired protective immunity develops will be advantageous
in furthering vaccine development, for identifying both relevant antigens and the protective
immune mediators which need to be stimulated. It is also important to understand how
other control measures, including mass chemotherapy, are likely to affect the development of
protective immunity, since if infection is not eliminated natural immunity will continue to play
a role in determining infection burdens.
In common with other parasitic infections, protective immunity against schistosomes takes
a long time to develop (Yazdanbakhsh & Sacks 2010). In endemic areas, increased resistance
to re-infection and the development of immune responses associated with protection are seen in
older children or adults, but this occurs only after many years of repeated exposure to infection.
In this thesis, I set out to identify some of the important mechanisms underlying the
slow development of naturally acquired protective immunity in communities with endemic
S. haematobium infection, and to investigate the potential impact of mass drug administration
programmes upon the development of naturally acquired immunity.
Studies of infection and immune responses in humans are subject to logistical and ethical
constraints. It is not possible to follow individuals for the many years that pass between initial
schistosome infection and development of protective immunity without being obliged to treat
them, which alters the dynamics of both infection and immune responses. Instead, population-
based cross-sectional and treatment-reinfection studies are frequently used to study schistosome
immunoepidemiology. Age is used as a proxy for length of exposure in these studies, requiring
the assumption to be made that transmission has remained stable over a number of years.
Mathematical models have an important role to play in interpreting data gathered in this way,
and in using such data to test hypotheses about the underlying immune mechanisms (Chan &
Isham 1998; Chan et al. 2000; Galvani 2005; Woolhouse 1998).
Here, I have used mathematical models to formally test different hypotheses for the slow
development of protective immunity against schistosomes. This is the first time that a pattern-
oriented modelling approach has been applied to models of helminth immunoepidemiology,
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identifying models which can simultaneously reproduce an array of robust patterns identified
from field data (Grimm et al. 2005). This approach proved to be very useful for excluding
particular model structures and parameter combinations, and for discriminating between
different hypotheses. This work has also included the first theoretical exploration of the
implications of an antigen threshold in helminth-specific immune responses, and to my
knowledge is the first time that the role of dying worms as a distinct source of antigen has
been considered in models of this nature. While previous population models of helminth
immunity have usually focussed upon infection patterns, I have also specifically looked at
antibody patterns, in particular antibody aggregation and both the naturally-occurring and
treatment-induced antibody switch.
In chapter 2, I set out the criteria which would be used to test the models. The peaked
age-intensity curve and aggregated infection have been used previously as patterns to test
models of schistosome infection (Chan & Isham 1998; Woolhouse 1992b), but I have refined
these criteria by identifying quantitative limits for them. The criteria stipulating the age of
the peak and the extent of aggregation were found to be highly discriminatory for the models
tested against them. Previous individual-based models of infection aggregation have tended
to give very high prevalence estimates (Chan & Isham 1998) and the prevalence criteria used
here also proved to be very discriminatory. While a concerted effort was made to use as many
different data sets as possible to draw up these criteria, information could not be used from
a number of published infection studies due to lack of reporting of age-stratified data, the
use of different mean calculations (which are not directly comparable) and limited reporting
of infection aggregation. Acquisition of the raw data from these studies would enable these
criteria to be based upon a wider range of data sets, and increase the general applicability of
the findings from these models.
Antibody aggregation and the antibody switch have been reported previously for schistosome
specific antibody responses (Mutapi 1997; Mutapi & Roddam 2002; Ndhlovu et al. 1996b), but
this is the first time they have been used as patterns for mathematical modelling. Correlations
between different schistosome-specific antibody isotypes are rarely reported in the literature,
meaning that the characterisation of the antibody switch relied heavily upon two data sets for
three populations from Zimbabwe (Milner et al. 2010; Mutapi et al. 1997). The antibody switch
proved to be a robust phenomenon across several different isotypes in two of these populations,
but was not found in the third, possibly because relatively few adults (who will tend to have
the highest levels of the late-developing antibody) were included in this study population.
Correlation patterns consistent with the antibody switch were also reported across a number
of isotypes in a separate published field study (Ndhlovu et al. 1996b). The antibody switch
proved to be a very discriminatory criterion for the models tested in both the deterministic
and stochastic modelling frameworks. Given the importance of this criterion in testing these
models, it would be of great interest to investigate how wide-spread this pattern is in different
study populations from different countries. The antibodies involved in the switch were all highly
aggregated across the population, but to varying degrees. The criterion drawn up for antibody
aggregation proved to have very little discriminatory ability, and so was not used in the final
analysis. Levels of both the initial and protective antibody responses were consistently highly
aggregated in the stochastic models (chapter 5), indicating that aggregation in exposure (leading
to aggregated infection levels) is sufficient to explain the observed aggregation in antibodies
without having to consider additional mechanisms to explain this aggregation, such as variability
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in immune competence between individuals.
One pattern which has been modelled several times previously but was not considered here
is changing levels of infection aggregation with age (Chan et al. 2000; Duerr et al. 2003a;
Fulford et al. 1992; Woolhouse 1994a). This was not included because there does not seem
to be a consensus as to the exact form of this relationship (previous studies have reported it
decreasing with age or following a peaked profile), and there was no clear pattern seen in the
infection data analysed in chapter 2. Previous simulation modelling has shown that estimates
of aggregation can be biassed by small sample sizes, which leads to particular problems when
sample sizes decline with age, as frequently occurs in cross-sectional immunoepidemiological
studies (Gregory & Woolhouse 1993). If larger data sets were available from which more robust
age-related patterns in infection aggregation could be estimated, this could form the basis of
a further criterion with which to test the models. The antibody data analysed in chapter 2
suggested that there may be age-related changes in antibody aggregation, although this was
not included as a criterion owing to the variation between different isotypes in the magnitude of
this effect. If this pattern could be identified consistently across a number of different data sets,
it could also form the basis for an additional criterion with which to test these models. The
data from the Burma Valley study (Mutapi 1997) show not only a very rapid individual-level
antibody switch (evidenced by the dichotomous distribution of the isotypes involved), but also
a fairly rapid antibody change at the population level over a narrow age range. Again, if this
striking pattern could be demonstrated in multiple settings, it could form the basis of a highly
discriminatory criterion with which to test future models.
While the models used in this thesis should be applicable to any of the major human
schistosome species, the data used to draw up the criteria were for S. haematobium, which
means that strictly the conclusions drawn in later chapters apply only to S. haematobium
infection and antibody responses. The patterns of infection explored here, including the
peaked age intensity curve, the peak shift and infection aggregation have all been reported
for human S. mansoni infections (Fulford et al. 1992; Woolhouse 1998), suggesting that such
patterns are robust across different schistosome species. However, the quantitative limits for
these patterns vary between species, for example, infection intensity has been reported to peak
between 10–25 years old for S. mansoni (Fulford et al. 1992), older than the age range reported
for S. haematobium of 6–20 years (chapter 2). This could lead to quantitative differences
in the parameter distributions of successful models if they were tested against S. mansoni -
specific criteria, although the qualitative conclusions may not be affected. There is a paucity of
published data in S. mansoni testing for an antibody switch, but this would be an interesting
pattern to test for in S. mansoni data, to see how robust the data patterns and model findings
in this thesis are across the different schistosome species.
In chapters 3 to 5, different combinations of the criteria were used to test and eliminate
candidate hypotheses and model structures. Different models were used in each chapter, with
the type and complexity of the model determined by the field patterns which were being used to
test them. In chapter 3, where the outcomes of interest were a delay in the protective antibody
response, and meeting the criteria for the age-intensity curve and the peak shift, deterministic
population-level models with a single antibody response were sufficient. In chapter 4, two
antibody responses were included in this deterministic modelling framework in order to test
whether the models could reproduce the antibody switch. In chapter 5, where aggregation of
infection and antibody were also used as criteria, stochastic individual based models (IBMs)
143
were used to allow distributions of infection and antibody to be simulated. Introducing the
different criteria in separate stages made it easier to determine the relative importance of
particular criteria in excluding certain models, and this is an approach I would use again.
However, if I were to repeat this analysis, I would use the fully stochastic IBMs throughout
for consistency, although it might not be possible to use these to test the same range of
model structures and parameter combinations as was done in chapter 4, owing to the greater
computational requirements of the stochastic models.
Although parasite-induced immunosuppression was able to delay the development of
protective immunity in these models, it was predicted to maintain high levels of infection in older
people in highly exposed populations, in clear opposition to field data for endemic schistosome
infection. For this reason, immunosuppression was excluded as a potential explanation for the
slow development of protective immunity in human schistosome infection. This is not to say
that suppression does not occur, since it has been clearly demonstrated in both animal models
and human studies (Grogan et al. 1998a; Maizels & Yazdanbakhsh 2003). It is possible that the
principal role of such suppression is to reduce early lethal inflammatory responses, rather than
having a substantial impact upon the Th2-type responses which are generally associated with
protection in human studies. This analysis suggests that the late development of the Th2-type
protective response is not primarily due to immunosuppression, but that a separate mechanism
is responsible.
The antigen threshold, which was included in the models in a rather conceptual way, proved
to be very effective at delaying the development of protective antibody. Models including a
cumulative threshold were favoured over those with an antigen threshold based upon current
levels of antigen exposure, which could reproduce the peaked age-intensity profile only over
a much reduced range of infection rates (chapter 3). In chapters 3–5, a cumulative antigen
threshold was found to greatly enhance the ability of the model to reproduce all of the
cross-sectional field patterns tested, including age-intensity profiles and the antibody switch.
However, it was not found to be essential in any of these models. It is therefore suggested
as a potential mechanism for delaying the development of protective immunity, but not an
essential one. The antigen threshold was represented in the models as a plausible immunological
phenomenon rather than representation of a specific cellular mechanism. It may be thought
of as representing a cascade of different activation and expansion events that need to happen
upstream of antibody production, particularly for antibody class switching. This could include
repeated T cell activation and accumulation of a polarised T cell response leading to a change
in the cytokine environment. Models have shown that with repeated antigen exposure, it is
possible to see a delayed but rapid change in the cytokine balance due to the highly nonlinear
dynamics of cytokine interactions (Schweitzer & Anderson 1992a).
In chapter 5, the only models which were able to meet all of the cross-sectional and
post-treatment criteria had dying worms providing the main source of protective antigen, in
agreement with the hypothesis that antigen from dying worms is needed to stimulate protective
immunity (Woolhouse & Hagan 1999). This study therefore strongly suggests that the main
source of antigen stimulating protective responses comes from dying worms. However, this
was not necessarily due to delayed antigenic exposure as the original hypothesis suggested
(Woolhouse & Hagan 1999). In chapter 3, it was shown that in order to delay the development
of protective antibody through delayed antigenic exposure, models with antigen coming from
dying worms needed to have non-exponential worm survival. In chapters 3 and 4, models
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with exponential worm survival and dying worm antigen were still able to reproduce all of
the required patterns. Throughout chapters 3–5, it was demonstrated that models with other
stages of the life cycle (cercariae or live worms) stimulating protective antibody could reproduce
all of the cross-sectional patterns of infection and antibody required. Dying worms had to be
the source of protective antigen in these models only in order to reproduce the post-treatment
antibody switch (chapter 5). Together, these findings suggest that delayed antigenic exposure
is not necessary to explain patterns associated with naturally acquired protective immunity,
and that the particular form of the worm survival curve may not be critical.
The analysis very clearly indicated that protective antibody had to reduce worm fecundity
in order for models to reproduce patterns of infection aggregation as well as the antibody
switch and age intensity profiles. Models with reduced re-infection were unable to pass all
of the criteria used in chapter 5, which included patterns of infection aggregation. This
is in agreement with the findings of Galvani (2003), that anti-reinfection immunity reduces
infection aggregation to a much greater extent than anti-fecundity responses. The finding
that protective antibody responses are likely to target worm fecundity is in agreement with
animal and human studies suggesting that S. haematobium is susceptible to anti-fecundity
responses (Agnew et al. 1996, 1992; Webbe et al. 1976). It also fits with the observation that
the leading vaccine candidate for S. haematobium, Sh28GST, induces anti-fecundity responses in
primates (Boulanger et al. 1999). Praziquantel treatment has been shown to enhance serological
recognition of S. haematobium GST in people from areas with endemic S. haematobium infection
(Mutapi et al. 2005), making it a putative antigen stimulating the protective immune responses
described here.
In models with immune-mediated worm death, it was seen that this mechanism reduced
worm life span to very short lengths in models which were able to meet all of the field criteria.
The majority of these models were excluded on the grounds that worm life span was reduced
below 1 year, much lower than field estimates. The few remaining models with immune-
mediated worm death (chapter 4) were not explored further in the stochastic individual based
models, but all of these had worm life span estimates of less than 2 years, still well below field
estimates of 3-10 years (Goddard & Jordan 1980; Vermund et al. 1983; Wilkins et al. 1984). One
note of caution in dismissing these models is that the estimates of worm life span quoted come
from studies in which transmission had stopped and infection levels were decreasing, meaning
that immune pressure may have been waning.
Very specific predictions were made about the initial antibody response involved in the
antibody switch: it had to be stimulated by antigens from recently laid eggs, have little or
no protective capacity, and be relatively short-lived. Woolhouse (1993) demonstrated that the
epidemiological patterns associated with ‘blocking’ antibodies could be best explained if these
were neutral antibodies with rapid decay, similar to the initial antibody response described
here. It seems most likely that the antigen stimulating this response is a secreted egg antigen,
which would be rapidly sequestered from the immune system by granuloma formation around
trapped eggs (von Lichtenberg 1964). The combination of a protective anti-fecundity response
and a neutral antibody response stimulated by egg antigens was the main driver of the antibody
switch in these models, with the protective antibody removing the antigen source for the initial
response as it developed.
The models used throughout this thesis assumed that each antibody response was stimulated
by a single stage of the schistosome life cycle and targeted a single stage. In reality, overlapping
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antigen expression between different stages (Curwen et al. 2004) means that antibody responses
to a specific antigen could be stimulated by more than one stage of the life cycle and could
have damaging effects upon multiple life stages. The models described here could easily be
extended to test this, although the number of potential combinations to be tested would vastly
increase. A more feasible first step might be to model responses to particular antigens for which
the antigen-specific antibody responses have been measured and the stage-specific expression
is known, such as Sm22.6 (Fitzsimmons et al. 2007).
I have deliberately avoided modelling particular antibody isotype responses in this thesis,
choosing instead to model general characteristics of two distinct groups of antibodies seen in
three different populations (Mutapi et al. 1997; Ndhlovu et al. 1996b). This is partly because
the isotypes included in each group can differ depending upon the antigen preparation used
(egg or whole worm) and also differ between populations. In general, but with exceptions,
IgG1 or IgE responses best fit the bill for the ‘protective’ responses modelled here. Several
studies have suggested that IgE antibodies specific for egg or adult worm antigen preparations
are protective (Dunne et al. 1992a; Hagan et al. 1991), and IgE levels have been reported to be
boosted by treatment (Fitzsimmons et al. 2007; Mutapi et al. 1998). Egg-specific IgE responses
were consistently involved in the antibody switch in one of the studies showed switches (Ndhlovu
et al. 1996b) and occasionally in the other (analysis in chapter 2). Worm-specific IgG1 has also
been associated with protection against S. mansoni re-infection (Satti et al. 1996), and in the
data analysed here, egg-specific IgG1 was negatively associated with infection intensity in the
Valhalla population (chapter 2). In this population, IgG1 was highly and persistently boosted
after treatment (Mutapi et al. 1998), and both worm- and egg-specific IgG1 were frequently
involved in the antibody switch (chapter 2). The initial response in the antibody switch may
correspond to egg-specific IgM (Ndhlovu et al. 1996b), worm-specific IgM (Mutapi et al. 1997),
or either egg- or worm-specific IgA responses (Mutapi et al. 1997).
Having demonstrated that only models with dying worms providing protective antigen were
able to reproduce both cross-sectional patterns of infection and antibody and the treatment-
induced antibody switch, these models were used to predict the long-term impact of treatment
in chapter 6. This is the first time that this has been done using models in which antigens
from dying worms provide the main antigenic stimulus, so that treatment can boost protective
antibody responses. In previous models with live worms assumed to stimulate the protective
response, it was shown that, because treatment removed the antigenic stimulus, overshoots
in infection levels were sometimes (although not always) predicted to occur after control
programmes ceased (Chan et al. 1996). It was found here that overshoots in infection could
also occur after the cessation of treatment when dying worms provided the protective antigen,
despite boosting of antibody responses during treatment. The treatment models developed
here looked at infection and antibody levels in the whole population. In an actual field
programme, these are not what would be measured – for example, infection levels are unlikely
to be recorded for individuals who do not receive treatment (either because they fall outside the
target population or miss one or more rounds of treatment). An advantage of using IBMs like
those developed here is that they can be adapted to mimic any real field population, including
specific treatment and sampling schedules. Although the analysis of the potential effects of
treatment was not a formal sensitivity analysis, some parameters clearly had an independent
effect on the development of protective antibody responses during and after treatment, namely
the rate of decay of the plasma cells producing the protective antibody, and the mean worm life
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span. The very different predicted behaviour of models with different plasma cell decay rates
or worm life spans means that additional criteria based upon long-term changes in antibody
levels following single or repeated treatments could be used to further discriminate between the
successful models identified here. However, since the models also demonstrated that a significant
reduction in transmission could alter antibody dynamics, effects of treatment on transmission
would need to be either avoided or accurately measured. An independent measure of turnover
rates of the B cells involved could be obtained using in vivo labelling with deuterated glucose,
which has been successfully used to measure turnover rates of B cells in healthy individuals
(Macallan et al. 2005), and has already been optimised in tropical field settings (Ghattas et al.
2005).
Another hypothesis for the slow development of protective immunity in human schistosomi-
asis which has not been considered in this work is age-related changes in immune competence.
While it seems unlikely that this could fully account for the peak shift in infection intensity,
it could be a contributing factor to the delay seen in mounting protective antibody responses
(Yazdanbakhsh & Sacks 2010). This could easily be incorporated into the models developed
here to investigate whether age-related changes in immune competence are consistent with
patterns seen in the field.
In the final analysis of the plasma cell-only models, it was found that the protective antibody
response almost always had a slower intrinsic decay rate than the initial response. This could
be because the initial response does not form a robust memory response, while the protective
response does so; it could reflect differences in the survival of the plasma cell populations
stimulated; or it may reflect differences in memory cell turnover rates, which have been shown
to differ between B cells expressing different isotypes (Wirths & Lanzavecchia 2005). The
differences could be related to the type of antigen stimulating the different responses, since
carbohydrate and protein antigens differ in their ability to stimulate effective memory responses
(Woolhouse & Hagan 1999).
The representation of protective immune dynamics in these models was fairly simple,
although based upon B cell maturation pathways as they are currently understood (Gray
2002). In the final analysis in chapter 5, only models with long-lived plasma cells were
considered, although as noted, these could equivalently represent populations of memory
B cells with continual antigen-independent activation to short-lived plasma cells. These
models do not distinguish between these two alternative proposed mechanisms for antigen-
independent antibody maintenance. In chapter 4, models with antigen-dependent activation of
explicit memory cell populations to form short-lived plasma cells were also considered. These
demonstrated broadly similar results to the simpler plasma cell models, although they did allow
some additional combinations of antigen and target for the two different antibody responses to
meet all of the criteria, most notably models with antibody responses reducing worm survival.
However, these were relatively few in number and had very low worm life span estimates as
discussed above. Nonetheless, it would be of interest to explore these models more thoroughly in
a stochastic framework, and to extend them to consider models with both memory cells and long-
lived plasma cells. More complex models with explicit T cell populations and cytokine dynamics
could also be developed, although T cell maturation pathways are still being determined (Gray
2002) and models of current understanding of T cell and cytokine interaction can rapidly become
outdated (Schweitzer & Anderson 1992a). Models of cytokine interactions could quickly become
complex due to the highly non-linear interactions involved (Callard et al. 1999), and their
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development would need to be closely guided by extensive data sets. The analysis here has
demonstrated that by starting with relatively simple models and adding in only as much detail
as is necessary to make valid comparisons with field data and reproduce robust patterns in this
data, a number of complex patterns can be adequately explained.
The main finding from this work, that protective immune responses against schistosomes
are likely to be stimulated by antigens which are released from dying worms, and that these
responses reduce worm fecundity, has implications for the development of schistosome vaccines.
It suggests that, if the aim of vaccination is to mimic effective protective responses which occur
naturally, then the most suitable antigen candidates are those which are highly expressed within
adult worms, with low expression on the worm surface or by other stages of the life cycle. It
also suggests that initial trials should look for anti-fecundity effects. However, the models
also suggest that natural protective immunity receives constant boosting from the continued
presence of live worms, while a vaccine would need to induce long-lasting immunity even in the
absence of infection. Although an anti-fecundity vaccine would not prevent infection in those
who had been vaccinated, it would be expected to reduce infection intensity at the population
level by reducing onwards transmission (Chan et al. 1997). Similarly, the longevity of the
‘immunizing’ effect of chemotherapy was shown here to be dependent upon both the duration
of protective responses and levels of subsequent antigen exposure.
The work presented here has demonstrated that the pattern-oriented modelling approach is a
highly effective one in identifying underlying immune mechanisms from immunoepidemiological
studies. A large panel of criteria based upon patterns of both infection and parasite-specific
antibody levels proved to be highly discriminatory in excluding possible model structures and
parameter combinations, enabling a small group of likely models to be identified that could be
used to make long-term predictions. This approach can easily be extended to explore different
model structures, or to refine the current models through identification of additional criteria.
Individual based models like those developed here are highly versatile and can be tailored to
any particular field study, making them a powerful tool in analysing and interpreting field data.
As more data on immune markers becomes available, particularly from long-term treatment
studies, it is hoped that these models can be refined to provide further insights into the processes






1. Identify robust patterns in field data on infection intensity and specific antibody responses,
from as many studies as possible. Where relevant, determine quantitative upper and lower
bounds for these patterns from available field data.
2. For each of the patterns identified in step (1), draw up one or more criteria which models
must meet.
3. Construct mathematical model to test hypotheses. Decide upon which of the criteria
drawn up in step (2) will be used to test the compatibility of the model with the data,
and ensure that the model includes all of the components necessary to be able to test it
against these criteria.
4. Parameterise model. Conduct thorough literature search to identify values and plausible
ranges for parameters where possible. Where no data is available, use wide ranges on
parameters.
5. For each parameter to be varied, use a geometric series of values covering the full range
identified in step (4).
6. Run repeat simulations using the model, performing a grid search of the parameter space,
using all possible combinations of the values of each parameter determined in step (5).
7. For each parameter set, test whether the model outputs pass all of the criteria selected
in step (3) or not.
8. For each model, record how many of the parameter combinations meet all of the criteria























































































































Figure B.1: Kaswa village: antibodies that decrease with age. Antibody distributions are
shown in two age groups for antibody responses which are significantly negatively correlated
with other responses, and which decrease with host age. Frequencies within each age group are




























































































































































































































































































































































































































































































































































exponential (n = 1) approximately Gaussian (n = 9)
Figure C.1: Memory decay rates for memory models which pass all criteria. Plots show the
total number of times parameter combinations including the different possible combinations of
decay rates for the two memory cell populations pass all criteria. (a,b) Memory models without
cross-regulation or thresholds, (c,d) total frequencies summed over all of the cross-regulation
models and (e,f) models with a threshold on M2. The left-hand panels are for models with
exponentially-distributed worm life span (n = 1) (a,c,e), the right-hand ones are for models
with approximately Gaussian-distributed worm life span (n = 9) (b,d,f). All of the different
combinations of decay rates that were used have a bar on the chart; black bars indicate that no
successful parameter combination had this combination of memory decay rates, blue bars that
at least one successful parameter combination had this combination of memory decay rates.
































































































exponential (n = 1) approximately Gaussian (n = 9)
Figure C.2: Mean natural worm life span for plasma cell models which pass all criteria. Plots
show the total number of times parameter combinations including the different possible values
for natural worm life span are able to meet all criteria for plasma cell models, with results
broken down by the life cycle stage providing the antigenic stimulus for A2. Yellow bars: mean
natural life span 3 years; light green bars: mean natural life span 6.5 years; dark green bars:
mean natural life span 10 years. (a,b) Plasma cell models without cross-regulation or thresholds,
(c,d) total frequencies summed over all of the cross-regulation models and (e,f) models with
a threshold on A2. The left-hand panels are for models with exponentially-distributed worm
life span (n = 1) (a,c,e), the right-hand ones are for models with approximately Gaussian-







































































































A pilot mapping study was carried out to test whether exposure to S. haematobium infection
correlated with distance lived from the nearest river water contact site, as was found in a
previous study in Zanzibar (Rudge et al. 2008). If this was the case, it was expected that
infection intensities would be negatively correlated with this distance in young children who
had not yet developed protective immunity against infection. After confirming this, I calculated
the rates at which individuals in the study population (up to the age of 20) moved house, as a
proxy for the rate at which they changed their contact rate (parameter φ in chapter 5).
D.1 Data sources
The data presented here were collected as part of a cross-sectional study carried out in the
Magaya schools and local community in the Murehwa district of Zimbabwe in September–
November 2008. Age and parasitology data were collected as part of the main survey. As part
of a pilot mapping study, a GPS receiver was used to record the co-ordinates of active water
contact sites used by residents of Magaya village, and the co-ordinates of the households of a
number of study participants living in Magaya village. The straight-line distance between each
participant’s household and the nearest active water contact site was calculated by Eric Fèvre
using ArcGIS. When households were mapped, wherever possible information was obtained
from adults in the household on the number of years that each study participant had lived
in that household. Additional data was obtained from questionnaires given to a subset of the
study participants as part of the main study, which included a question asking participants to
list the number of previous villages that they had lived in.
D.2 Relationship between infection intensity and distance
lived from nearest water contact site
A strong negative correlation was found between individual infection intensity and the distance
between household and nearest active water contact site for 29 children in grades 0 or 1 of
Magaya primary school, who were aged 4–8 years old (figure D.1, Spearman’s ρ = -0.42, p =
0.023). An even stronger negative correlation was found for the 19 children whose parents told
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all in grades 0 or 1
life-long residents in
grades 0 or 1
Figure D.1: Relationship between infection intensity (natural log of meo(mean egg output) + 1,
where egg counts come from two or three 10ml urine samples collected on consecutive days), and
distance lived from water contact site (straight line distance in metres between household and
nearest active water contact site on a river) for children in grades 0 or 1 at Magaya primary
school. Data shown for all of the children in this group (n = 29, dark blue diamonds) and
highlighted for those who were life-long residents at their current household (n = 19, light blue
diamonds).
No relationship between infection intensity and distance lived from an active water contact site
was found in older individuals (data not shown).
D.3 Rates of moving house
The rate of movement between households was calculated independently from two different
data sets. Firstly, information gathered from adults interviewed during the household mapping
studies was selected for the eldest child from each household mapped on how long they had
lived in that household, and whether they had lived there since birth. Only the eldest child was
used to avoid potential biases from siblings moving to households at the same time. Data was
available for individuals from 42 different households. The moving rate was calculated as the
number of children who had moved to their current household since birth divided by the total
length of time that all children had lived in their current household. 21 of the children had
moved to their current household since birth, and a total of 367.3 years of residence in current
household was reported across all 42 individuals, giving a moving rate of 0.057 per year.
The second method used to estimate moving rates came from questionnaire data for 283
individuals under the age of 20. The number of previous villages which individuals reported
living in were added up for each person, and divided by the summed ages for all of these
individuals. 179 moves were reported altogether, and the total summed ages came to 3447
years, giving a moving rate of 0.052 per year. Although this method will have missed within-
village moves, interviews in the household survey suggested that the majority of local moves
occurred between villages.
Both estimates of moving rate (φ) were very similar, and so a final value of 0.05 year-1 was














































































































































































































































Figure E.1: Performance curves for the nine parameter sets which passed all of the criteria most
frequently, for the cross-regulation models which had dying worms stimulating a protective
anti-fecundity response, with a second non-protective antibody stimulated by egg antigen. The
following numbers of repeat simulations were used ten times each: 20, 40, 100, 200, 400,
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The slow development of acquired immunity is thought to be
responsible for the characteristic convex age–intensity curve
seen in human schistosome infection, which peaks earlier in
more heavily infected populations (this is described as a
peak shift). Schistosomes are able to suppress protective
host responses, and it is hypothesized that this suppression
is responsible for the delayed development of protective
responses. A deterministic mathematical model is used to
describe levels of infection and immunity in an endemic
population, incorporating protective immune responses which
either reduce adult worm burden or reduce superinfection.
Suppression, related to current worm burden, is also included
and acts against one or both protective responses. If suppres-
sion acts against the entire protective response, it is able to
delay the development of protective immunity, and the peak
shift is predicted to be reversed at higher infection intensities,
with removal of the peaks altogether at the highest levels of
infection and/or suppression. If  only the anti-adult worm
protective immune response is vulnerable to suppression, while
the anti-reinfection response remains intact, then suppression
does not remove the peak in the age–intensity curve. These


















In human populations with endemic schistosomiasis, a
characteristic age–intensity pattern is seen, with infection
intensity (measured by egg output in faeces or urine) rising
rapidly through the childhood years to peak at around
8–15 years of age, then falling again in adulthood (1,2). The
peak level of intensity is higher and occurs at a younger age
in populations with a higher overall infection intensity when
compared with areas of lower infection intensity, a pheno-
menon termed the ‘peak shift’ (3). The peaks also become
more convex at higher levels of overall population infection
intensity (1,4). Both phenomena are reproduced by simple
mathematical models of acquired immunity (5). Protective
immunity seems to develop slowly, as individuals endure
chronic infection by long-lived adult worms, with frequent
superinfection (6). There is increasing evidence that
schistosomes are able to modulate the host immune
response, suppressing both specific responses to schistosomes,
and responses to bystander antigens and other pathogens
(reviewed by Maizels and Yazdanbakhsh) (7). This active
immunosuppression may be able to explain the delayed
development of immunity.





suppression of immunopathological responses to trapped
eggs in chronic infection has been clearly shown (8), and
suppressor activity can be transferred from chronically to
acutely infected mice by adoptive transfer of spleen cells (9).
In humans, experiments using peripheral blood mononuclear
cells (PBMCs) from chronically infected individuals have
shown that schistosome antigen-specific proliferation and
cytokine production are reduced in chronic infection
(10–15). This does not appear to be due to tolerance (deletion
of antigen-reactive T cells), since antigen-specific responses




, either by neutralization of  IL-10
or by culture with dendritic-like cells (which improve
antigen presentation by unelucidated contact-dependent and
-independent mechanisms) (12,14,16–18). Antigen-specific
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infected individuals are inversely correlated with infection
intensity (10,13), and in one study the percentage increase in
cell proliferation upon IL-10 neutralization was shown to be
strongly positively correlated with the amount of adult
worm-specific IL-10 produced by PBMCs (14). Schistosome
antigen-specific IL-10 – a possible marker for suppression –
is positively correlated with infection intensity (19,20).
Together, these findings suggest that the degree of  sup-
pression is related to infection intensity. Proliferative and
cytokine responses to schistosome antigens are restored by
praziquantel treatment, which kills adult worms (21,22).
The aim of this study was to determine the effects of
active immunosuppression by schistosomes on population-
level patterns of infection and immunity, in particular to
investigate whether it could significantly delay the development
of protective immunity and whether it could delay the age at
which infection intensity peaks. A simple mathematical
model of immunity was used, building on previous work by
Woolhouse (5,23). Protective immunity was modelled as
a function of cumulative exposure to adult worms, either
reducing worm life span (24) or reducing the rate of
superinfection by larval stages (concomitant immunity)
(25), or both. Suppression was then introduced to reduce
the impact of the protective responses, having the effect of
increasing worm survival or increasing the rate of superin-
fection, respectively (up to the levels seen in the absence of
immunity). Suppression was incorporated as a function
of  current worm burden, reflecting the correlation seen
with infection intensity. In contrast to protective responses,
suppression was assumed to have no immune memory, as it
is lifted by chemotherapy (15,21). The model is used to
predict the infection intensity curve with age, and the
pattern of peak shifts, if  suppression is assumed to act upon




A mathematical model consisting of a set of differential
equations was developed, building upon previous models of
schistosome immunity (5,23). Protective immunity was
modelled as anti-larval (concomitant) immunity – a response
triggered by adult worms but acting against incoming larvae
– and direct anti-adult immunity, triggered by and active
against adult worms, with these responses acting alone or
together. Suppression of either or both of these responses
were also included.
The model outline is shown schematically in Figure 1,
and the equations describing the model are given below.
Parameters are defined in detail in Table 1.
(1)
Figure 1 Schematic diagram of the model, showing the main state 
variables, worm burden (P) and experience of infection (I ), and 
development of anti-larval (RL) and anti-adult (RA) resistance and 
suppressive (S) responses. θ, ψ and ν are indices of responsiveness, 
used in the Gumbel function to determine the strength of resistance 
or suppression based upon infection experience (for resistance) or 
current worm burden (for suppression), respectively. Loss of 
immune memory occurs at a rate γ. Parameter α, which governs the 
maximum rate of immune-induced death of adult worms, is set to 
1 for all analyses. All parameters are defined in Table 1, with 
parameter values given.  indicates suppression of a response.
Table 1 Parameters used in the model, with initial values, units and source from the literature where relevant. ‘Cell’ refers to immune memory 
cell, unit of experience of infection (I )
Parameter Meaning Initial value Units Source/rationale
Λ Rate of infection 40 Year–1 person–1 (5)
θ Strength of concomitant immunity 0·0028 Cell–1 Set to give peak worm burden of 110 (5)
ψ Strength of antiworm immunity 0·0015 Cell–1 Set to give peak worm burden of 110
γ Rate of immune memory loss 0·1 Year–1 cell–1 (5)
μ Natural death rate of adult worms 0·25 Year–1 worm–1 (26,27)
α Maximum level of additional immune-
induced death rate of adult worms
1 Year–1 worm–1 Set to give realistic minimum life span
ν Strength of suppression 0·01 Cell–1 Set to give significant suppressive effect
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The model describes a homogeneous endemic population
with a constant rate of infection with respect to both age




) changes with age
according to an immigration death process, with a constant














at 0·25 throughout this analysis, giving an average worm life
span of 4 years (26,27). A second differential equation (2)





). This is roughly equivalent to a
pool of memory cells, and increases with cumulative exposure





proportional to the memory cell population size (5). Both
resistant responses are dependent upon this ‘infection
experience’ and are related to it by a parameter determining






















using a Gumbel function (as in previous models) (5), which
scales the response to a value between 0 and 1 (equations 3
and 4). Anti-larval (or concomitant) immunity acts to







as resistance increases, the rate of acquisition of new infec-
tion decreases. Anti-adult immunity is modelled here as a


















 set to 1 for this analysis. The model can be altered so that
only anti-larval or only anti-adult immunity is acting, or a













) is 40 new worms per year.
Suppression is modelled as acting against either or both
of the protective responses. This should be regarded as a
generic representation of the parasite-specific suppressive
response rather than as an accurate representation of any
particular immune mediator. Suppression is modelled as a









, again scaling the level of
suppression between 0 and 1 (equation 5). Suppression may





















Alternatives to the Gumbel function for scaling both
resistance and suppression were also investigated to see
whether this changed the model output substantially. The

































]), with equivalent equations for the
anti-larval and suppression responses.
The combinations of resistance and suppression that were
explored using this model were:







sion of this response.






), with suppression of
this response.







suppression of both responses.







ing proportions, with suppression of only the anti-adult
response.
For each scenario, the magnitude of suppression was varied
to assess the effects on the age-intensity curve and the level
of overall protective immunity, and the rate of infection was
also varied to assess the impact of suppression upon the
peak shift.
The expected fractional increase in the protective
response if  suppression were removed (analogous to IL-10














































 model, the expected impact of anti-adult
immunity upon average worm life span was also assessed





























. Equations were solved numerically using a fourth





When the immune response is modelled as a single mecha-


















) increases, the level of peak intensity is raised and occurs
at an earlier age, with increasing curve convexity (Figure 2a,b).







), then the age–intensity profile is inter-
mediate between that generated with anti-larval or anti-
adult immunity alone, and again the peak shift is clearly
seen (Figure 2c).













), then increasing the strength of suppres-




) raises the level of the peak parasite
burden and delays the age at which the peak occurs, until,
when suppression is sufficiently strong, the age–intensity curve
tends towards the monotonically increasing immigration–
death curve seen when there is no resistance at all. This is






 model (Figure 3a). The trend is similar for
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the RL model (not shown). Increasing suppression decreases
the convexity of the age–intensity curve. The simultaneous
effect of increasing suppression on the effective immune
response [RA × (1 − S)] is shown in Figure 3(b) for the RA
model. Increasing suppression delays the development of
protective immunity, and also reduces the final level of
resistance attained. At the higher levels of suppression
explored, the protective response doesn’t develop at all.
Suppression also delays and reduces the development of
protective immunity in the RL model (data not shown).
Suppression affects the peak shift in both the RA and the
RL models. For a constant strength of suppression, then at
the lowest rates of infection, the peak shift is still observed,
but as the rate of infection increases, the peak shift is
Figure 2 The peak shift in the basic models without suppression. 
Individual worm burden is shown changing with age for the 
following values of Λ (rate of infection) from bottom to top (with 
arrow): 10, 20, 40, 80, 160. For all graphs μ = 0·25, γ = 0·1 and 
ν = 0. (a) Model RA: θ = 0, ψ = 0·0015 (b) Model RL: θ = 0·0028, 
ψ = 0 (c) Model RAL: θ = 0·0014, ψ = 0·00125.
Figure 3 The effect of increasingly severe suppression in the RA 
(anti-adult resistance) model upon (a) worm burden and (b) level of 
overall resistance [RA × (1 − S)]. Age–intensity profiles are displayed 
for both. Λ = 40, ψ = 0·0015. Bold lines indicate no suppression 
and no resistance as marked. Lines in between, increasing strength 
of suppression ν (in direction of arrow): 0·01, 0·02, 0·03, 0·04.
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reversed, before complete loss of the peaks occurs at the
highest infection intensity levels (Figure 4a,b). If  an equal
level of suppression against both responses is included in the
RAL model, then similar effects with increasing suppression
and increasing infection rate are seen as for each response
modelled separately – suppression can reverse the peak shift
and remove the peaks altogether at a sufficiently high level
of suppression or infection rate (data not shown). Removal
of the peak at the highest infection intensity levels corresponds
with almost complete prevention of acquired immunity
developing.
The changing levels of the suppressive and protective
responses were plotted for the RA model, when Λ = 40 and
ν = 0·01, along with the expected percentage increase in the
protective response if  suppression were removed (Figure 5).
Suppression closely follows the level of worm burden, peaking
at an early age, while the effective protective response
[RA (1 – S)] rises more slowly, and peaks later on. The
percentage increase in protection if  suppression were
removed (illustrative of  what is measured with an IL-10
neutralization assay) follows a similar trend with age to
suppression level, peaking at 60%, but averaging out to
around 30% over the whole age profile. The small effect that
this apparently sizable suppression effect has on the overall
age intensity profile can be seen by comparing the bottom
two lines in Figure 3(a), with ν = 0 (no suppression) and
ν = 0·01. This corresponds to a modest delay in the develop-
ment of anti-adult resistance (top two lines in Figure 3(b),
with ν = 0 (no suppression) and ν = 0·01).
When both types of immunity are included in the RAL
model but suppression acts only against the anti-adult
response, different population-level effects are seen. Increasing
the strength of suppression raises the height and decreases
the convexity of the peak, and makes it occur at a later age,
but cannot remove the peak altogether (Figure 6a). Whether
or not the peak shift remains depends upon the relative
strengths of the initial anti-adult and anti-larval responses.
If  both responses are quite strong (prior to the effects of
suppression) then the magnitude of the peak shift is progres-
sively reduced at higher levels of infection, but the peak shift
is not reversed (Figure 6b: AL). However, if  the anti-adult
response is much stronger than the anti-larval response,
then the peak shift may be reversed at intermediate levels
of infection rate (Figure 6b: A » L). The peaks are never
removed in this model so long as an unsuppressed protective
anti-larval response is still acting.
In the RAL model without suppression, the anti-adult
immunity component has a large impact upon the average
Figure 4 The effect of suppression on the peak shift for the (a) RA 
and (b) RL models. Individual worm burden is shown changing with 
age with increasing Λ (rate of infection) from 10 to 160 in steps of 
10, going in the direction of the arrow. The trend of the peak shift 
is highlighted. (a) θ = 0, ψ = 0·0015, ν = 0·01. (b) θ = 0·0028, ψ = 0, 
ν = 0·01. Other parameters are as in Figures 2(a,b).
Figure 5 Dynamics of the suppression effect (S), the overall 
resistance level [RA × (1 − S)], and the expected rise in resistance 
level if  suppression is removed. This is shown for the RA model with 
Λ = 40, ψ = 0·0015 and ν = 0·01. This corresponds to the 
second-lowest line in Figure 3(a), which shows the overall effect of 
this suppression on the population pattern of infection.
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worm life span, which decreases both with host age and with
increasing infection rate (Figure 7a). When suppression of
anti-adult immunity is included, then at the highest levels
of infection rate, the reduction in life span within the host is
delayed by a few years, and the final equilibrium life span is
slightly increased (Figure 7b).
Using alternative functions (linear or exponential) for the
relationship between infection experience and resistance did
not change the predicted trends for this model.
DISCUSSION
The model suggests that suppression can delay and reduce
the development of protective immunity in humans, but may
have complex effects upon population patterns of infection.
The model shows that very strong immunosuppression of
the entire protective response can completely overwhelm it,
removing all evidence of acquired immunity and removing
the ‘peak’ in infection intensity altogether, while very weak
Figure 6 Suppression of RA alone in the RAL model. (a) Effect of 
increasing suppression on age–intensity profile. Bold lines indicate 
no suppression and no anti-adult (RA) resistance, as marked. Lines 
in between, increasing strength of suppression ν (in direction of 
arrow): 0·01, 0·02, 0·03, 0·04. Λ = 40, θ = 0·0014, ψ = 0·00125. 
(b) Effect of suppression on the peak shift when the two resistant 
responses are strong (AL) or when the anti-adult response is much 
stronger (A » L). The trend for age and intensity at peaks is shown 
with and without suppression acting (ν = 0·01 or 0). Black 
diamonds: AL, no suppression; white diamonds: AL, with RA 
suppressed; black squares: A » L, no suppression; white squares: 
A » L, with RA suppressed. AL: θ = 0·0014, ψ = 0·00125. 
A » L: θ = 0·00028, ψ = 0·00144. Points marked are 
Λ = 10, 20, 40, 80, 160.
Figure 7 Effect of anti-adult immunity and suppression of 
anti-adult immunity on worm life span at different host ages 
(a) RAL model, no suppression. (b) RAL model with suppression of 
RA response (ν = 0·01). For both graphs, θ = 0·0014, ψ = 0·00125, 
Λ (top to bottom, in direction of arrow): 10, 20, 40, 80, 160.
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immunosuppression will have little or no effect on the age
and intensity of peak infection, as protective immunity is
scarcely affected. With the parameter values given in
Table 1, and suppression acting against all protective
immune responses, then at low rates of infection the peak
shift will remain, but at increasingly high rates of infection
the suppressive effect should be able to reverse the peak shift
and reduce the convexity of peaks, and then remove the
peaks altogether.
Alternatively, if  immunosuppression only acts against
part of the immune response (in this case only the anti-adult
response, leaving the anti-larval response intact), then
suppression is predicted to be unable to remove the peaks,
and have a much more modest effect upon the peak shift.
The age at which the peak occurs will be increasingly
delayed at higher rates of infection, but the peak shift will
only be reversed if  the unsuppressed anti-larval response is
very weak. Suppression is predicted to extend the worm
life span considerably in the youngest hosts, but have very
little effect on worm survival in older hosts.
Using a mathematical modelling approach to investigate
this question is useful because it allows findings from
laboratory studies to be applied to a hypothetical population
setting, under a set of explicit and verifiable assumptions,
producing outputs that can be compared with field data.
The development and action of  generic protective and
suppressive immune responses were modelled, with protective
responses a function of cumulative exposure to adult worms
and suppression a function of current worm burden. The
relatively simple structure of the model made it ideal for
exploratory analyses of the hypothesis that suppression may
delay the development of immunity and occurrence of the
peak in infection intensity. This framework can be adapted
for more detailed models which incorporate more realistic
and specific immune responses and age-varying exposure
levels, generating model outputs which can be fitted to field
data, to allow more quantitative conclusions to be drawn.
Parasite-induced immunosuppression has previously been
included in other mathematical models of macroparasite
infection (28,29). Duerr and colleagues modelled parasite-
associated suppression as an increasing rate of parasite
establishment (Λ) with increasing parasite burden (29,30),
with their null model (with no suppression) equivalent to
our full suppression model (with no resistance). Their model
predicted sigmoidal age–intensity curves, consistent with
onchocerciasis data (30) (which displays very different
patterns to schistosomiasis) (31), and their model could not
generate peaks or a peak shift, as was seen with very high
suppression in our model. Schweitzer and Anderson
included parasite-induced suppression of T cell responses in
their more mechanistic models of parasite immunology;
removal of activated T cells by parasites permitted a stable
state with high parasite burden and low numbers of activated
T cells, with high levels of repeated exposure tending to
move the system towards this state. In a more complex
model where parasites suppressed IL-2-driven T cell prolif-
eration, progression from an immunosuppressed to an immune
state was increasingly delayed at higher infective doses (28).
This is in general agreement with our model output.
In contrast to the predictions from the suppression
model, existing field data on S. mansoni and S. haematobium
demonstrates a definite peak in infection intensities in
childhood, which is increasingly strongly convex at higher
infection intensities (4), and a clear peak shift towards
younger individuals is seen in more heavily infected popula-
tions (32). Similar peak shifts have also been demonstrated
for filarial and hookworm infections in human populations
(3). This suggests that significant intensity-related parasite-
specific suppression of all immune responses is inconsistent
with observed population patterns of schistosome infection
intensity.
A cross-sectional population study of schistosome-specific
immune responses has demonstrated a change with age in
the cytokine response, from an IL-10 dominated suppressive
response in younger children to a (putatively protective) Th2
response in older individuals (19). Blocking of IL-10 led to
a 27% increase in parasite-specific IL-5 release by cells in
culture (19). While representations of immunity in our
model are very generic and cannot be directly attributed to
specific cytokines, it is interesting to observe that a switch
from a suppressive to a protective response, with a similar
level of  percentage increase in the protective response if
suppression is lifted, can be generated by our model (Figure 5),
without having a great impact on the age–intensity curve
(Figure 3a). This is not a stable outcome in our model,
however, as very different patterns are seen at different levels
of infection.
The alternative scenario set forward in this paper, that
only part of the immune response is suppressed, requires
experimental verification. There is some indication that
innate toll-like receptor (TLR)-controlled responses are
selectively down-regulated in schistosomiasis (33), and the
same may be true for protective adaptive immune responses.
In deciding between the complete and partial suppression
model, more rigorous demonstration of  the biological
plausibility of the parameters used will also be necessary,
including infection rates and the extent of suppression that
occurs. Water contact rates, measured in the field, can be
used to estimate infection rates and to parameterize models
of immunity (34). In the model, an assumed natural worm
life span of 4 years is considerably shortened by anti-adult
immunity, to as little as 1·5 years, in contrast to the
estimates of 3–6 years previously calculated from field data
(26–27, 35); more realistic parameterization of the model will
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be necessary to determine whether this is a significant
problem. The prediction that, if  there is significant immune
attrition of adult worms, then worm life expectancy will be
shorter in adults than in children (Figure 7a), has been
previously tested in two field studies of S. mansoni; one study,
following transmission control in St. Lucia, showed some
evidence of a longer worm life span in children (26), while
another study analysing pre- and post-treatment data from
Kenya failed to find evidence of a significant difference (36).
In developing these ideas further, it will be informative to
explicitly model the egg stage of the schistosome life cycle,
since there is evidence that responses to eggs dominate early
on in infection, and may be more strongly suppressed than
responses to adult worm antigens in chronic infection
(15,37). Modelling the egg stage will also allow the model to
be fitted to field data on egg output.
While our model indicates that worm-induced immuno-
suppression may be able to delay the development of
protective immunity, it also can have effects on population
levels of infection intensity which have not been reported in
field data, in particular reducing the convexity of the age–
intensity curve, and reversing the peak-shift. This suggests
that intensity-related immunosuppression of the specific
immune response does not occur to a significant extent
during schistosome infection.
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